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Background: Hospital-acquired infections (HAIs) are a major cause of morbidity and mortality. Critically ill
patients in intensive care units (ICUs) are particularly susceptible to these infections. One intervention that
has gained much attention in reducing HAIs is selective decontamination of the digestive tract (SDD).
SDD involves the application of topical non-absorbable antibiotics to the oropharynx and stomach and a
short course of intravenous (i.v.) antibiotics. SDD may reduce infections and improve mortality, but has not
been widely adopted in the UK or internationally. Hence, there is a need to identify the reasons for low
uptake and whether or not further clinical research is needed before wider implementation would be
considered appropriate.
Objectives: The project objectives were to (1) identify and describe the SDD intervention, (2) identify views
about the evidence base, (3) identify acceptability of further research and (4) identify feasibility of further
randomised controlled trials (RCTs).
Design: A four-stage approach involving (1) case studies of two ICUs in which SDD is delivered including
observations, interviews and documentary analysis, (2) a three-round Delphi study for in-depth
investigation of clinicians’ views, including semi-structured interviews and two iterations of questionnaires
with structured feedback, (3) a nationwide online survey of consultants in intensive care medicine and
clinical microbiology and (4) semistructured interviews with international clinical triallists to identify the
feasibility of further research.
Setting: Case studies were set in two UK ICUs. Other stages of this research were conducted by
telephone and online with NHS staff working in ICUs.
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Participants: (1) Staff involved in SDD adoption or delivery in two UK ICUs, (2) ICU experts (intensive care
consultants, clinical microbiologists, hospital pharmacists and ICU clinical leads), (3) all intensive care
consultants and clinical microbiologists in the UK with responsibility for patients in ICUs were invited and
(4) international triallists, selected from their research proﬁles in intensive care, clinical trials and/or
implementation trials.
Interventions: SDD involves the application of topical non-absorbable antibiotics to the oropharynx and
stomach and a short course of i.v. antibiotics.
Main outcome measures: Levels of support for, or opposition to, SDD in UK ICUs; views about the SDD
evidence base and about barriers to implementation; and feasibility of further SDD research (e.g. likely
participation rates).
Results: (1) The two case studies identiﬁed complexity in the interplay of clinical and behavioural
components of SDD, involving multiple staff. However, from the perspective of individual staff, delivery of
SDD was regarded as simple and straightforward. (2) The Delphi study (n = 42) identiﬁed (a) speciﬁc
barriers to SDD implementation, (b) uncertainty about the evidence base and (c) bimodal distributions for
key variables, e.g. support for, or opposition to, SDD. (3) The national survey (n = 468) identiﬁed
uncertainty about the effect of SDD on antimicrobial resistance, infection rates, mortality and
cost-effectiveness. Most participants would participate in further SDD research. (4) The triallist interviews
(n = 10) focused largely on the substantial challenges of conducting a large, multinational clinical
effectiveness trial.
Conclusions: There was considerable uncertainty about possible beneﬁts and harms of SDD. Further
large-scale clinical effectiveness trials of SDD in ICUs may be required to address these uncertainties,
especially relating to antimicrobial resistance. There was a general willingness to participate in a future
effectiveness RCT of SDD. However, support was not unanimous. Future research should address the
barriers to acceptance and participation in any trial. There was some, but a low level of, interest in
adoption of SDD, or studies to encourage implementation of SDD into practice.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 18, No. 25. See the NIHR Journals Library website
for further project information.
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Scientiﬁc summary
Background
Hospital-acquired infections (HAIs) are a major cause of morbidity and mortality and markedly increased
health-care costs. Critically ill patients who require management in an intensive care unit (ICU) are
particularly susceptible to these infections. Selective decontamination of the digestive tract (SDD) may
reduce these infections and improve mortality. Recent meta-analyses based on 36 randomised studies
demonstrate a beneﬁt in terms of mortality and reducing pneumonia rates; however, SDD has not been
widely adopted into practice.
Objectives
The overall aim was to identify the perceived risks, beneﬁts and barriers to the use of SDD in UK.
Objectives with matching research questions:
Objective 1: To identify and precisely describe the clinical intervention in ICUs and hospitals that deliver SDD.
Research question 1: What are the components of the SDD intervention?
Research question 2: How has SDD been implemented and delivered into practice?
Objective 2: To identify the range of beliefs, interpretation and views about the current evidence base
relating to the use of SDD in key stakeholder groups.
Research question 3: What are the views of key stakeholders about the internal/external validity and
adequacy of the existing evidence base for SDD and how willing are they to participate in further research?
Research question 4: What are the views of key stakeholders about the likely positive and negative
consequences of implementing SDD in ICUs and what is the relative importance of these beliefs in
inﬂuencing overall views about SDD?
Research question 5: What are the views of key stakeholders about the likely barriers to implementing
SDD in ICUs?
Objective 3: To identify current practice and assess the acceptability of further randomised controlled trials
in the ﬁeld of SDD in a wide group of intensive care consultants and clinical microbiologists.
Research question 6: What are the stated current practices and intentions of intensive care consultants
and clinical microbiologists with responsibility for critically ill patients about SDD?
Research question 7: If there are uncertainties in the evidence base, do these clinicians believe they could
be addressed in a clinical trial? Which research questions, trial design(s) and interventions would be optimal,
and what predicts these beliefs?
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Objective 4: To assess the feasibility of a proposed effectiveness randomised controlled trial comparing
SDD against a control group in ICUs, or a proposed implementation study to increase uptake in ICUs, among
international clinical triallists.
Research question 8: What are the likely challenges in undertaking a large multinational randomised
controlled study of SDD in an ICU?
Methods
We used a ‘multilens’ approach comprising four stages:
Stage 1: In case studies of two ICUs in which SDD is routinely delivered, we used observations of SDD
delivery at the bedside, interviews with staff involved in SDD policy, monitoring or delivery, and
documentary analysis (e.g. of SDD protocols, training materials) to identify and describe how SDD has
been adopted and implemented.
Stage 2: A three-round Delphi study was designed to assess consensus (rather than to achieve consensus).
Participants were professionals from four stakeholder groups with a potential interest in SDD: intensive
care consultants, clinical microbiologists, hospital pharmacists and ICU clinical leads or nurse managers/
educators. We used semistructured interviews based on a theoretical framework of health professional
behaviour change and structured questionnaire instruments to identify the range of stakeholders’ beliefs,
views and perceived barriers to the use of SDD. A topic guide was developed for round 1 (semistructured
interviews). Questions about barriers to SDD delivery were based on a framework of ‘theoretical domains’
that describe barriers to clinical behaviour change and other questions focused on participants’ views
about the need for, and acceptability of, further SDD research. Interviews were audio recorded, transcribed
verbatim and analysed using content analysis. The identiﬁed beliefs were used to populate a questionnaire
instrument for rounds 2 and 3. These further rounds were conducted using online materials. Round 3
materials included group-level feedback of the round 2 responses (frequency distributions) and
individualised reminders of participants’ response to each question in round 2. We assessed the stability of
views across rounds 2 and 3 at the within-person level (individual change scores) and the group level
(changes in group means). We also assessed the importance of the identiﬁed views using multiple indices
and described the levels of consensus in the sample about the beliefs identiﬁed. Findings from the Delphi
study were used to develop the questionnaire instrument for the next stage.
Stage 3: In a large-scale nationwide online questionnaire survey, we invited to participate (1) all intensive
care consultant members of the UK Intensive Care Society (ICS) and (2) all clinical microbiologists with
responsibility for patients in intensive care who were members of the Health Infection Society (HIS) and/or
the British Society for Antimicrobial Chemotherapy (BSAC). We used multiple regression techniques to
identify the factors that predict three key outcomes: support for, or opposition to, SDD; ethical
acceptability of an effectiveness trial; and willingness to participate in further SDD research.
Stage 4: The research team identiﬁed expert international triallists with known expertise in intensive care
trials and/or implementation trials based on their professional proﬁle and the research team’s knowledge
of the ﬁeld. Twenty expert triallists were initially approached by personal e-mail from a clinical member of
the research team, followed by another e-mail, information sheet and consent form from the project
manager. Semistructured telephone interviews were conducted with international clinical triallists.
Participants were selected on the basis of their research proﬁles in intensive care, clinical trials and/or
implementation trials. The triallists discussed the feasibility of either a randomised controlled effectiveness
trial or a randomised controlled implementation trial. They were asked to identify challenges and barriers
to undertaking further research in the ﬁeld of SDD.
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Findings from the four stages of this study were compared and contrasted in order to address the overall
research objectives. Findings were then compared with a series of decision rules (developed a priori)
that facilitated the formulation of recommendations for further research.
Results
Stage 1: The two case studies identiﬁed the clinical components (drug speciﬁcation) and behavioural
components (who does what, when and how) of SDD as delivered in practice. There was some complexity
in the interplay and ﬂow of the clinical and behavioural components of SDD, involving multiple staff.
However, provision of SDD was simple from the perspective of individual staff and delivery was regarded
as straightforward.
Stage 2: In the Delphi study (round 1, n = 47; round 2, n = 44; round 3, n = 42), scores were stable at
both the individual and group levels between rounds 2 and 3. The most important consequence of SDD
was identiﬁed as the potential for SDD to increase antibiotic resistance. In terms of the theoretical domains
framework (TDF), the domain Beliefs about consequences was regarded as the most important domain.
Other important domains were Knowledge (of the evidence base) and Motivation and decision
processes (around SDD adoption). We identiﬁed various levels of consensus, including patterns that
signiﬁed (1) consensus around agreement with respect to a range of barriers to implementation of SDD,
(2) consensus around uncertainty with regard to the effect of SDD on a number of key clinical outcomes
and (3) bimodal distributions for key variables such as opposition to SDD and the generalisability of the
current evidence base. Further effectiveness research in the ﬁeld was reported to be both ethical and
acceptable, and there was a high level of reported willingness to participate in future SDD research.
Stage 3: The national survey (n = 419 intensivists, n = 49 microbiologists) conﬁrmed the general ﬁndings of
the Delphi study, with reported uncertainty about the effect of SDD on antimicrobial resistance, infection
rates, mortality, length of stay and cost-effectiveness. In terms of current SDD practice, we identiﬁed
different stages of consideration, or adoption, of SDD. Approximately 10% of the sample reported
currently delivering components of SDD whereas approximately 40% had not yet considered SDD. As with
the Delphi study ﬁndings, the distribution of survey scores reﬂecting opposition to SDD was bimodal and
this bimodality was evident among both intensive care consultants and clinical microbiologists. In other
words, both groups included a substantial proportion (approximately 20%) who were not opposed to
SDD. The other, primary, mode was at the mid-point of the scale (reﬂecting uncertainty) for intensivists
and at the ‘opposed’ end of the scale for microbiologists. Level of opposition to, or in support of, SDD was
signiﬁcantly predicted by all the items in the questionnaire that assessed the beliefs about consequences
[i.e. about whether or not SDD affects antibiotic resistance, HAIs, Clostridium difficile infections,
ventilator-associated pneumonia (VAP) and mortality] but was not predicted by self-assessed knowledge
of the SDD evidence base.
A large majority of the participating clinicians reported that uncertainties should be addressed in a new
study and that further SDD research would be ethically acceptable. Seventy-eight per cent of participants
reported that they would participate in a clinical effectiveness randomised controlled trial (RCT) and 94%
of participants would support such a study if their colleagues were in favour. Sixty-three per cent reported
being prepared to participate in a RCT to evaluate an intervention to promote the uptake of SDD (i.e. an
implementation trial). There was strong support for the following design features in a clinical effectiveness
trial: the measurement of antibiotic resistance as a major outcome measure, a control group to receive
VAP bundles and/or chlorhexidine mouthwash.
As expected, current practice was associated with opposition to SDD. From the beliefs data, belief about
whether or not SDD increases antibiotic resistance was the strongest predictor of two key opinions:
opposition to SDD and further SDD research being ethically acceptable. The belief that current
uncertainties in the evidence base should be addressed in a new study was the strongest predictor of
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two intentions: willingness to participate in future effectiveness research and willingness to participate in
future implementation research.
Stage 4: Within the triallist study (n = 10), several triallists accepted the current evidence about beneﬁts
of SDD for the individual patient, although most expressed uncertainty about its effects on antibiotic
resistance. Reﬂecting this uncertainty, the triallists focused largely on the challenges of conducting an
effectiveness trial. These challenges were seen as substantial. In particular, such a trial would need to
be extremely large and multinational in nature. To adequately address the uncertainty about antibiotic
resistance, a trial would need to use a cluster-randomised design. There was concern about the impact of
the ethical and regulatory requirements within the various nations in the UK relating to patient consent in
a cluster RCT. There was also considerable uncertainty about whether or not national funding bodies
would be willing and able to fund a multinational trial.
Conclusions
Implications for health care
l There was a striking level of uncertainty about the effects of SDD on clinical outcomes that are
regarded as important. This uncertainty suggests considerable potential for improvement in prevention
of HAIs in critically ill patients, but further evidence is required to clarify the balance between potential
individual-level beneﬁts (e.g. infections, mortality) and potential society-level harms (e.g. antibiotic
resistance) related to SDD.
l There was signiﬁcant confusion apparent in clinicians’ understanding and perceptions of the
components that constitute SDD and related interventions, e.g. selective oral decontamination (SOD).
The importance of detailed guidance on what constitutes different interventions was clear.
l For those units considering the adoption of SDD, it was apparent from our research that the delivery of
SDD is feasible and can be adopted into unit practices. However, a detailed speciﬁcation of the
proposed clinical and behavioural components of the intervention should be developed.
l This study highlighted that the introduction of SDD, whether into routine practice or within a research
context, requires consensus across a range of different stakeholders (including ICU colleagues, clinical
microbiologists and medical directors/those with decisional authority within units). Our study also
highlighted that microbiologists appear to be more opposed to SDD than intensivists, although a
substantial minority are not opposed. Representatives of these stakeholder groups should be engaged
early in any discussions around the use/introduction of SDD.
l A substantial minority of participants reported that SDD would be adopted (apparently quite
straightforwardly) if adoption was mandated by regulatory bodies.
Recommendations for research
Further SDD research was viewed as important, acceptable and feasible to the key stakeholder groups who
participated in this study. However, further effectiveness research would need to be on a scale that raises
challenges for trial design and trial conduct. Research priorities are as follows:
1. A study within UK ICUs is required to model resistance patterns as a function of SDD use.
2. Further large-scale effectiveness trials of SDD in intensive care practice are required to answer remaining
uncertainties, especially those issues relating to antimicrobial resistance.
3. There is general willingness to participate in a future effectiveness RCT of SDD; however, support for
further research is time-sensitive (owing to the changing context) and is not unanimous. Future research
needs to address the substantial barriers to acceptance and participation in any trial. These barriers
should be addressed with reference to the study ﬁndings, for example (1) clinicians with lower
self-assessed knowledge of the SDD evidence base shifted their opinions following feedback about
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others’ views, suggesting a role for discussion among clinical colleagues, (2) concerns about antibiotic
resistance and other potential harms were of paramount importance, suggesting the importance of
emphasising that a UK trial would assess antibiotic resistance patterns, (3) consensus between ICU
colleagues was seen as important, suggesting that consensus building and development are key to
acceptance and participation and (4) a substantial proportion of clinicians would be prepared to
participate in a trial of SDD if their colleagues were in favour, suggesting that the presence of a SDD
‘champion’ in an ICU could inﬂuence participation.
4. Future trials should include (1) a primary mortality outcome, (2) pre-trial, during-trial and post-trial
monitoring of antimicrobial resistance, (3) a control group that includes chlorhexidine and/or VAP
bundles and (4) a cost–beneﬁt analysis, and (5) a qualitative study to investigate the ﬁdelity of the SDD
intervention as delivered.
5. Groups proposing to undertake such a trial need to overcome the following challenges: (1) gaining
sufﬁcient acceptance of the trial, (2) gaining adequate participation in the trial, (3) the clear
speciﬁcation of the trial intervention, (4) major methodological issues relating to trial design and
conduct, (5) clariﬁcation of the acceptability (to ethics committees) of cluster-level consent in the case
of a cluster RCT and (6) major funding issues.
6. At this time, there is a much lower level of interest in adoption of SDD, or studies designed to
encourage implementation of SDD, into practice.
Funding
This project was funded by the NIHR Health Technology Assessment programme and will be published in
full in Health Technology Assessment; Vol. 18, No. 25. See the NIHR Journals Library website for further
project information.
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Chapter 1 Introduction
Each year in the UK, 140,000 patients are admitted to intensive care and, of these, almost 60,000 willdie within a year of admission.1 Hospital-acquired infections (HAIs) are a major clinical problem for
modern health services. Critically ill patients requiring intensive care unit (ICU) care are extremely
susceptible to HAIs and these infections are associated with high additional mortality, prolonged hospital
stays and large health-care resource utilisation. Between 20% and 50% of ICU patients suffer from such
infections. Reducing the incidence and mortality from HAIs is currently the focus of many intensive care
quality improvement programmes and government initiatives in the UK and worldwide.2,3
One intervention that has gained much attention in reducing HAIs is selective decontamination of the
digestive tract (SDD). SDD involves the application of topical non-absorbable antibiotics to the oropharynx
and stomach and a short course of intravenous (i.v.) antibiotics.4 The evidence base relating to SDD is
reasonably strong, with the recent Cochrane review reporting a beneﬁt in terms of reducing pneumonia
rates.4 A recent large cluster randomised study from the Netherlands enrolling an impressive 5939 patients
demonstrated a 3.5% reduction in adjusted mortality with SDD, although the conclusion remains
controversial and the authors concede that ‘since our study was performed in Dutch ICUs with a low
prevalence of antibiotic resistance, our ﬁndings may not be applicable to settings with a markedly different
bacterial ecology or different practices for preventing ventilator-associated pneumonia’.5
In the Cochrane review, clinical heterogeneity is a problem potentially resulting from combining studies
using both topical [which, when used on their own in the absence of systemic (i.v.) antibiotics, is called
selective oral decontamination (SOD)] and topical plus systemic antimicrobials in the same analyses.
Included studies suffered from several methodological ﬂaws including lack of blinding, lack of data on
compliance with intervention, mixing of studies of diverse patient groups, only including subgroups or no
description of studies included.4 The Cochrane review demonstrated that SDD was associated with
reduction in pneumonia [odds ratio (OR) 0.32; 95% conﬁdence interval (CI) 0.26 to 0.38] and death
(OR 0.75; 95% CI 0.65 to 0.87).4 Since the Cochrane review, additional primary research has been
published, which also showed a mortality beneﬁt (OR 0.63; 95% CI 0.46 to 0.87).5,6 However, a degree
of controversy exists, with Hurley et al.7 challenging that, across these studies, the incidence of
ventilator-associated pneumonia (VAP) at baseline was signiﬁcantly lower in the ventilated control groups
than in the SDD groups, which could falsely give the impression of beneﬁt.8 Nonetheless, if the
documented mortality beneﬁt could be realised in UK practice, then it could prevent as many as
2000–3000 avoidable deaths per annum.
Despite this evidence base, the UK ICU community has not widely adopted this intervention, with only
10–15 ICUs out of 240 reporting that they undertake SDD.9,10 Existing practice surveys and our preliminary
investigations as to why this strategy has not been fully adopted suggest three possibilities:9,10
1. Provision of prophylactic broad-spectrum antibiotics to critically ill patients may be counterintuitive to
the principles of antibiotic stewardship whereby clinicians are encouraged to use antibiotics in a rational
and sparing way to prevent the development of multiresistant organisms.11–14
2. The current evidence base is inadequate in two ways.9,10 First, there is a perception that the magnitude
of the reported mortality beneﬁt is not biologically plausible for such an intervention. Second, there is
concern about the external validity and generalisability of the evidence. Most of the existing SDD trials
have been conducted in countries where infections due to multiresistant Gram-positive organisms are
uncommon and the incidence of multiresistant organisms, such as methicillin-resistant Staphylococcus
aureus (MRSA), is low. Patterns of Gram-negative resistance are also different between the UK and the
Netherlands, the country with the greatest evidence base for SDD. Hence, clinicians who take an
evidence-based stance may come to radically different conclusions about SDD because they may doubt
the validity or the applicability of the evidence that suggests clinical beneﬁt.
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3. It is a common perception that implementation is difﬁcult in practice as SDD is time-consuming
and difﬁcult to administer, although this may be a secondary point compared with the reasons
outlined above.10
However, these simple surveys fail to fully dissect the complex issues related to SDD use in the UK
or internationally.
Many clinicians argue that existing evidence should be replicated in health-care systems in which infections
due to multiresistant organisms are common and the incidence of multiresistant organisms such as MRSA
and Clostridium difficile is comparatively high, such as in the UK. Furthermore, they argue that no existing
study has included parallel high-quality infection surveillance programmes to study the long-term effects of
SDD on the microbial ecology of the ICU. This may be the single most important weakness of the current
evidence base and has brought about appropriate caution with the use of SDD. There is also the potential
that clinicians believe that with the widespread use of chlorhexidine, especially for ventilated patients,
coupled with the broad adoption of care bundles aimed at preventing VAP, there now may be no need for
SDD. Existing data on the ecological impact of SDD are indeed limited, with some studies suggesting an
increase in the incidence of Gram-positive organisms such as S. aureus and others failing to show such
effects.5,15–17 In addition, it is possible that SDD is so counterintuitive to existing views on antibiotic use that
clinicians will not change their practice regardless of the evidence base or that one clinician group may
prevent others in favour of the intervention from implementing it. For example, Silvestri et al. argue that
‘the longstanding disagreement amongst opinion leaders, with the predominance of detractors on those
who advocate SDD, is an important factor contributing to the confusion’.18 Other writers have called for
immediate implementation of SDD into routine practice. For example, Zandstra et al. argue that
‘withholding SDD is now ethically questionable given the vast body of evidence on the technique reducing
severe infections and mortality, requiring less antibiotic use, and providing less resistance’.19
In summary, despite the limited surveys undertaken to date, little systematic evidence is available about
clinicians’ beliefs regarding the existing evidence base, perceived beneﬁts and risks of SDD in clinical
practice, factors that inﬂuence current practice and the likely barriers to implementation. In addition, it is
unclear whether or not further high-level evidence of clinical effectiveness and ecological impact of SDD
from within the UK is required before implementation would become acceptable and what sort of study
would be feasible and acceptable to clinicians and triallists.
The multimethod exploratory study reported here attempted to address these issues. It investigated the
perspectives of a wide range of stakeholders in multiple settings, using a mixed-methods approach that
combined observational, interview and questionnaire data analysed both qualitatively and quantitatively.
To facilitate a robust approach informed by previous research and focused on the views and actions of
health-care professionals, we used the theoretical domains framework (TDF) of health professional
behaviour change to inform our programme of research.20 It has a good ﬁt with the kinds of issues that
health-care providers consider when making clinical decisions and has been used in > 20 studies of
health-care professional behaviour.21 This framework enables systematic identiﬁcation of a wide range of
potential barriers to changing clinical practice. The TDF is elaborated and exempliﬁed in Chapter 3. The
results of this research programme thus reﬂect a comprehensive, theoretically robust and multifaceted
evidence base to inform a decision about the kind of research that is needed to address the SDD issue.
A recent National Institute for Health and Care Excellence (NICE) and National Patient Safety Agency
(NPSA) pilot study on patient safety made a strong research recommendation that SDD be subject to study
including investigation of barriers to implementation.22 The current clinical focus on HAIs, the move to
making HAIs a key target of patient safety initiatives, the political prioritisation of HAIs and increased
interest in this subject from research funding bodies indicated that this research was timely. The study
[known as the selective decontamination of the digestive tract in intensive care units (SuDDICU) study] was
also formally adopted and ﬁnancially supported by the Intensive Care Foundation as one of its new UK
National research studies. This highlights the importance of this question to the UK ICU community.
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The variable uptake in SDD is also apparent in other countries outside of the UK, for example in Canada,
Australia and New Zealand, where no ICUs currently deliver SDD. Reﬂecting the international importance
of the topic, partner teams in Canada and in Australia and New Zealand also acquired funding to
undertake parallel investigations (using the SuDDICU protocol) into the reasons for low uptake in these
countries. These partner projects were each designed to stand independently (and were funded
independently), but add to the generalisability of the UK study ﬁndings.
Research objectives and research questions
The overall aim of the SuDDICU study was to identify the perceived risks, beneﬁts and barriers to the use
of SDD in UK ICUs to inform recommendations for further research.
The investigation involved four inter-related stages (expanded further in Chapters 2–6) and culminated in
an assessment of the need for – and acceptability of – an effectiveness trial, an implementation trial or
further exploratory observational research. Figure 1 provides a linear representation of the four-stage study
design and the associated objectives and research questions. It was our intention that the evidence from
this investigation would then form the basis on which to design a trial or other study and to specify the
intervention to be evaluated or, for an implementation trial, to develop the intervention to be evaluated.
Reﬂecting the different stages of the research (as outlined in Figure 1), the results of the case studies are
presented in Chapter 2, the results of the Delphi study are presented in Chapters 3 and 4, the results of
the national survey are presented in Chapter 5 and the triallist interview data are presented in Chapter 6.
In Chapter 7, the implications of the study as a whole are discussed, together with a summary of the
implications for practice and for future research.
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STAGE 2 (see Chapters 3 and 4):
Delphi study
Objective: To identify the range of beliefs, interpretation and views about the current evidence
base relating to the use of SDD in key stakeholder groups.
What are the views of key stakeholders of the internal/external validity and
adequacy of the existing evidence base for SDD, and how willing are they to participate
in further research?
RQ3:
RQ4:
RQ5:
What are the views of key stakeholders about the likely positive and negative
consequences of implementing SDD in ICUs?
What are the views of key stakeholders about the likely barriers to implementing SDD
in ICUs?
STAGE 3 (see Chapter 5):
Nationwide survey of current practice
Objective: To identify current practice and assess the acceptability of further randomised
controlled trials in the field of SDD in a wide group of intensive care consultants and 
clinical microbiologists
What are the stated current practices and intentions of intensive care consultants and
clinical microbiologists with responsibility for critically ill patients about SDD?
RQ6:
RQ7: If there are uncertainties in the evidence base, do these clinicians believe they
could be addressed in a clinical trial; what research questions, trial design(s) and
interventions would be optimal; and what predicts these beliefs? 
RQ8:
STAGE 4 (see Chapter 6):
Semistructured interviews with active clinical trialists
Objective: To assess the feasibility of a proposed effectiveness RCT comparing SDD against a
control group in ICUs, or a proposed implementation study to increase uptake in ICUs, among
international clinical triallists
What are the likely challenges in undertaking a large multinational randomised
controlled study of SDD in ICU?
Integration of findings, general conclusions and recommendations (see Chapter 7)
Conclusion 1: Summary of the perceived risks, benefits and barriers to the use of SDD in UK
intensive care units
Conclusion 2: Application of a priori decision rules to identify the need for, and acceptability
of, a SDD effectiveness trial, or a SDD implementation trial, or further exploratory or
observational research
Case studies of units in which SDD has already been adopted
STAGE 1 (see Chapter 2):
Objective: To identify and describe the clinical intervention in ICUs and hospitals that deliver SDD
RQ1: What are the components of the SDD intervention?
RQ2: How has SDD been implemented and delivered into practice?
FIGURE 1 Design of exploratory study showing links to research questions. RQ, research question.
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Chapter 2 Case studies to identify and precisely
describe the clinical intervention in units and
hospitals that deliver selective decontamination of the
digestive tract
Background
Some of the uncertainty around the evidence relating to SDD may be associated with changes in the way
SDD is speciﬁed in trial literature over time. A recent systematic Cochrane review noted that trials used
different SDD protocols and investigators use different deﬁnitions for SDD.4 Furthermore, some critics have
proposed that SDD is difﬁcult to deliver in practice.10 Hence, before commencing a study to investigate
clinicians’ views of SDD, it was important to be clear about its current speciﬁcation and delivery in the UK
practice setting. To this end, an observational study was conducted in two ICUs delivering SDD, to identify
the similarities and differences in terms of the clinical and behavioural components (i.e. delivery features)
of this intervention. Such speciﬁcation would have implications for future research, but a more immediate
objective was to ensure that all stages of this study were investigating SDD, based on an explicit and
consistent deﬁnition. Thus, this study sought to address the following research questions:
Research question 1: What are the components of the SDD intervention?
Research question 2: How has SDD been implemented and delivered into practice?
At a more general level, health-care interventions are typically complex23 and involve two broad interacting
categories of components: (1) clinical components, i.e. the clinical materials or equipment of the
intervention and related features and (2) behavioural components, i.e. the actual behaviours required to
deliver the intervention in practice. Health-care interventions are often speciﬁed clinically without explicitly
addressing behavioural components.24,25 Thus, interventions may be implemented differently across sites,
potentially leading to variable effectiveness and resultant consequences for patient outcomes. The need to
fully specify health-care interventions has been widely recognised, together with the need to report
interventions in such a way as they could be directly replicated by others.26
As described in Chapter 1, SDD is a complex intervention that has been shown to reduce HAI rates and
mortality in critically ill patients.4,5,27 SDD involves the application of antibiotics and antifungals to the
mouth, throat and stomach combined with a short course of i.v. antibiotics.28 Despite considerable
evidence supporting the beneﬁt of SDD,4,5,27 adoption internationally is low.9,10 Among proposed reasons
for this lack of adoption are controversies surrounding prophylactic use of antibiotics and associated risk of
antibiotic resistance,29,30 and purported difﬁculty of SDD implementation and delivery.31
In addition to the variation in the clinical components of SDD described in trials and used in clinical
practice, behavioural components of SDD have not been systematically outlined in the empirical literature.
A fully speciﬁed protocol describing both clinical and behavioural components of SDD implementation and
delivery does not exist but could facilitate both widespread adoption and future implementation trials.
Hence, this study sought to characterise the clinical and behavioural components of SDD as implemented
in clinical practice.
DOI: 10.3310/hta18250 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 25
5
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Methods
Case study methodology32 was used in two UK ICUs routinely delivering SDD, with the ‘case’ (unit of
analysis) consisting of an ICU. Data were collected from three sources: direct observation of SDD delivery at
the bedside, face-to-face semistructured interviews with clinicians responsible for implementing and/or
delivering SDD, and systematic assessment of written documentation (e.g. SDD protocols, training
documents). The use of multiple data sources in case study research is considered to be one of its
methodological strengths.32 The chosen data sources were consistent with those commonly used in case
studies and enabled triangulation for exploring the features of SDD delivery and implementation in context.32
Sample
All UK ICUs delivering SDD, identiﬁed from a recent national SDD survey9 or known by the study
investigators to deliver SDD, were deemed eligible for inclusion (15 ICUs). Two ICUs were purposively
selected to represent different lengths of time since SDD adoption (one had adopted SDD < 5 years earlier
and the other had adopted SDD > 5 years earlier) and different geographical locations (i.e. geographically
dispersed ICUs to ensure different organisational proﬁles). Clinicians from different professions
(i.e. intensive care consultants, clinical microbiologists, specialist clinical pharmacists and ICU nurses) have
responsibility for the implementation and/or delivery of SDD. In each of the case study ICUs, all clinicians
with potential involvement in the implementation and/or delivery of SDD were eligible for interview.
From these, we recruited a purposive sample of clinicians from different professions.33 Not all eligible
clinicians were interviewed owing to lack of availability or time. Purposive sampling was appropriate
for this small-scale exploratory qualitative study and the sample was not intended to be
statistically representative.33
Data collection
Direct observation offers the opportunity to record and analyse clinical behaviours and interactions as
they occur in ‘real world’ contexts.34 The use of direct observation as a data source allowed the process of
SDD delivery to be ‘seen’ through the eyes of the researcher. Observations were conducted using an
investigator-designed form to record all behaviours relating to ‘real time’ delivery of SDD. Additionally, the
context (i.e. the physical environment where behaviours were performed), timing of procedures and
physical presence of clinicians at time of delivery were recorded (see Appendix 1).
Semi-structured face-to-face clinician interviews were conducted in the study hospitals using a topic guide
with prespeciﬁed prompts to ensure consistent coverage of key issues including behaviours relating
to SDD implementation and SDD delivery as well as barriers and facilitators of described behaviours1
(see Appendix 1).
Finally, all written documentation relating to SDD implementation and delivery (e.g. SDD protocols,
training documents) was provided by the participating ICUs for systematic analysis. This documentary
information provided an unobtrusive and veriﬁable data source, which augmented and corroborated
information from interviews and observations. The presence of relevant documents was established during
the interviews. After the interviews, these documents were obtained.
Procedure
Data collection commenced with observation of SDD delivery performed by various ICU nurses to
different patients at the bedside. A single researcher (SUD) visited the ICUs for 2 (case study 1) or 3 days
(case study 2). Observation opportunities were identiﬁed by senior ICU nurses (i.e. they informed the
researcher when and to whom SDD would be delivered). The number of patients eligible for, and receiving,
SDD varied from day to day; therefore, it was not possible to prespecify the number of direct observations
of SDD delivery that would occur during SUD’s visit. Semi-structured interviews were conducted in parallel
with observations. Observed nurses were included in the interview sample to gain an in-depth
understanding of observed behaviours. With participants’ permission, interviews were audio recorded,
transcribed verbatim and anonymised. All observations and interviews were conducted by SUD. Written
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documentation from each ICU was examined (by SUD) following completion of all observations and
interviews, in order to minimise researcher bias during these stages.
The written documentation was examined to identify clinical and behavioural components of SDD delivery.
Clinical components were deﬁned as the pharmaceutical regimens forming part of SDD including drug,
dose, route, frequency and duration. Behavioural components were deﬁned as any actions that were/
would be directly observable. We recorded the behaviours involved in delivering clinical components and
those not related speciﬁcally to drug administration.
Data management and analysis
Data from the three sources were analysed within case to describe the clinical and behavioural SDD
components, and synthesised across case to identify emergent themes describing SDD implementation and
delivery in context. The analytical process was guided by the study aims, which included identiﬁcation of
SDD clinical and behavioural components and exploration of SDD implementation and delivery.
The three data sources were analysed separately within ICUs and in reverse order to data collection. First,
we systematically examined written documentation and extracted clinical and behavioural components of
SDD delivery. Second, we performed content analysis35 of interview transcripts to identify additional
behaviours involved in SDD delivery (i.e. those not speciﬁed in the documents). Third, direct observations
provided contextual ‘real time’ data32 and identiﬁed new and corroborative evidence on SDD clinical and
behavioural components (i.e. data triangulation from multiple sources).32
To identify features of SDD implementation and delivery across ICUs, a thematic analysis of the interview
data was conducted using a framework approach.36 This approach involves ﬁve stages: (1) familiarisation
with the raw data, (2) identiﬁcation of emergent themes associated with SDD implementation and delivery
(i.e. relating to the behaviours and clinician groups involved), (3) systematic coding/indexing of all data
relevant to each theme within each transcript, (4) creating charts (Microsoft Word tables) that contain the
coded data for each theme and distilled summaries of views and experiences, and (5) interpretation of the
data (e.g. identifying associations between themes and providing explanations for the ﬁndings).36 A single
researcher (SUD) conducted the thematic analysis, a second researcher (EMD) independently coded
randomly selected portions of the data set to identify clinical and behavioural components and three
researchers (MEP, JJF, LR) provided critical comments on analyses drafts.
This study was classiﬁed as service evaluation by the Research Ethics Committee (10/MRE00/32) and,
therefore, was deemed by them not to require ethical approval. All participants who were observed and
interviewed were aware of the study purpose and provided verbal consent prior to data collection.
Results
Case 1 implemented SDD 3.5 years prior to this study in response to increased HAI rates. Collected data
comprised four observations, eight interviews [intensive care consultants (n = 3), nurses (n = 3), clinical
microbiologists (n = 1) and pharmacists (n = 1)] and three SDD documents (protocol, prescription chart,
training slides). Case 2 implemented SDD as part of a clinical effectiveness trial 26 years prior to this study.
Interview data identiﬁed that the rationale for continued use of SDD was its perceived effectiveness.
Collected data comprised three observations, eight interviews [intensive care consultants (n = 3), nurses
(n = 3) and pharmacists (n = 2)] and one document (protocol).
Selective decontamination of the digestive tract clinical and
behavioural components
Protocols documenting the speciﬁc clinical behaviours required for drug preparation and administration in
the two ICUs are detailed in Table 1, demonstrating the degree of clinical complexity and also the variation
encountered in clinical aspects of SDD. The documents identiﬁed in the interviews and subsequently
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TABLE 1 Protocolised or documented clinical components and behaviours involved in delivery of SDD medications in the two ICUs
Drugs Dose Route Frequency Behaviours (what) Directions (how)
Frequency/duration
(when)
Case study 1
Cefuroxime 1.5 g (six doses)
over 3–5 minutes
i.v. 8-hourly Prepare drug,
administer drug
Dilute 1.5 g in 15ml of water for
injection. Administer intravenously
over 3–5 minutes
Immediately after obtaining
all admission surveillance and
diagnostic microbiological
samples and then at 8-hourly
intervals
Ciproﬂoxacin (if allergic to
cefuroxime)
400mg (four
doses) over 60
minutes
i.v. 12-hourly Prepare drug,
administer drug
Administer 400mg intravenously
over 60 minutes
Immediately after obtaining
all admission surveillance and
diagnostic microbiological
samples and then at
12-hourly intervals
Nystatin 100,000 units/ml Oral and gastric
tube
8-hourly Prepare drug,
administer drug
Administer 5 ml topically to mouth
and 5ml via gastric tube. Use a
new 30-ml bottle every 24 hours.
If the tube in the stomach is
draining freely into a drainage bag,
ﬂush tube with 20ml sterile
water and clamp for 30 minutes
after administration of
antibiotics/antifungals
Three times daily after oral
hygiene regimen
Vancomycin 500mg Oral and gastric
tube
6-hourly
a
Prepare drug,
administer drug
Reconstitute a 500-mg vial with
10ml water for injections and
administer 250mg into the mouth
and 250mg via gastric tube
Four times daily after oral
hygiene regimen
Colistin sulphate 250,000 units/ml Oral and gastric
tube
6-hourly
a
Prepare drug,
administer drug
Reconstitute a vial (licensed for
injection) of 1,000,000 units with
0.9% sodium chloride (NaCl). Dilute
the reconstituted vial to a total of
40ml with NaCl 0.9%. This solution
may be kept at the bed space for
24 hours. Administer 5ml
(125,000 units) of this solution into
the mouth and 5ml via gastric tube
Four times daily after oral
hygiene regimen
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Drugs Dose Route Frequency Behaviours (what) Directions (how)
Frequency/duration
(when)
Tobramycin 80mg Oral and gastric
tube
6-hourlya Prepare drug,
administer drug
Dilute one ampoule of 80mg
(licensed for injection) in 10ml NaCl
0.9%. Give 5ml (40mg) into mouth
and 5ml (40mg) by gastric tube
Four times daily after oral
hygiene regimen
Chlorhexidine
gluconate; 4% liquid
soap
15ml Topical 12-hourly Administer body
wash
Use 15ml for body wash with
water
Twice daily
Chlorhexidine
gluconate; 0.2%
mouthwash
10ml Topical 6-hourly
a
Administer
mouthwash
Not to be swallowed. Apply with
pink sponge stick to teeth, gums,
tongue and lining of the mouth as
part of thorough mouth care
Twice daily before each
application of topical
antibiotics
Case study 2
Cefotaxime 1 g i.v. 8-hourly Prepare drug,
administer drug
Administer 1 g intravenously Within 4 hours of admission.
Administer ﬁrst does prior to
intubation and other invasive
ITU procedures
Three times daily only for ﬁrst
4 days of ITU admission
Tobramycin, colistin
sulphate, amphotericin B,
prepared by pharmacy
manufacturing unit
2% w/w of each
constituent
Topical 6-hourly
a
Administer gel to
oropharynx
Apply gel to palate and buccal
surfaces
Within 4 hours of admission.
Four times daily for duration
of ITU admission until
discharge
Tobramycin 27mg/ml
liquidb
80mg Nasogastric tube 6-hourly
a
Administer solution/
suspension
Deliver solution/suspension via
nasogastric tube
Four times daily for duration
of ITU admission
Colistimethate sodium
(colistin) 50mg/ml
liquidb
100mg Nasogastric tube 6-hourly
a
Administer solution/
suspension
Deliver solution/suspension via
nasogastric tube
Four times daily for duration
of ITU admission
Amphotericin B
100mg/ml liquidb
500mg Nasogastric tube 6-hourlya Administer solution/
suspension
Deliver solution/suspension via
nasogastric tube
Four times daily for duration
of ITU admission
ITU, intensive therapy unit.
a Components typically administered at the same time as each other.
b Prepared separately by local pharmacy manufacturing unit and drawn up by the nurse together into an oral syringe, prior to administration.
D
O
I:
1
0
.3
3
1
0
/h
ta
1
8
2
5
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
4
V
O
L.
1
8
N
O
.
2
5
9
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
4
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
Fra
n
cis
et
al.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
analysed listed nine different medications and a total of 13 different preparations as part of SDD in the
two case studies (see Table 1). Several behaviours directly relevant for drug administration were identiﬁed
in examined documentation.
Aside from clinical and behavioural components directly relevant to SDD delivery, documents from both
cases revealed several additional delivery behaviours performed by multiple clinicians in various clinical and
environmental contexts (Table 2). To complement understanding of behavioural components that are
important in SDD, but not speciﬁcally mentioned in the examined documentation, Table 3 outlines additional
delivery behaviours identiﬁed through interviews and observations. Behaviours outlined in Tables 2 and 3
were performed by various clinician groups (e.g. nurses, physicians, pharmacists) in a variety of clinical and
environmental contexts (e.g. bedside, ICU nursing stations, pharmacy).
Participant interviews provided most data relating to behavioural components, 49 components were
identiﬁed through interviews, 22 through documentation and 12 through observations. Each data source
gave rise to unique behaviours not mentioned in other sources (28, seven and four unique behavioural
components for interviews, documentation and observations, respectively), conﬁrming the added value of
analysing multiple information sources. The number of unique behavioural components was 29
(case study 1) and nine (case study 2). Twenty-six behavioural components were common across ICUs,
being identiﬁed in at least one data source for each case.
Selective decontamination of the digestive tract implementation and delivery
Based on our analysis, SDD implementation and delivery was conceptualised as a complex procedure
consisting of four overlapping processes, each involving speciﬁc behaviours: adoption, operationalisation,
provision and surveillance. Adoption concerned the decision to introduce SDD; operationalisation referred
to the processes required to introduce SDD into clinical practice; SDD provision included actions involved in
delivery of the clinical components; and surveillance, mentioned in both case studies, provided the
foundation for adoption, operationalisation and provision by checking that SDD was effective in
preventing infection.
TABLE 2 Documented behaviours for delivery of SDD not related speciﬁcally to drug administration
Behaviour Professional group Context CS1 CS2
Clarifying SDD regimen
(in ambiguous cases)
Nurse, intensivist, pharmacist,
clinical microbiologist
ICU and bedside ✓ ✓
Authorise SDD delivery Intensivist, pharmacist ICU (admission)
and bedside
✓
Prompt SDD authorisation Nurse ICU (admission)
and bedside
✓
Judging SDD delivery in unclear cases Intensivist ICU (admission)
and bedside
✓
Documenting SDD delivery Nurse ICU and bedside ✓
Discarding of antibiotics
(when out of date)
Nurse Bedside ✓
Storing reusable antibiotics Nurse ICU and bedside ✓
Labelling leftover antibiotics/antifungals Nurse ICU and bedside ✓
Check SDD is continued and operating Intensivist, pharmacist ICU, bedside ✓
✓, identiﬁed within the case study; CS1, case study site 1; CS2, case study site 2.
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Adoption and operationalisation
For adoption, we identiﬁed that actions often occurred at the organisational and team level involving
organisational and group processes as well as individual action. As the implementation process moved
from adoption to operationalisation, more behaviours emerged that were performed by individual staff
(see Tables 2 and 3). Although operationalisation was complete following SDD introduction, elements of
operationalisation continued owing to clinician staff turnover (e.g. although SDD was a standard
procedure within the ICUs, the low national baseline adoption meant that additional training for clinicians
new to these ICUs and SDD delivery was required).
Provision of selective decontamination of the digestive tract
Three themes emerged from the interviews on SDD provision: complexity/difﬁculty, protocol adaptation
in practice, and facilitators and barriers.
TABLE 3 Additional behaviours of SDD delivery identiﬁed in interviews and observations but not in written
protocols or procedures
Behavioural Professional group Context CS1 CS2
Check patient eligibility for SDD Intensivist, pharmacist ICU (admission)
and bedside
✓
a
✓
a
Review and optimise SDD delivery Intensivist, pharmacist,
clinical microbiologist
ICU, bedside ✓
a
✓
a
Attend ward rounds (at which SDD is discussed) Intensivist, pharmacist,
clinical microbiologist
ICU, bedside ✓
a
✓
a
Dispose of SDD waste Nurse Bedside ✓a
,b
✓
b
Order SDD drugs from pharmacy Nurse ICU ✓
a
✓
a
Reassure patient/patient visitors before/during
SDD administration
Nurse Bedside ✓b ✓
a,b
Reposition patient for SDD administration Nurse Bedside ✓b ✓b
Decision to discontinue SDD drugs Intensivist, pharmacist ICU and bedside ✓
a
✓
a
Print SDD documentation Ward clerk ICU ✓
a
Monitor for SDD drug reactions Intensivist, pharmacist Bedside ✓
a
Check stock and supply SDD drugs Pharmacy technician ICU ✓
a
Order SDD drugs from suppliers Pharmacy technician ICU ✓
a
Describe SDD during shift communication Nurse ICU and bedside ✓a
Handling contraindications Nurse Bedside ✓b
Collecting SDD drugs Nurse ICU and bedside ✓
a,b
Preparation of antibiotics Pharmacist Production unit2 ✓
a
Order raw materials Pharmacist Analytic lab2 ✓
a
Check of antibiotic quality Pharmacist Quality Assurance
Department2
✓
a
Liaise with pharmacy production unit Pharmacist ICU ✓
a
Check naso/orogastric aspirate Nurse Bedside ✓
a,b
✓, identiﬁed within the case study; CS1, case study site 1; CS2, case study site 2.
a Identiﬁed through interview.
b Identiﬁed through observation.
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Complexity/difficulty
Reﬂecting the theme of complexity, one intensive care consultant and several nurses reported that SDD
provision represented additional and time-consuming work that made it unpopular with staff. When
examining the sequencing and ﬂow of actions, we identiﬁed evidence of complexity – multiple clinicians
were involved in managing various behaviours within multiple clinical and environmental contexts using
a range of materials delivered in speciﬁc sequences in a continuing ﬂow of action (see Box 1 for
quotations: P, participant). However, most nurses and doctors refuted the idea that SDD was complex
and time-consuming, stating that providing SDD was effortless (Box 1). Low complexity/difﬁculty of SDD
for these staff was supported by observational data indicating that administration of clinical components
took no longer than 5 minutes, often less, and was performed in a swift sequence of actions. However,
it is important to note that these were highly practised actions and may require considerable skill
development to achieve this high level of expertise.
BOX 1 Selected data on the level of difficulty/complexity of providing SDD (continued)
Supporting difﬁculty of providing SDD:
. . . there is extra work, four times a day . . .
P1
. . . it’s relatively unpopular with most of the nursing staff [. . .] because they see it as excess workload.
P10
. . . delivery [. . .] can be difficult.
P5
It only takes five/ten minutes, although that is another five/ten minutes added on to the other five/ten
minutes for everything else that you have to do.
P7
Not supporting difﬁculty of providing SDD:
. . . it’s a part of your routine already so I don’t find it difficult, it’s just finding ways of how to do it,
I mean it’s not too difficult.
P6
[SDD provision] is really straightforward.
P7
. . . very simple [. . .], a fairly straight forward thing to do.
P3
. . . the main message to take across is that it’s, it works well. It is very easy to do.
P13
I don’t find it difficult.
P14
It is not that hard. It is really straightforward.
P15
CASE STUDIES TO IDENTIFY AND PRECISELY DESCRIBE THE CLINICAL INTERVENTION
12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Protocol adaptation in practice
Protocol adaptation in SDD delivery was noted in observational and interview data. Preparation of
antibiotics/antifungals varied, suggesting some deviation from recommended practice. Further adaptation
was evident in the provision of SDD oral components such as different ways of applying oral drug
components and timing with other nursing interventions such as oral hygiene. Authorising SDD involved
multiple staff and deviation from recommended practice was noted. Although documentation indicated
that patients should be routinely commenced on SDD, this did not always occur, owing to more
pressing clinical concerns. As a result, multiple layers of control to ensure protocol adherence were
described (Box 2).
BOX 2 Protocol adaptation in practice
. . . although it says the dose is 500 mg I have been taught, in order to better manage my time, that I
use [a] 1 g bottle instead and instead of reconstituting it with 10 ml I reconstitute it with 20 ml.
P5
‘I have different ways [. . .] because there are a lot of antibiotics’ and he/she did not ‘know if it’s a good
thing to mix all 4 antibiotics in one go and put them orally in one go also’ and that ‘. . . others might do
it differently’.
P14
. . . it sometimes slips off the main agenda of the patient’s day . . .
P8
I would ensure that all the relevant people get SDD.
P17
I just make sure it is being put on.
P11
. . . if they haven’t prescribed it, I’ll ask them to prescribe.
P14
Supporting complexity of providing SDD:
[Overall, SDD delivery] involves a large amount of co-operation between the microbiologists, the
nursing staff and the medical staff to [. . .] maintain an appropriate antibiotic policy; it also involves [. . .]
quite a lot of monitoring of what is involved with the patients [. . .] so that we can manage the
infections appropriately [. . .] it involves applying some paste and some nasogastric SDD, but these are
relatively minor parts of the whole. It is a system of which that is part.
P11
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Facilitators and barriers
Facilitators and barriers to SDD delivery were evident across both cases (Box 3). One facilitating factor
frequently reported was dovetailing of SDD with other established and routine procedures. Thus, intensive
care consultants might include SDD delivery behaviours as part of the admission process, nurses might
include SDD as part of oral hygiene or other activities and clinical microbiologists and pharmacists
dovetailed SDD actions within ward rounds. Dovetailing was evident in multiple interviews and in
documentary data on SDD provision for oral hygiene. Although barriers were commonly reported during
interviews in response to speciﬁc prompts, these were often referred to as minor inconveniences, rather
than signiﬁcant obstacles to SDD delivery (see Box 3).
Infection surveillance
A fourth theme emerged from the documentary analysis. Surveillance was speciﬁed in the SDD protocol in
one of the case study sites, but not in the other, in which it was part of the wider regimen to combat
HAIs. Despite these differences, surveillance was integral to the provision of SDD and included the
performance of multiple behaviours of various clinicians in several clinical and environmental contexts.
Discussion
In line with frameworks for intervention development23 and description,26 this study has speciﬁed
(for the ﬁrst time) the full clinical and behavioural components of SDD and has described how they
impact on SDD implementation and delivery. There are several advantages of specifying an intervention
behaviourally alongside clinical speciﬁcations. First, it demonstrates procedural complexity and the
situations in which complexity may be experienced. This information has direct relevance to clinicians and
hospital decision-makers considering implementation of particular health-care interventions. It also can
inform the scale and content of implementation strategies to facilitate diffusion and adoption within
speciﬁc contexts.37 Second, behavioural speciﬁcation identiﬁes potential areas where behavioural variation
in practice may occur and, thus, allows prior speciﬁcation of acceptable limits of protocol adaptation.
Third, it may identify training needs to facilitate adherence to an expected standard. Fourth, behaviour
BOX 3 Facilitators and barriers reported to influence SDD implementation and delivery
Facilitators
l Policies and protocols, e.g. ‘We have an admission policy, so [patients] come in and we have a set of
investigations and [. . .] they’ll get SDD and [. . .] that’s just part of the admission’ [P10].
l Patient state, e.g. ‘patient is deeply sedated, it’s easier’ [P1].
l Perceived effectiveness, e.g. ‘the fact that you have a very few incidents of pneumonia’ [P17].
l Colleague support, e.g. ‘if you’re working side by side with a nurse, that nurse will help you’ [P5].
l Dovetailing, e.g. ‘you just tag it on with your aspirating stomachs’ [P15].
Barriers
l Workload, e.g. ‘When it’s a really busy day then it gets a lot to do’ [P5].
l Patient state, e.g. ‘if they’re intubated and they’re just maybe biting’ [P6].
l Side effects, e.g. ‘patients tend to get more diarrhoea when they are [on] SDD’ [P1].
l Staff changes, e.g. ‘losing a senior microbiologist was a stress, he was very supportive’ [P10].
l Cost, e.g. ‘The main challenges are the cost. The drugs themselves cost a lot of money’ [P10].
l Materials, e.g. ‘there’s been a few supply problems over the last couple of years. Sometimes [. . .] there
can be national shortages which can be a bit of a problem’ [P16].
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speciﬁcation facilitates precision in protocols and training materials by describing who should do what and
when and where this should occur.
Answers to research questions
We found variation in SDD clinical components, in terms of the drug regimen, mode of drug delivery and
speciﬁcation of components (i.e. surveillance) between the two study sites. This may be appropriate to
make the intervention simple and feasible to deliver within a local context. Various behaviours related
directly to drug provision as well as other aspects of the SDD intervention (e.g. authorisation of SDD
delivery) were performed by multiple clinicians in differing contexts. In terms of clinical components,
topical antibiotics/antifungals and i.v. antibiotics were identiﬁed as SDD components in documents, but
surveillance, general hygiene and general infection control regimen were not. Such inconsistency is also
identiﬁed in the literature.18 Both ICUs administered i.v. as well as topical/oral components. Overall, SDD
implementation and delivery comprised the interrelated phases of SDD adoption, operationalisation,
provision and surveillance.
Additional behaviours to those speciﬁed in documentation were identiﬁed and these behaviours are
essential for SDD delivery. SDD involved a range of health-care professionals performing various behaviours
in differing contexts. These ﬁndings emerged in the interview and observational evidence but were not
always clearly speciﬁed in the documentation. Ensuring that these additional behaviours are speciﬁed in
protocols, guidelines and the academic literature should lead to improvements in implementation, delivery
and reproducibility of SDD.24,25
Various behaviours were identiﬁed for SDD implementation, many at the organisational and team levels
and others at the individual level. Several features of operationalisation involved an ongoing process
(e.g. nurse training for SDD provision) as a result of staff turnover. SDD could thus be construed as a
simple and easy intervention from the individual behavioural perspective that becomes increasingly
complex when focusing on the ﬂow of actions required at an organisational level for its delivery in
practice. Consequently, some of the barriers and facilitators to SDD provision tended to centre on the
environmental context and resource issues, rather than speciﬁc attitudinal (e.g. beliefs about SDD
effectiveness) or skills barriers.
Strengths and limitations
The current study is the ﬁrst to systematically identify and specify a full range of SDD components
throughout the steps of SDD implementation and delivery. A limitation is the potential lack of
generalisability owing to the use of two cases only. Additional clinical and behavioural components, as
well as alternative methods of SDD implementation and delivery, may be evident if investigating SDD
practice in a larger number of ICUs. However, the study was exploratory in nature with the goal of
providing information-rich case studies that facilitate in-depth understanding of SDD in practice rather than
a comprehensive picture of SDD across all UK ICUs. We recruited one microbiologist only, limiting the
perspective from this profession. Finally, clinicians in ICUs that did not deliver SDD may have different
views about barriers to SDD implementation. This was investigated in subsequent stages of the study.
Conclusion
This study was the ﬁrst to provide a formal speciﬁcation of the full clinical and behavioural components of
SDD. We described a wide range of behaviours involved in delivering SDD, several of which were not
included in local SDD protocols. Signiﬁcant protocol adaptations resulting from these behaviours were
observed across sites, suggesting the need for routine behavioural speciﬁcation in SDD delivery protocols.
Such speciﬁcation would greatly facilitate the subsequent detection of acceptable variations and those that
may lead to signiﬁcant differences in patient outcomes.
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Key messages from the case studies are reported in Box 4. The ﬁndings of this study phase informed the
next stages of the current study in the following way. At the start of interviews or questionnaires that
sought clinicians’ views about SDD, we ﬁrst deﬁned the clinical components of the intervention. For
brevity, we did not specify the behavioural components; however, such speciﬁcations would be an
important aspect of future trial design.
BOX 4 Key messages from case studies
l Delivering selective decontamination of the digestive tract included more than the provision of clinical
components and involved multiple behaviours performed by multiple clinical team members.
l Not all behaviours relevant for SDD provision were speciﬁed in SDD documentation.
l SDD implementation included the interrelated phases of deciding whether or not to implement SDD
(adoption phase) and deciding how to implement SDD (operationalisation phase), with both phases
involving organisation-, team- and individual-level behaviours.
l There was some complexity in the interplay and ﬂow of the clinical and behavioural components of SDD,
involving multiple staff. However, provision of SDD was simple from the perspective of individual staff
and delivery was regarded as straightforward.
l Infection surveillance provided the foundation for SDD implementation and delivery, but may not be seen
as part of the SDD regimen itself.
CASE STUDIES TO IDENTIFY AND PRECISELY DESCRIBE THE CLINICAL INTERVENTION
16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Chapter 3 Delphi study to identify stakeholder
views about selective decontamination of the
digestive tract: round 1 interviews
Background
The second stage in the study was an in-depth investigation, using Delphi methods, of the views of key
stakeholders most likely to have decisional authority with respect to local SDD policy (i.e. those people
most likely to be involved in the decision to adopt SDD). This stage of the study was conducted in
collaboration with a multinational research team, with parallel studies being conducted in Canada,
Australia and New Zealand [funded by the Canadian Institutes of Health Research, Intensive Care
Foundation (Australia) and the Australian and New Zealand College of Anaesthetists Foundation].
The Delphi approach uses a structured, iterative process including anonymised feedback, in a series of
sequential questionnaires or ‘rounds’. The Delphi approach has been widely applied in health-care
research.38–40 Although the approach was originally designed to achieve expert consensus,41 it has
developed into a method that can also assess levels of agreement (or disagreement) within an expert
group.42,43 The objective of assessing consensus rather than achieving consensus was the goal of this study
phase and inﬂuenced a number of the design features.
The Delphi study was thus designed to generate iterative evidence about consensus and stability of views
about SDD and addressed the following research questions:
Research question 3: What are the views of key stakeholders of the internal/external validity and
adequacy of the existing evidence base for SDD and how willing are they to participate in
further research?
Research question 4:. What are the views of key stakeholders about the likely positive and negative
consequences of implementing SDD in ICUs and what is the relative importance of these beliefs in
inﬂuencing overall views about SDD?
Research question 5: What are the views of key stakeholders about the likely barriers to implementing
SDD in ICUs?
The Delphi study comprised an initial exploratory round involving interviews (reported in this chapter),
followed by two iterations (reported in Chapter 4) using items generated from interview data. Hence, the
ﬁrst Delphi round was used to generate round 2 items that represented the full range of views raised,
so that all could then be considered by participants in later rounds.1
Methods
The round 1 interviews were based on a topic guide (further details below) that was arranged in
three sections:
1. Asking about, and establishing, a deﬁnition of SDD (based on ﬁndings from the case studies).
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2. Asking about the likely consequences of delivering SDD and potential barriers to implementation.
This section was based on the TDF (see Table 4).20
3. Asking about participants’ willingness to participate in further research.
The TDF was developed to facilitate coverage of a full range of potential opinions about, and barriers to,
the use of health-care procedures.21 It was developed from 33 theories of individual and organisational
behaviour to assist researchers to identify constructs likely to inﬂuence health professionals’ behaviour.20
The framework proposes that determinants of health professionals’ behaviour cluster into 12 domains.
Each domain includes constructs from a number of behavioural theories that are potentially overlapping.
One domain of particular relevance to this study is labelled Beliefs about consequences, as it relates
directly to research question 4. Table 4 presents the labels and descriptions of the 12 TDF domains.
These descriptions were used to guide the data analysis.
TABLE 4 Domains from the TDF20 and their descriptions
Domain label Description
Behavioural regulation l Ways of doing things that relate to pursuing and achieving desired
goals, standards or targets
l Translating intention into action (e.g. at the individual level: action
planning, at the organisational level: regulatory frameworks)
Beliefs about capabilities l Self-efﬁcacy, perceived behavioural control, perceptions about
competence and conﬁdence in doing something
Beliefs about consequences l Perceptions about outcomes and advantages and disadvantages of
performing the behaviour
Emotion l Feelings, affect (positive or negative)
Environmental context/resources l Factors related to the setting in which the behaviour is performed (e.g.
people, organisational, cultural, political, physical and ﬁnancial factors)
Knowledge l Existing procedural knowledge, knowledge about guidelines,
knowledge about evidence
Memory, attention and decision processes l Attention control, decision-making, memory, i.e. is the target behaviour
problematic because people simply forget?
Motivation and goals l Priorities, importance, commitment to a certain course of actions or
behaviours
l Intentions
Nature of the behaviours l What is the person’s history of the behaviour, have they any experience
(done it often or not at all in the past), is the behaviour routine or
automatic?
Professional role and identity l Is this my job/responsibility or someone else’s?, when discussing ‘we’/
the collective, boundaries between professional groups
Skills l Competence, ability
Social inﬂuences l External pressure and inﬂuence from other people, views of other
professions, patients and families, doing what you are told
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Sample
A Delphi process gauges views from a panel of experts.44 Ideally, potential Delphi participants would thus
be experts in delivering SDD, or experts in terms of their knowledge of the SDD evidence base. Because of
the low SDD uptake in UK ICUs at the time of this study, restricting the study sample to those with direct
experience of SDD delivery or with a special interest in SDD research could systematically bias ﬁndings in
favour of SDD adoption and delivery. Therefore, we decided to deﬁne ‘expertise’ more broadly to include
the four stakeholder groups likely to exert decisional authority with regard to an ICU’s SDD policy or to
how such a policy would be implemented in practice. Hence, the participants for the Delphi study were
intensive care consultants, ICU pharmacists, clinical microbiologists with ICU responsibility and an ICU
leaders group (including medical leads, nurse managers and educators working in NHS hospitals
throughout the UK).
There is a broad range of estimates of suitable sizes for a Delphi panel, but smaller sizes (such as 10 for
each stakeholder group) have been deemed appropriate where panel members have similar training.45 Our
minimum target sample size was thus set at 40 (10 in each stakeholder group). We also sought participant
representation from across the four UK home nations.
Three clinical members of the research team (GB, APRW, RS) compiled lists of their clinician group and
ranked them according to predetermined diversity factors (location, ICU size, current SDD practice and
academic afﬁliation). A list of ICU nurse managers/educators was compiled by three members of the
research team (GB, BHC, MEP) and ranked for the above diversity factors. Study invitations were issued to
individuals according to rankings and in order of approvals made by the research and development (R&D)
ofﬁces of each participating hospital trust. Sample diversity was tracked during recruitment. Additional
participants from stakeholder lists (those working in NHS Trusts for which we had R&D approval) were
speciﬁcally targeted to maximise variation. To preserve a minimum sample size of 10 in each stakeholder
group by Delphi round 3, we oversampled by one to three participants in each of the four groups.
Data collection
At the start of each interview, to establish a shared understanding of SDD components, participants were
ﬁrst asked what they understood ‘selective decontamination of the digestive tract’ to mean. Irrespective of
their initial deﬁnition of SDD, participants were, for the remainder of the interview, asked to consider SDD
as application of antibiotics comprising all the following: (1) oral administration, to the mouth and throat,
(2) gastric application via a nasogastric tube or similar and (3) a short course of i.v. antibiotics. We then
asked whether or not SDD was delivered in the participant’s ICU. Responses to this second question
determined which of two topic guides was used for the remainder of the interview (‘ICU currently
delivering SDD’ or ‘ICU not currently delivering SDD’). Both topic guides are presented in Appendix 2 and
included questions about:
l factors that might inﬂuence adoption of SDD, such as participants’ views about the likely positive and
negative consequences of SDD and their knowledge of the evidence base
l participants’ views on the need for further research to settle questions around harms/beneﬁts of SDD,
what type of research [an effectiveness study or an implementation study (i.e. a study to evaluate
strategies to increase uptake of SDD)] would be most informative and whether or not further
effectiveness research on SDD was ethical
l whether participants would be willing to participate in an effectiveness study to evaluate SDD and/or
an implementation study to assess strategies that aim to increase uptake.
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Procedure
Potential participants from stakeholder groups were invited to take part by an investigator-signed e-mail
invitation (GB, APRW or RS). Expressions of interest were followed up with a short telephone call or e-mail
from the study co-ordinator to further describe the study, answer any questions and, if the participant
agreed to take part, arrange a convenient time for a 30-minute telephone interview. After 1 week,
non-responders were sent a reminder e-mail signed by the appropriate clinician researcher. No further
contact with non-responders was attempted. Recruitment continued until target sample sizes were
achieved for each stakeholder group.
At the start of each telephone interview, participants were reminded that the aim of the study was to
identify their personal views and opinions on SDD (there were no right or wrong answers). Consent to
audio record the interview was requested and received from all participants.
Data management and analysis
Recordings were transcribed verbatim, checked for accuracy and anonymised. The objective of the
analysis was to develop questionnaire items for the second round of the Delphi study, the quantitative
questionnaire round. Analysis of the transcripts proceeded through a number of stages. First, ‘speciﬁc
beliefs’ were identiﬁed within the transcripts. A speciﬁc belief was deﬁned as a statement for which the
content may indicate a perceived inﬂuence on SDD adoption or delivery. Speciﬁc beliefs that expressed the
same theme or were polar opposites of the same theme were grouped together and were considered as
repeats of the same belief. Summary statements representing these beliefs were devised, and these
became the basis of the round 2 questionnaire items. This analysis was performed using an iterative and
parallel process with the SuDDICU Canada team (who had adopted an identical topic guide and sampling
strategy). All summary statements identiﬁed in the analysis were discussed by an international working
group of study investigators to identify appropriate wording for representing the beliefs in round 2 of the
Delphi study. When it was justiﬁable from the interview data, identical wording of questionnaire items was
agreed across nations. When speciﬁc beliefs emerged only in the UK study, these were included in the UK
version of the round 2 materials.
The next stage in the analysis involved allocation of the speciﬁc beliefs to the prespeciﬁed TDF domains.
This was carried out independently by two researchers (JJF and one research assistant) using the TDF as an
analytic framework and content analysis methods previously employed by the research team in the context
of intensive care.46 When there was disagreement between coders, these were discussed with a third
researcher (MEP). Agreement was achieved for 42 of the 46 UK items; the remaining four items, for which
discrepancy in domain allocation persisted, were discussed with an expert group of 16 researchers who
were familiar with the TDF (the Aberdeen Health Psychology Group) and the majority view was taken for
domain allocation.
To address research question 4 we examined the Beliefs about Consequences domain in detail. A
preliminary assessment was made of the perceived importance of each speciﬁc belief in this domain. In
round 1, assessment of importance was based on evidence from cognitive psychology, which identiﬁes
that the ‘cognitive accessibility’ of a belief (i.e. the readiness with which it comes to mind) is an indicator
of its importance to an individual.47 In ‘social cognitive’ models of planned action,48,49 importance is
assessed at the group level by identifying the ‘modal salience’ of the belief, i.e. how many times the same
belief is elicited across the whole sample of study participants, relative to other beliefs. Hence, the
frequency with which a belief was elicited in the interviews was taken as an indicator of its relative
importance. It was recognised that this procedure is based on a range of assumptions and so this early
indicator of importance was later compared with data from rounds 2 and 3 (reported in Chapter 4), in
which participants were asked to report their ratings of the importance of each belief. Importance was also
examined quantitatively in the national survey (see Chapter 5) so that these three methods for assessing
the relative importance of consequences could be compared. This was done to ensure that robust
evidence could be used to identify the most important outcome measures to include in a possible
effectiveness trial of SDD.
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Using similar assumptions, the importance of each theoretical domain was assessed, in round 1, by
identifying the level of elaboration provided by participants in their responses to the interview questions.
The relative importance of the domains would identify key barriers to implementation, which would
provide an evidence base for the design of an intervention to increase uptake in a possible implementation
trial of SDD. For each domain, we identiﬁed how many utterances were coded, how many speciﬁc beliefs
were generated across the sample and the content of those beliefs. For example, if the belief was
essentially that the issue was not important or not a problem, this content was taken into account.
The project was coordinated by the Health Services Research Unit, University of Aberdeen. Ethics approval
for Delphi study was granted by NHS North of Scotland Ethics Service (10/S0801/69).
The project was subject to extreme delays and difﬁculties in obtaining research governance approvals for
sites in England, Northern Ireland and Wales. These delays negatively impacted upon recruitment and
hence may have compromised our attempt to sample for diversity. Despite repeated attempts to contact
trusts, 15 NHS trusts had failed to issue a decision on research governance by the time data collection
closed (6 months after submitting the documentation). Further details can be found in Appendix 3.
Results
Participant characteristics
Ninety-four health professionals were invited to take part. Eight participants were excluded as not
meeting eligibility criteria (had left the hospital or their profession) and three e-mails were returned
undelivered. Forty-seven participants consented to participate and were interviewed (57% consent rate).
Consent rates were highest among pharmacists (92%) and lowest among clinical microbiologists (39%),
shown in Table 5.
The mean age of the 47 participants was 45.7 years and 31 (66%) were male. Participants were working
in 25 different hospitals with ICU bed numbers ranging from 8 to 75. Five participants worked in ICUs that
currently delivered SDD, another ﬁve had personal experience of SDD from previous positions and the
remainder had no direct experience with SDD. Participants had a mean of 18.2 [standard deviation (SD)
7.2] years of ICU experience. Participants were recruited from all four home nations (30 participants from
England, 12 from Scotland, two from Wales and one from Northern Ireland).
Importance analysis at the level of theoretical domains
Table 6 provides details of the number of times participants made comments that were coded into each
theoretical domain and a brief description of the content of each domain, in so far as it indicates the
perceived importance of the domain.
TABLE 5 Consent rate by stakeholder group
Stakeholder group Invitations Participants Consent rate
ICU physicians 20 12 60%
ICU pharmacists 12 11 92%
Medical microbiologists 28 11 39%
ICU clinical leads/ICU nurse managers/educators
a
23 13 57%
Total 83 47 57%
a All nurses reported that at least part of their role was based on wards and involved the clinical care of patients.
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TABLE 6 Speciﬁc beliefs in each of the theoretical domains
Domains (ranked in
terms of frequency
in column 2)
Number of
utterances
a
(from 47
interviews) Brief description of content
Number of
items generated
for round 2
(speciﬁc beliefs)
Beliefs about
consequences
470 Highly elaborated by participants and discussed
as being an important inﬂuence on the
adoption of SDD
18
Memory, attention
and decision
processes
154 Decision-making processes relevant to adoption
of SDD were discussed as an important inﬂuence
3
Knowledge 154 Participants reported variable knowledge of the
evidence base for SDD and observed that this
would need to be addressed before SDD could
be adopted
3
Motivation and goals 122 A lack of motivation to adopt SDD was
highlighted by participants as being an
important barrier to adoption
6
Environmental
context and resources
90 Discrepancies between the clinical contexts in
which evidence has been gathered and
participants’ own clinical contexts were reported
to be an important inﬂuence on relevance of
the evidence to the UK
4
Skills 52 Skill was discussed by participants but was not
judged to be an important barrier to adopting
SDD. Participants reported that ICU staff already
have the skills necessary for delivering SDD
1
Nature of the
behaviours
31 Complexity of, or experience with, SDD delivery
behaviours were not judged to be an important
barrier to adopting SDD
3
Beliefs about
capabilities
18 Participants reported feeling conﬁdent in their
ability to inﬂuence SDD adoption when this was
in line with their professional responsibilities.
This domain was, therefore, not considered an
important barrier to adoption of SDD
1
Professional role and
identity
13 Participants discussed the importance of
professional obligations to reduce the use of
antibiotics and how such directives impacted
upon opinions about SDD adoption
3
Behavioural
regulation
15 This domain was elaborated by participants but
was mostly discussed in terms of recommended
strategies for the hypothetical situation of
adopting SDD
3
Social inﬂuences 6 Participants discussed the inﬂuence of other
people, such as the perceived majority position
among ICUs in the UK with respect to SDD
adoption
2
Emotion 1 One person discussed emotion in the sense that
it is difﬁcult to have a dispassionate discussion
with colleagues about SDD adoption
0
a The number of comments represents the number of utterances both across and within interviews.
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As shown in Table 6, most utterances were coded under the Beliefs about consequences domain and
these utterances were coded into 18 speciﬁc beliefs. However, not all domains showed a direct
relationship between the level of elaboration in interviews and the number of speciﬁc beliefs that were
identiﬁed. For example, although Memory, attention and decision processes was the second most
elaborated domain, the participants’ responses could be distilled into three speciﬁc beliefs relating to the
decision-making processes required for SDD adoption (see Table 9). Furthermore, Motivation and goals
produced the second highest number of speciﬁc beliefs but, in terms of the number of utterances, was
elaborated less than the Memory, attention and decision processes or Knowledge domains.
The following sections provide further detail about the speciﬁc beliefs that emerged in each of the
theoretical domains.
Beliefs about consequences
Participants discussed 18 Beliefs about the consequences of SDD, both positive and negative, and noted
that SDD could produce positive beneﬁts such as reduced morbidity, rates of HAIs including VAP and ICU
length of stay. The most frequently mentioned concern about the negative consequences of SDD adoption
was the potential for increased antibiotic resistance. Participants also discussed their concerns about the
potential for increased rates of C. difficile infections.
Non-nurse participants expressed concern that SDD delivery would increase nursing workload, speciﬁcally
relating to administration of SDD components, taking cultures for microbiology and dealing with patient
side-effects related to SDD such as diarrhoea. However, nurse participants raised none of these concerns.
The only nurse to mention the impact of SDD delivery on nursing workload reported that it was not a
barrier to implementation.
People who are wittering on about increased nursing time . . ., you cannot really use that as a great
reason not to do something.
P41
Participants also stressed the importance of weighing risks and beneﬁts associated with SDD. Speciﬁcally,
they questioned whether the potential reductions in mortality and VAP were enough to balance the
potential risk of increased antibiotic resistance and associated consequences. We noted considerable
variation in viewpoints in this domain.
Financial consequences also were discussed both as potential cost-savings (due to reducing VAP and
length of stay) but also the potential for increased costs in terms of SDD drugs and additional human
resources required to deliver them.
Memory, attention and decision processes
Three beliefs relating to decision-making processes were identiﬁed that would be required prior
to adoption of SDD: the need to review and appraise current evidence (n = 35), the need for
consensus among colleagues (n = 32) and the role of senior ICU doctors (consultant level) as key
decision-makers (n = 13).
Knowledge
Participants varied in their self-assessed levels of knowledge about SDD components and in their views of
their own and others’ knowledge of the evidence base. Importantly (but not surprisingly), knowledge of
the evidence base was linked by some to their rating of the importance of SDD:
I have never quite got round to looking at it and I have to be honest that . . . when I got the original
email to say . . . there’s going to be a questionnaire on this, I thought . . . this is something I have been
meaning to look into for a while so . . . having looked at the evidence now, it is very important.
P05
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Some participants were very knowledgeable:
There have been some very, very good trials recently . . . I think there is certainly plenty of evidence
there that some of us should be looking at and I think the big problem is . . . not everybody has fully
appraised the papers.
P05
Other participants identiﬁed a limited knowledge of existing evidence, which was potentially an important
factor in interpreting the study ﬁndings. Knowledge data are reported in Chapters 4 and 5.
Motivation and goals
Six beliefs were coded into this domain. These beliefs included the perception that SDD was not currently
a ‘front-and-centre issue’ and, therefore, not a topic of discussion in their units or among colleagues.
Two intensive care consultants and one microbiologist reported that VAP was already adequately
addressed by other interventions and, therefore, there was no motivation to pursue other options to
reduce HAIs such as SDD. Other clinical priorities were reported to be more important, such as the
adequate implementation of existing VAP bundle procedures.
The main reason is that we are on a very steep improvement curve for our intensive care unit, in
terms of trying to improve the outcome of our patients and just haven’t got to SDD yet. We haven’t
reached the level of sophistication by which we can look at interventions like SDD. We are still
working on simpler things like sedation holding and breathing trials, you know, much simpler things
and I think SDD will be on our list, I think we just haven’t got to it yet.
P19
Finally, four participants (two with previous experience of delivering SDD and two with no experience)
reported that SDD was considered ‘old news’ and no longer a relevant clinical topic.
Environmental context and resources
Potential barriers to SDD were discussed by participants with respect to the domain Environmental context
and resources. Previous trials, conducted outside the UK, were perceived to have limited generalisability
to the UK ICU context owing to different patient characteristics, ICU ecology or microbial ﬂora and
standards of care.
It would be very helpful . . . if there is good research from the UK, because we use antibiotics
differently, our ecology is different, our patients tend to be slightly different to other European ITUs
[intensive therapy units].
P25
Professional role and identity
Three beliefs were identiﬁed within the Professional role and identity domain. Speciﬁcally, three
participants reported that SDD conﬂicted with their professional obligations, most notably in reducing the
administration of prophylactic antibiotics.
It is kind of bred into us, hammered into us publicly that we should limit and target the use of
antibiotics as much as is possible.
P44
Participants reported that there were conﬂicting opinions among clinical microbiologists and intensive care
consultants (on antibiotic delivery used within SDD) that could inﬂuence SDD adoption.
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Behavioural regulation
Three beliefs coded into the Behavioural regulation domain were mentioned by ﬁve participants. They
discussed the inﬂuence of national guidelines and regulatory requirements on local policy with respect to
SDD adoption. There was a perception that endorsement of SDD from an authoritative body (e.g. mandate
by NICE) would lead to the adoption of SDD into a unit’s routine clinical practice.
. . . if, certain NICE or a group like that . . . came forward and said this is an absolute . . . necessity for
treatment in the ICU then I think it would happen in our unit.
P15
Social influences
Two beliefs were coded within the domain Social influence. Participants suggested that adoption would
require a clinical champion or SDD expert to put SDD on the agenda, educate others and drive SDD
forward. Two participants (a clinical lead and a microbiologist) also reported that their practice was
inﬂuenced by the practice of other ICUs; more speciﬁcally, they felt reassured that their position on not
delivering SDD was in line with the position of other ICUs.
Well I guess as the years go by and the lack of pressure to institute it, in other words, you know,
lack of a persuasive argument that what we are doing leaves us as an outlier, then it becomes
less important.
P31
Emotion
Finally, the domain Emotion was discussed by one participant, who described the emotion associated with
colleagues’ certainty about the SDD issue:
. . . it is very difficult to have a dispassionate discussion with people about it [SDD]. They have already
made up their minds.
P45
In the context of intensive care, three domains were similar conceptually, and all were viewed as not being
barriers to adoption. These domains were Skills, Nature of the behaviour and Beliefs about capabilities.
Skills was discussed by 34 participants, and the vast majority (n = 31) felt that delivering SDD was within
the existing competencies of ICU nurses and, therefore, skills were not a barrier to SDD adoption.
I don’t think in the ICU there would be any reason to say that the nursing staff shouldn’t be able to
give the drugs because they are doing that already.
P39
All participants (n = 47) made comments coded under the domain Nature of the behaviour, with most
participants reporting that delivering SDD would not be a dramatic shift from current practice. This domain
was not considered to be a barrier to SDD adoption and included in round 2.
I don’t think it would be that difficult [in comparison to what already doing].
P14
Participants’ Beliefs about capabilities (to inﬂuence adoption) were not considered to be a barrier to SDD
adoption. Those key professionals who were responsible for instigating changes in policy (medical leads,
intensivists and clinical microbiologists) reported that they felt they could inﬂuence the decision on
whether or not to adopt SDD.
I would say that if I personally made it my crusade to do it [adopt SDD], we would do it.
P19
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Nurses and pharmacists were less certain of their ability to inﬂuence SDD adoption, but most noted that
they could suggest changes in policy to colleagues.
I can definitely suggest changes and I would have to get agreement with the consultants before we
could institute a major change, but I could certainly discuss instituting major changes.
P24
In summary, when the theoretical domains were used as a framework for analysis, it was possible to
identify beliefs about the likely positive and negatives consequences on SDD and other factors that are
likely to be barriers to SDD adoption. Nine of the 12 domains were potentially important in this context;
Beliefs about consequences, Memory, attention and decision processes, Knowledge, Motivation and goals,
Environmental context and resources, Professional role and identity, Behavioural regulation, Social
influence and Emotion.
Participants were also asked their views on the existing SDD evidence base and about potential future
research directions. For discussion of data relating to these topics, see Views about the existing
evidence base.
Views about the existing evidence base
There was considerable variation in participants’ reported views of the existing evidence base for SDD. Six
participants reported that the evidence base for SDD was sufﬁcient and three speciﬁcally stated that
further effectiveness research would not be helpful in determining the next steps for SDD.
I think they have done enough research on it to show it is a good thing . . . the research has been
done and it’s time to implement it.
P05
In contrast, 26 participants were not convinced by the existing evidence.
[Would further research settle some of the issues surrounding SDD?] I think so. I mean the problem
with ITU is that we know that whatever is published one day, in about 6 months time or a year, there
could be something different that will contradict it. But it [the research] has to be pretty definitive
before, you know, we rush into anything.
P27
Most felt that further research was needed to address clinical uncertainties (see Table 9), in particular
beliefs about the consequences of routine delivery of SDD.
The 26 participants who discussed further research needs mentioned the limitations of SDD studies
reported to date, including the length of follow-up (as this was not sufﬁcient to assess antibiotic resistance
in the longer term) and the need for studies conducted in the context of patient populations with a
resistance proﬁle similar to that of the UK. Given the variation in self-assessed knowledge of the evidence,
we investigated associations between knowledge and views about further research. Views about further
research that are based on poor knowledge of the current evidence would clearly have a different status
from views based on a sophisticated level of knowledge. Such associations were more effectively explored
in the context of the quantitative Delphi rounds and are reported in Chapter 4.
Views about further research
Despite variation in participants’ views of the existing evidence base, most participants (n = 32) reported
that they would be willing to facilitate recruitment of patients to a randomised controlled trial (RCT) to
evaluate the effectiveness of SDD. The importance of obtaining agreement from colleagues to participate
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in any further research was raised by nine of these participants. Reasons for willingness to participate in
effectiveness research included:
l such a study would be important as it would help to resolve an unanswered question in critical
care research
l a general interest in research
l a desire to improve patient care.
The case in favour of an effectiveness RCT is strengthened by the extent of elaboration of the Beliefs
about consequences domain. Table 7 provides illustrative quotes that suggest an effectiveness RCT may
be appropriate.
In contrast, ﬁve participants reported being unwilling to recruit patients to further effectiveness research as
they perceived that enough research had been conducted (n = 3), they already delivered SDD and lacked
equipoise (n = 3) and they wanted to implement SDD without further delay (n = 1). Contrasting views
about the ethics of conducting further research were expressed: 27 participants reported that further
research was ethical, 10 participants qualiﬁed this answer by stating that questions remained unanswered
and ﬁve explicitly mentioned that equipoise existed. In contrast to this view, three participants reported
TABLE 7 Data suggesting that an effectiveness RCT could be appropriate
Domain Illustrative quotations from interview transcripts
Knowledge I feel there has to be overwhelming evidence of the benefits in using it and also some kind
of reassurance in the evidence that using the i.v. component wasn’t going to have a
negative impact in terms of development of resistance.
P17
I think we would need conclusive evidence . . . that it was an effective treatment and that
. . . there wasn’t a significant risk of the emergence of resistant organisms.
P36
Beliefs about
consequences
. . . in my opinion the jury is still out on the overall benefit of SDD and I think that we need
to try and get data from [a] broad, multilocations study to see whether the overall benefit
is worth pursuing.
P03
I don’t think that there is enough evidence in using the i.v. cephalosporins to suggest that
it wouldn’t cause harm.
P17
Environmental context
and resources
. . . at the moment we are extrapolating data taken from different areas . . . although the
majority of them do suggest a mortality benefit, the number needed to treat is quite
variable. The actual range of antimicrobials is quite variable and the data on resistance,
antimicrobial resistance, is quite variable in terms of the bugs . . . I think there’s still
enough uncertainty there to actually say there is another study needed.
P23
There are a large number of multinational studies [which have] become biased by the use
of non European or North American sites, where practice is very different and baseline
infections are different and the microflora are potential[ly] different.
P35
Memory, attention and
decision processes
. . . the other thing that I am slightly worried about is the number you need to treat . . .
and the selection of the patient population. Which one would get most benefit from SDD?
It is not clear to me yet.
P42
DOI: 10.3310/hta18250 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 25
27
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
that further SDD research would not necessarily be ethically sound because the question of effectiveness
had already been answered in favour of delivering SDD.
When asked whether or not they would support an implementation study (i.e. a study to evaluate
strategies to increase uptake of SDD), participants were hesitant. Seven participants felt that they would
need more information about an implementation study before they could comment on participating in
such a study and nine participants reported that there was insufﬁcient evidence of effectiveness to proceed
with such a study at this time. However, there was substantial evidence to suggest that the reasons for
holding back on adoption of SDD were not strong. Table 8 presents quotes that suggest an
implementation study may be appropriate or that propose speciﬁc implementation strategies.
TABLE 8 Data suggesting that an implementation study may be appropriate
Theoretical domain Illustrative quotations from interview transcripts
Beliefs about consequences There is plenty of research to show what we should be doing, the big problem now is,
is actually making sure it is adopted.
P05
I think the evidence is no better or no worse than a lot of things that we do regularly
on intensive care.
P09
Behavioural regulation What would need to happen . . . it is going to take some form of national guideline . . .
from an authoritative body . . . to state that this is a standard care that is expected.
P31
[We] would be looking for guidance from a higher source . . . some sort of
national guidance.
P01
[I]f . . . NICE or a group like that . . . said this is . . . a necessity for treatment in the ICU
then I think it would happen in our unit.
P15
There has never been a stimulus to start.
P01
Motivation and goals I think there are a lot of people who view it as one of those things that has been
published that has got good results and questions asked why are we [not] doing it, but
no-one is really getting round to doing it.
P14
Nobody has a strong feeling either way to be honest. It’s . . . not that anybody is
violently opposed to it. It’s just that nobody’s violently [in favour] either . . . I think it is
basically they have other interests that they concentrate on and SDD isn’t one of them.
P15
Social inﬂuences What is the main reason you would say that you don’t use it [SDD] now? I think
basically there’s the individual who was enthusiastic about it stopped working at the
trust and interest sort of waned as a result of it really. Basically we just stopped using it.
P15
We have never really had anyone that was interested in it, . . . As the years go by and
the lack of pressure to institute it, . . . lack of a persuasive argument that what we are
doing leaves us as an outlier, then it becomes less important. But that is describing
human nature then rather than anything else.
P31
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In addition, there was considerable evidence that some participants were not aware of what is meant by
‘implementation study’. For example, when asked if they would be willing to participate in a study whose
aim was to increase adoption of SDD based on current evidence, responses included:
It is not really a study is it? It is just a NICE guideline?
P19
I am not sure how that could be a study, it would be educational programme to raise awareness but
I am not sure how in practice this would be a relevant study.
P44
In summary, participants reported a range of views on the existing evidence base and directions for future
research. In general, they were willing to participate in effectiveness studies (although some voiced uncertainty
about the ethics of conducting further effectiveness research in SDD). There was less support for participating in
implementation studies, but also less clarity in understanding what an implementation study involves.
Findings from round 1 used to develop round 2 materials
In collaboration with the SuDDICU research teams in Canada and Australia/New Zealand, the results from
the round 1 interviews were used to develop a set of 47 domains-based statements for inclusion in the
instrument used for the quantitative rounds of the Delphi study (round 2 and round 3). The ﬁnalised items
are displayed in Table 9. There were eight positively worded items (i.e. in favour of SDD), 31 negatively
worded items (i.e. opposed to SDD) and eight neutrally worded items. Further detail on the methods used
to decide item wording is provided in Chapter 4.
TABLE 9 Round 2 items relating to potential barriers and corresponding quotes from round 1 interviews
Domain Round 2 item Supporting quotes from interview transcripts
Knowledge
(three items)
I know to which patients I would
administer SDD
I am not quite sure to be honest. That is one
thing I haven’t gone into in great detail
about, the exclusion criteria.
P05
I know the SDD evidence base
well enough to have an informed
opinion regarding its use
I think it is one of those things that, over the last
couple of years, there has been more and more
evidence published in the intensive care literature
where it fairly consistently pointed to a good
result in terms of outcomes in patients, and the
reasons for not doing it in the UK are becoming
less and less.
P14
Research to date has not
adequately addressed concerns
about antibiotic resistance
and SDD
The long term ecological consequences of using
antibiotics in this way is . . . always going to be
an uncertainty and it makes it very difficult for
anyone reviewing the evidence to come down
clearly with statements to the effect that this is
something we ought to be doing . . . the
evidence comes [from] short term studies and
ecological changes take a long time to
develop . . . like, global warming or changes in
animal populations, these are things that don’t
happen straight away; they take a long time
to develop.
P13
continued
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TABLE 9 Round 2 items relating to potential barriers and corresponding quotes from round 1 interviews
(continued )
Domain Round 2 item Supporting quotes from interview transcripts
Motivation (six items) SDD is not a topic of discussion
among my colleagues
I think again, embarrassing and simplistic as it
sounds, we’ve just never seriously discussed it.
P02
SDD is not on my unit’s list of
clinical priorities
The main reason is that we are on a very steep
improvement curve for our intensive care unit,
in terms of trying to improve the outcome of
our patients and just haven’t got to SDD yet.
We haven’t reached the level of sophistication
by which we can look at interventions like SDD.
We are still working on simpler things like
sedation holding and breathing trials, you know,
much simpler things . . . I think SDD will be on
our list, I think we just have not got to it yet.
P19
We are addressing hospital-
acquired infections using other
strategies
Clearly the reduction of infection risk is a major
priority in the ICU but . . . the other initiatives
that are in place are, by definition, deemed
more important because we are doing those . . .
whereas we are not doing SDD.
P31
We are addressing ventilator-
associated pneumonia using other
strategies
I do not think it [SDD] is hugely important right
at the moment because I think there are a
variety of other techniques and regimes and
therapies that have been instigated in . . .
intensive care in the last 2–3 years in an attempt
to tackle ventilator associated pneumonia.
P26
Our unit VAP rates are low I think we have a pretty low rate of
ventilator-associated pneumonia and other
nosocomial infections.
P27
SDD is outdated It’s fallen out of fashion.
P30
SDD is a hot topic again.
P45
Professional role and
identity (three items)
There are conﬂicting opinions on
antibiotic use among medical
microbiologists/ID physicians and
ICU physicians
Our main area of scepticism comes from our
new consultant microbiologist whose
background is from another intensive care unit
and though he was hostile, he is now passively
accepting of our continued use of SDD.
P18
Prophylactic antibiotic use in SDD
is at odds with my professional
training
It is kind of bred into us, hammered into us
publicly that we should limit and target the
use of antibiotics as much as is possible.
P44
Prophylactic antibiotic use in SDD
is at odds with my professional
responsibilities
See quote above
Social influence
(two items)
I am reassured that our position
on SDD adoption is in line with
other hospitals’
Well I guess as the years go by and the lack of
pressure to institute it, . . . [a] lack of a persuasive
argument that what we are doing leaves us as
an outlier, then it becomes less important.
P31
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TABLE 9 Round 2 items relating to potential barriers and corresponding quotes from round 1 interviews
(continued )
Domain Round 2 item Supporting quotes from interview transcripts
SDD will not be adopted without
a local champion
I don’t think it is going to push forward unless
we get an individual in the unit who is an
absolute, you know, you know, very, very keen
on the idea and can persuade his colleagues.
P15
Behavioural regulation
(three items)
There are no national guidelines
about SDD
I guess now it [implementing SDD] is going to
take some form of national guideline. [Implies
that there are no national guidelines currently.]
P31
The local decision to adopt SDD
would be inﬂuenced by regulatory
requirements
I think for starters they would be looking for
guidance from a higher source, as it were.
Some sort of national guidance that we
would be following.
P01
My hospital tries to reduce
antibiotic use
. . . antibiotic prescribing . . . we try to limit as
far as possible.
P02
Beliefs about
consequences (18 items)
There is no mortality beneﬁt
associated with SDD
It has got to show that it’s of benefit in
reducing patient morbidity and mortality and
that is where I think at the moment the case
hasn’t been proven.
P03
The risks of SDD outweigh the
beneﬁts
It looks like the benefits will outweigh any
potential risk.
P05
SDD reduces VAP It reduces the incidence of ventilator
associated pneumonia, we believe.
P18
SDD reduces length of stay The benefit is hopefully reduced length of stay
because you have got reduced infection rates.
P14
Overall SDD beneﬁts patients I think it is beneficial to the patient. We don’t
tend to see the more complicated infections.
P06
SDD increases nursing workload It would be extra nursing time as well, because
most of these drugs are being given four times a
day. So on top of all the other drugs that they
are giving the patients, it is going to take a bit of
extra time for them to prepare each of the
agents of four lots of drugs, four times a day.
P17
SDD increases pharmacy workload (Item included to achieve balance across
stakeholder groups)
continued
DOI: 10.3310/hta18250 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 25
31
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 9 Round 2 items relating to potential barriers and corresponding quotes from round 1 interviews
(continued )
Domain Round 2 item Supporting quotes from interview transcripts
SDD increases microbiology
workload
There is a cost, to our microbiology
department.
P18
SDD increases antibiotic resistance I still have concerns about resistance but I
know that there is a lot of evidence to
suggest you don’t get that.
P29
Units using SDD have better
clinical outcomes
One of the big things putting me off is that
there is one unit . . . that does use a lot of
SDD and they also have very good audit data
for outcomes and that unit is certainly no
better than any other unit so it cannot be
making that big a difference to outcomes.
P01
SDD causes unpleasant
side-effects for patients
It often causes diarrhoea. . .[staff] end up
putting bowel management systems into the
patients, which is a risk in itself.
P21
SDD reduces hospital-acquired
infections
It will lower your infection rates but I am not
sure how solid that evidence is really.
P09
I have concerns about the speciﬁc
antimicrobials you need to use
One of the antibiotics most commonly
recommended is cefotaxime for the
intravenous component and we are actively
trying to limit our use of cephalosporin
because of concerns about Clostridium
difﬁcile infection.
P02
I am opposed to the i.v.
component of SDD
I think the concerns over using i.v.
antibiotics. . . prior to any signs of infection,
is a big concern in terms of development
of resistance.
P17
I am opposed to SDD In fact some people are opposed to SDD
drastically . . . But I personally want to move
SDD [towards being adopted].
P25
SDD would increase ICU
C. difficile infections
There are unanswered questions I think over
C. diff.
P07
Overall, SDD is cost-effective The cost implication of course is going to be
completely thrown out by the fact that if you
are preventing infection then you are saving
money. But you do have some initial outlay
in the first place in order to provide the
antibiotic cover.
P10
DELPHI STUDY: ROUND 1 INTERVIEWS
32
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 9 Round 2 items relating to potential barriers and corresponding quotes from round 1 interviews
(continued )
Domain Round 2 item Supporting quotes from interview transcripts
Educating staff would be
expensive
So that would all take time – to educate the
staff about antibiotics, about why you are
giving it, about the fact that everybody is
covered in bacteria, including themselves.
So that time is a huge issue.
P45
Skills (one item) The skills required to administer
SDD fall within the competencies
of our ICU nursing staff
I don’t think in the ICU there would be any
reason to say that the nursing staff shouldn’t
be able to give the drugs because they are
doing that already.
P39
Nature of behaviours
(three items)
SDD is straightforward to deliver I don’t think it would be that difficult at all.
P14
The use of pastes may interfere
with other treatments
[Interviewer: would SDD interrupt the feeding
process?] No, we tend to feed for 24 hours
and we give the antibiotics with the feed.
P40
SDD would be a dramatic shift
from our current practice
I don’t think it would be that difficult [in
comparison to what already doing].
P14
Environmental context
and resources (four items)
The SDD evidence base is not
generalisable to my country
If the problem is that people say it is not done
in the UK indeed our setting is indeed
different to the Netherlands where the most
of the studies is coming from then you could
say the data from the Netherlands does
not qualify.
P44
The SDD evidence base is
generated in countries with
different resistance proﬁles to
my country
See quote above
The SDD evidence base is not
generalisable to my patient
population
I think their feeling is that there hasn’t been
enough research in their population group.
P27
SDD drugs are expensive It is quite expensive to do both in actual
purchase costs for the materials and for the
time involved for the nurses to administer
it all.
P01
Beliefs about capabilities
(one item)
I could inﬂuence whether SDD is
adopted in my hospital
I can definitely suggest changes and I would
have to get agreement with the consultants
before we could institute a major change,
but I could certainly discuss instituting
major changes.
P24
continued
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TABLE 9 Round 2 items relating to potential barriers and corresponding quotes from round 1 interviews
(continued )
Domain Round 2 item Supporting quotes from interview transcripts
Memory, attention and
decision processes
(three items)
The decision to adopt SDD
requires a review and appraisal of
the current best evidence
We would need to review literature and
determine whether there is sufficient evidence
to support it. We’d also look at what sort of
studies have been conducted whether
randomised, blinded whether there was high
levels of evidence.
P30
The decision to adopt SDD
requires consensus between my
colleagues
One tends to work as a group, so anything
that we tend to treat, we treat as a package
. . . a consensus discussion and a consensus
opinion.
P22
Part of the decision to adopt SDD
requires agreement about which
patients will receive it
You would need to identify which patients
you were going to do it on or which patients
you might wish to exclude.
P02
Future research
(four items)
I would support my ICU
participating in a nationwide
randomised control trial (RCT)
[Recruit patients to effectiveness RCT?] I
would be willing to advocate that our unit
take part in that – yes. [Why?] Because I think
it is an unanswered question within the UK.
P38
Further SDD RCTs are ethical I think it would only be unethical if we were
already doing something that was proven to
work and we were going to stop doing it to
try this. Or we in some way thought we were
going to run this against it and it was worse. I
don’t think that’s the situation.
P09
My concerns about antibiotic
resistance limit my willingness to
participate in future RCTs in SDD
I guess there’s some ethical dilemmas [about
further research] . . . if you genuinely believe
that [antibiotic] resistance.
P38
I would support my centre being
involved in a study to promote the
adoption of SDD
If someone can present the evidence in a format
that . . . satisfies some of the anxieties I, and my
colleagues have, then that sort of a strategy may
work as well. I mean a lot of people recognise
that there is evidence to support the use of SDD,
as gut decontamination, and the fact that we
haven’t taken it up suggests that the message is
not convincing people. So I think a strategy that
improved communication, improved information
dissemination, may be beneficial but . . . you
have got a big mountain to climb here at the
moment.
P34
ID, infectious diseases.
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Discussion
The Delphi study recruited 47 participants from four clinical stakeholder groups, regarded as experts in
critical care, to identify key issues to consider about the topics of SDD adoption and delivery, and further
SDD research. An immediate objective was to generate items for inclusion in the materials used in later
rounds of the Delphi study and eventually in a questionnaire for a national survey. Delphi approaches have
previously been used for these purposes. For example, a Delphi technique has been used to identify
potentially relevant determinants of innovation in health-care organisations50 and to develop a national
survey about views on medical instrumentation.51
Answers to research questions
Round 1 of the Delphi study provided preliminary answers to research questions 3, 4 and 5:
3. Stakeholders held mixed views of the internal/external validity and adequacy of the existing evidence
base for SDD. They were willing to participate in further research but the most appropriate kind of
research was not clearly informed by these interviews.
4. Stakeholders also held mixed views about the likely positive and negative consequences of
implementing SDD in ICUs. The relative importance of these beliefs in inﬂuencing overall views about
SDD was assessed using assumptions from cognitive psychology (but a range of further importance
indices was examined in later stages of the study).
5. Stakeholders had a lot to say about the likely barriers to implementing SDD in ICUs. These tended to
focus on Motivation and goals (simply not high on the priority list) or on Behavioural regulation
(a national guideline would change practice) but there was also considerable doubt about the
evidence base.
These preliminary results were used to generate questionnaire items for further consideration in later
rounds of the Delphi study (see Chapter 4). All the beliefs generated in round 1 of the Delphi study
(including minority beliefs) were to be taken forward for consideration by the panel in rounds 2 and 3.1
In view of the importance of considering the full range of views about SDD, we used two approaches.
First, we based the round 1 interviews on the TDF of clinical behaviour, as this framework has been shown
to generate more beliefs (including lesser discussed issues such as emotion).52 Second, we conducted a
data saturation analysis, using previously published methods, to provide evidence that saturation had
been reached.
Evidence of data saturation
Data saturation principles did not drive our sampling strategy as sample size was based on
recommendations for Delphi studies.53 Therefore, data saturation analysis was conducted after completion
of data collection and content analysis. Published guidance for determining data saturation54 recommends
a two-step process involving analysis of consecutive interviews to (1) plot all ‘new’ beliefs (i.e. not counting
repeats of beliefs previously mentioned) in an ‘initial analysis sample’54 of 10 cases with adequate diversity
and (2) declare saturation when there are three consecutive interviews with no new beliefs emerging. This
is referred to as the ’10 + 3 rule’,54 according to which the smallest sample size for data saturation would
be 13. Saturation analysis of our data illustrating these two steps is displayed in Figure 2. After the 13th
interview, the 10 + 3 rule had not been met. After interview 22 (represented by the dotted vertical line),
there were three consecutive interviews without new beliefs emerging (at interview 25, represented by the
solid vertical line), whereas recruitment continued to interview 47. This indicates that the sampling process
was more than adequate to achieve data saturation in terms of beliefs about SDD. However, Figure 2 also
shows that new beliefs were elicited in interviews 40 and 45. These beliefs were included with all other
beliefs in the materials for round 2 (see Chapter 4).
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Details of findings
The aim of the round 1 interviews, described in this chapter, was to identify – in four groups of key clinical
stakeholders – the perceived positive and negative consequences of SDD implementation in UK ICUs, likely
barriers to adoption, stakeholders’ views on the existing evidence base related to SDD, and potential
willingness to facilitate recruitment into future studies of either SDD effectiveness or SDD implementation.
Nine domains of the TDF55 were potentially important in characterising perceptions regarding SDD
adoption and delivery. These included Beliefs about consequences (which was the focus of research
question 4) and eight possible types of barriers to SDD adoption and delivery: Memory, Attention and
decision processes, Knowledge, Motivation and goals, Environmental context and resources, Professional
role and identity, Behavioural regulation, Social influence and Emotion. This is a coherent ﬁnding in the
context of health care delivered in ICUs. First, knowledge of the research evidence is fundamental to the
provision of evidence-based care. Second, such evidence focuses on the consequences (beneﬁts and risks)
of providing, or not providing, certain interventions. Third, clinical decision making is a core aspect of
practice and covers both decisions about individual patients but also (importantly for SDD) decisions about
local policy. Hence, these three domains encapsulate the kind of thinking that is required for delivering
high-quality care. Fourth, motivation is important in the context of intensive care as there are many
potentially important interventions to consider and clinicians need to consider the relative importance of
SDD in comparison with other urgent priorities. Environmental context and resources are potentially
important for two reasons: if the settings in which evidence has been developed have poor environmental
ﬁt with the UK, in terms of background infection rates, the evidence may not be seen as applicable. In
addition, the ﬁnancial costs in terms of drug supplies and staff time should be weighed against the
beneﬁts and other priorities in the intensive care setting. Some interesting ﬁndings relating to Professional
role and identity highlighted that the training and responsibilities of the different clinical professions may
have a bearing on SDD policy. Beliefs relating to Behavioural regulation drew on participants’ hypotheses
about what might work to change their own behaviour. Such hypotheses are opinion based and do not
represent a high level of evidence; indeed, there is evidence to suggest systematic bias in people’s views
about what will change their behaviour.56 However, such hypotheses are, in principle, testable and could
provide a list of strategies to consider for implementation. There was a clear view that Social influence
could be important, as intensive care involves a collaborative approach between disciplines and policies are
inﬂuenced by ICU practice more broadly. Emotion was potentially a factor determining whether or not
people were prepared to engage in dispassionate discussion about SDD.
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FIGURE 2 Evidence of data saturation and cumulative frequency of new beliefs about SDD for Delphi
round 1 analysis.
DELPHI STUDY: ROUND 1 INTERVIEWS
36
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Domains that appeared to be unimportant were Skills, Nature of the behaviours and Beliefs about
capabilities. In other words, the interviews identiﬁed beliefs that lack of appropriate skills would not be a
barrier to SDD delivery; the demands of the behaviour itself, while complex, would again be unproblematic
in so far as they reﬂect the kinds of demands that intensive care staff routinely manage. Consistent with
this, participants were conﬁdent that staff would be capable to manage a SDD regimen if it were adopted
into the ICU. Notwithstanding their apparent unimportance, beliefs within these domains were taken
forward into round 2 for further consideration, as speciﬁed in the study protocol.
Even when there was clear evidence of the importance of certain issues, participants placed themselves
differently along the continuum from negative to positive. In terms of Beliefs about consequences, divergent
opinions were expressed about the effect of SDD on patient outcomes and impact on clinician workload. The
need for informed decisions, as well as collegial and leadership support to implement SDD, was acknowledged.
However, lack of relevance to current perceived priorities in delivery of ICU care was also noted, as well as
potential differences in the UK ICU ecological environment that may inﬂuence SDD effectiveness and potential
adverse consequences, such as increased antimicrobial resistance. In general, participants perceived that
acquisition of new skills and behaviours was not a major barrier to SDD adoption. This is in contrast to a
previous survey that identiﬁed perceived difﬁculty associated with the behaviours needed to deliver SDD.31
Divergent opinions also were noted in terms of the adequacy of the existing evidence about SDD effectiveness.
In particular, respondents reported that existing evidence conducted in countries such as the Netherlands may
not be applicable to the UK context, owing to differences in the microbial ecological proﬁle. Another key area
in which there was perceived to be insufﬁcient evidence was in the long-term effect of SDD.
Most respondents indicated they would support further research on the effectiveness of SDD. Fewer
positive views were expressed for a trial of SDD implementation but what was also noted was a lack of
awareness among some participants about what implementation research involves and what it might
achieve. There were many instances in which participants’ views would be consistent with criteria to
support an implementation study (see Table 8). The ﬁndings of this ﬁrst Delphi round were then used to
inform the content of the next two Delphi rounds designed to reﬁne and conﬁrm participant views on
barriers to SDD implementation and the need for further research.
Strengths and limitations
It should be noted that the sample was mixed in terms of direct experience of delivering SDD in practice.
Hence, some of the opinion-based data presented in this chapter may reﬂect erroneous beliefs. For
example, the concerns of non-nurse participants about nursing workload were not shared by the nurse
participants and the belief that people have already made up their minds about SDD was not consistent
with other participants’ reports about their own change of mind (reported above under Knowledge and
Behavioural regulation). Hence, it would not be appropriate to make recommendations for future research
based solely on these opinion-based data. Therefore, later stages of this study tested the robustness of
these views but could not fully offset the problem of using data involving opinions.
Box 5 presents the key ﬁndings that inform the need for, and acceptability of, a clinical effectiveness
RCT or an implementation RCT. There were some initial indications that these participants consider the
evidence base sufﬁciently uncertain to warrant further effectiveness research. However, there was also
evidence that implementation would be appropriate. Four ideas to support implementation, based on four
of the theoretical domains, emerged in the analysis. First, in the domain Beliefs about consequences, some
participants felt that there was sufﬁcient evidence in favour of SDD to warrant adoption now. Second, in
the Motivation and goals domain, there was a view that SDD was simply not high enough on the unit’s
priority list to be considered at this time. Third, in the Social influence domain, it was clear that the
personal inﬂuence of key individuals (rather than problems with the evidence) could be sufﬁcient to trigger
adoption. Fourth, in the part of the interview that probed potential Behavioural regulation strategies, a
recurring response was that SDD would be adopted (apparently quite straightforwardly) if adoption was
mandated by regulatory bodies.
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BOX 5 How does this stage of the research inform the need for, and acceptability of, an effectiveness RCT or an
implementation RCT?
l There was considerable uncertainty as to the adequacy of the existing evidence base for SDD and
about the potential harm and beneﬁts. Some of this uncertainty could be related to unfamiliarity with
existing evidence.
l The likely barriers to implementing SDD in ICUs include Motivation (simply not high on the priority list) or
on Behavioural regulation (a national guideline would change practice). There was some evidence that an
implementation study (to raise awareness or the raise priority of SDD) could be appropriate. There was
little evidence that practical issues such as skills, capabilities or costs are signiﬁcant barriers.
l Further research was feasible and acceptable but there was uncertainty regarding the most appropriate
kind of research that should follow this study.
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Chapter 4 Delphi study to identify stakeholder
views about selective decontamination of the
digestive tract: quantitative rounds
Background
Following round 1 of the Delphi study (reported in Chapter 3), two further rounds were conducted
with the same sample, comprising four key stakeholder groups (intensive care consultants, clinical
microbiologists, pharmacists and ICU clinical leads or nurse managers). A fourth, international, round was
also planned, involving all participating nations (Australia/New Zealand, Canada, UK) and in which the
feedback would include a breakdown of responses by nation.1 In line with Delphi methodology, the
quantitative rounds were designed to generate iterative evidence. Whereas Delphi studies are often
designed to achieve consensus (e.g. to agree recommendations for a clinical guideline), this study was
designed to assess levels of consensus in the ﬁeld about the evidence base relating to SDD, the likely
consequences of delivering SDD and the feasibility of conducting further SDD research. Consistent with
round 1 of the Delphi study, the rounds reported in this chapter focused on the following
research questions:
Research question 3: What are the views of key stakeholders of the internal/external validity and
adequacy of the existing evidence base for SDD and how willing are they to participate in
further research?
Research question 4: What are the views of key stakeholders about the likely positive and negative
consequences of implementing SDD in ICUs and what is the relative importance of these beliefs in
inﬂuencing overall views about SDD?
Research question 5: What are the views of key stakeholders about the likely barriers to implementing
SDD in ICUs?
Methods
Sample
All participants interviewed in round 1 were invited to participate in round 2. Only those who responded
at round 2 were invited to participate in round 3.
Materials
An instrument was developed in questionnaire format. Item content was based on the ﬁndings from the
ﬁrst round of the Delphi study (see Table 9). The number of items included in round 2 relating to the
Behavioural regulation domain was limited to ensure the resulting questionnaire did not suggest a bias
towards adopting SDD. For example, beliefs reported in the Delphi interviews included hypothetical views
about what would change practice and made the hypothetical assumption that SDD adoption is desirable.
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No speciﬁc item relating to the emotion domain was taken into round 2 because participants were able to
represent the extent of their emotional reaction in the questionnaire response scale (i.e. strongly against,
neutral or strongly in favour). All other beliefs identiﬁed in the analysis were converted into questionnaire
items. The content of these statements was decided using two principles:
1. The wording was chosen to reﬂect the language used in the interview data when possible.
2. The principles of questionnaire design and correct grammar were also observed (i.e. to assure
brevity and maximise clarity and to avoid double negatives in the context of a ‘disagree to agree’
response format).
In round 2, participants were asked to consider 47 items based on the TDF20 and 10 questions relating to
their views about further SDD research. For 46 of the 47 domains-based items, there were two questions:
(1) ‘to what extent do you agree or disagree?’ (on a nine-point Likert scale, with 1 indicating strongly
disagree and 9 indicating strongly agree) and (2) ‘how important is this issue in your overall opinion about
the delivery of SDD to critically ill patients?’ (on a nine-point Likert scale, with 1 indicating not at all
important and 9 indicating very important).57 Importance ratings were not requested for the item relating
to overall opinion on SDD (‘I am opposed to SDD’) because the importance of this item is reﬂected in the
response format that assessed strength of agreement/disagreement.
The questionnaire was piloted with ﬁve clinicians who were not part of the Delphi study sample (one from
the UK, one from Canada and three from Australia). The pilot process was also used to inform the
wording of the participant information sheet. In round 3, participants were provided with feedback about
the overall group responses to each question (in the form of a frequency histogram, Figure 3), they were
given a reminder of their own previous response and were then asked to rate to the item again. Both
rounds 2 and 3 were delivered online.
Procedure
E-mails were sent to all 47 participants from round 1 with individual links to the electronic questionnaire.
Responses were monitored and reminders sent to non-responders after a 2-week interval. After a further
week, remaining non-responders were sent a second reminder (by telephone when possible, or by e-mail if
unreachable by telephone).
Data management and analysis
Two participants responded late to round 2 (after feedback material had been produced). They were
nevertheless included in the analysis reported in this chapter.
Ethics approval for the Delphi study was granted by NHS North of Scotland Ethics Service (10/S0801/69).
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FIGURE 3 Screenshot of a round 3 item.
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Results
Participant characteristics
Forty-four participants completed round 2 (94%) and 42 completed round 3 (95% of round 2 participants,
89% of total sample). The breakdown of participation by stakeholder group is given in Table 10. The table
shows that the recruitment target of 10 participants (see Chapter 3, Methods) per professional group was
met at the end of round 3. The participants who had experience of using SDD were spread across all
professional groups (one, one, ﬁve and two of the intensivists, pharmacists, microbiologists and ICU
leads, respectively).
Participants’ perception of their own knowledge was measured with the item ‘I know the SDD evidence
base well enough to have an informed opinion of its use’. As shown in Figure 4, the participants generally
tended to rate themselves as knowledgeable about SDD (modal score of 7 on a nine-point scale).
However, 12 participants rated themselves below the mid-point of the scale. It was expected that these
participants would be more likely to alter their responses in round 3 after viewing the round 2 feedback.
This prediction was tested on the round 3 data, reported below (see Figure 7). Further participant
characteristics are reported in Chapter 3.
TABLE 10 Breakdown of Delphi participation by stakeholder group
Delphi
round Intensivists ICU pharmacists Medical microbiologists
ICU clinical leads/ICU nurse
managers or educators Total
2 11 11 11 6/5 (group total: 11) 44
3 11 10 10 6/5 (group total: 11) 42
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FIGURE 4 Round 3 responses to knowledge item ‘I know the SDD evidence base well enough to have an informed
opinion of its use’.
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The frequency distributions of all items at round 3 are presented in Appendix 4. The following sections
report the remaining results of the quantitative Delphi rounds in four parts. First, we report the stability of
responses between round 2 and round 3, addressing both individual-level and group-level stability.
Second, we provide summary data relating to beliefs about the consequences of delivering SDD,
addressing the question ’what is the perceived importance of these beliefs in inﬂuencing overall views
about SDD?’ Third, we describe the range and level of participants’ agreement with each questionnaire
item in terms of levels of consensus among the Delphi panel. Finally, we describe data relating to
participants’ views about further SDD research.
Stability of ratings from round 2 to round 3
The Delphi literature provides a range of guidance about assessing stability.58,59 Our innovative approach
was to assess stability at the within-individual level (individual change scores) and at the within-group level
(changes in group means) as follows. Individual-level change scores were calculated, such that a score of
zero, signifying identical responses in round 2 and round 3, demonstrated high stability. As shown in
Table 11, the percentage of individuals whose round 3 response differed by≤ 1 scale point ranged from
100% (for the item ‘SDD reduces VAP’) to 76% (for the item ‘There are conflicting opinions on antibiotic
use among clinical microbiologists/ID physicians and ICU physicians’). Histograms of these two items are
given in Figure 5. There was thus high individual-level stability of responses from round 2 to round 3,
with > 75% of change scores in the range −1 to 1 for all items.
TABLE 11 Stability of responses from round 2 to round 3
Item
Individual-level change Group-level change
% of participants
with change
score of 0
% of participants
with change
score of +/–1
Change in mean score,
round 2 to round 3
Units using SDD have better clinical
outcomes
95 3 0.03
SDD reduces VAP 90 10 0.10
The decision to adopt SDD requires a
review and appraisal of the current
best evidence
88 10 0.14
SDD would be a dramatic shift from our
current practice
86 10 0.10
I would support my ICU participating in a
nationwide randomised control trial (RCT)
of SDD
85 10 0.10
I know the SDD evidence base well enough
to have an informed opinion regarding its use
85 13 0.20
SDD reduces length of stay 85 10 0.00
I would support my centre being involved in
a study to promote the adoption of SDD
83 14 0.19
SDD causes unpleasant side-effects for patients 83 12 –0.12
SDD increases antibiotic resistance 83 10 –0.07
There is no mortality beneﬁt associated
with SDD
83 12 –0.07
SDD is outdated 83 12 –0.12
The skills required to administer SDD fall within
the competencies of our ICU nursing staff
81 19 0.19
continued
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TABLE 11 Stability of responses from round 2 to round 3 (continued )
Item
Individual-level change Group-level change
% of participants
with change
score of 0
% of participants
with change
score of +/–1
Change in mean score,
round 2 to round 3
The SDD evidence base is not generalisable
to my patient population
81 17 0.10
SDD drugs are expensive 81 14 0.07
SDD increases nursing workload 81 14 0.00
I am opposed to the i.v. component of SDD 81 10 0.12
I would be more likely to participate in a
RCT if patients in the control arm received
VAP bundles as usual care (including
chlorhexidine mouthwash/gel and head
up positioning)
81 10 0.33
I could inﬂuence whether SDD is adopted in
my hospital
79 21 0.17
Educating staff would be expensive 79 12 –0.19
I am opposed to SDD 78 22 –0.12
Part of the decision to adopt SDD requires
agreement about which patients will
receive it
78 20 0.20
We are addressing ventilator-associated
pneumonia using other strategies
78 20 0.20
The decision to adopt SDD requires
consensus between my colleagues
78 20 0.10
Prophylactic antibiotic use in SDD is at odds
with my professional responsibilities
78 17 0.05
Prophylactic antibiotic use in SDD is at odds
with my professional training
78 15 –0.05
SDD reduces hospital-acquired infections 78 23 0.03
I would be more likely to participate in a
RCT if it included pretrial, during-trial and
post-trial monitoring of antibiotic resistance
in all patients whether in the RCT or not
77 18 0.41
The SDD evidence base is not generalisable
to my country
76 19 0.17
Overall, SDD is cost-effective 76 17 0.02
SDD increases pharmacy workload 76 24 0.00
I would be more likely to participate in a
RCT if cost–beneﬁt analysis was included
76 22 0.12
SDD is straightforward to deliver 74 19 0.33
I would be more likely to participate in a
RCT if it included pretrial, during-trial and
post-trial monitoring of antibiotic resistance
in patients in the RCT
74 17 0.38
I have concerns about the speciﬁc
antimicrobials you need to use
74 17 –0.02
Further SDD RCTs are ethical 73 22 0.32
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TABLE 11 Stability of responses from round 2 to round 3 (continued )
Item
Individual-level change Group-level change
% of participants
with change
score of 0
% of participants
with change
score of +/–1
Change in mean score,
round 2 to round 3
We are addressing hospital-acquired
infections using other strategies
73 20 0.34
SDD will not be adopted without a local
champion
73 17 0.39
The SDD evidence base has been generated
in countries with different resistance proﬁles
to my country
73 20 0.28
Overall, SDD beneﬁts the patients to whom
it is delivered
71 24 –0.05
SDD would increase ICU C. difficile
infections
71 21 0.07
I would be more likely to participate in a
RCT if mortality is the end point
71 19 –0.02
I know to which patients I would
administer SDD
71 22 0.32
The local decision to adopt SDD would be
inﬂuenced by regulatory requirements
71 20 0.41
There are no national guidelines about SDD 71 15 0.44
The use of pastes may interfere with other
treatments
69 19 0.14
My hospital tries to reduce antibiotic use 68 24 0.44
SDD increases microbiology workload 68 20 0.07
I am reassured that our position on SDD
adoption is in line with other hospitals
68 17 0.12
Our unit VAP rates are low 67 26 0.02
The risks of SDD outweigh the beneﬁts 67 21 –0.07
SDD is not on my units list of clinical
priorities
66 29 0.10
There are conﬂicting opinions on antibiotic
use among medical microbiologists/ID
physicians and ICU physicians
66 10 0.39
My concerns about antibiotic resistance
limit my willingness to participate in future
RCTs of SDD
64 21 0.00
SDD is not a topic of discussion among my
colleagues
63 24 0.17
Research to date has not adequately
addressed concerns about antibiotic
resistance and SDD
63 23 0.58
I would be more likely to participate in a
RCT if patients in the control arm received
selective oral decontamination as usual care
(oral antibiotic pastes only)
62 17 –0.52
ID, infectious diseases.
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Item: SDD reduces VAP
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Item: there are conflicting opinions on antibiotic use
among medical microbiologists/infectious diseases
physicians and ICU physicians
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FIGURE 5 Histograms of change scores (to indicate individual-level stability) from round 2 to round 3 for the items
with (a) the most and (b) the least stability.
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Group-level stability for each item was assessed by computing the change in arithmetic mean from
round 2 to round 3. On the nine-point scale, a change of one scale point in the mean agreement level for
any item was considered a potentially important change in views. Mean change scores are displayed in the
last column of Table 11 (items presented in order of stability). These showed a high level of stability of
views about SDD, with mean differences ranging from 0 to 0.52. In summary, at both the individual and
group levels, the data appeared to be highly stable; therefore, the Delphi study did not proceed to a
fourth round.
Group-level stability was also compared across stakeholder groups. Analysis of variance on change scores
by group showed that there was a greater level of change from round 2 to round 3 in the clinical lead/
nurse managers group than in the other stakeholder groups (Figure 6).
Participants who reported a low level of perceived knowledge (i.e. scoring below the mid-point for the item
‘I know the SDD evidence base well enough to have an informed opinion of its use’ at round 2) showed
greater change in their responses from round 2 to round 3 (mean change 0.23, SD 0.35) than participants
with a higher level of perceived knowledge (mean change 0.08, SD 0.18), as displayed in Figure 7.
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FIGURE 6 Stability of responses from round 2 to round 3 for each stakeholder group. Note: the clinical lead group
includes ICU clinical leads and ICU nurse managers or educators.
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Importance ratings at round 3: beliefs about the consequences of selective
decontamination of the digestive tract
The importance of each questionnaire item was assessed by calculating the mean rating of importance
given by participants to the question ‘How important is this issue in your overall opinion about the delivery
of SDD to critically ill patients?’. Table 12 presents the mean ratings of importance for each item assessing
beliefs about consequences, presented in order of importance.
Importance ratings at round 3: domains level
Table 13 presents a range of indices that may indicate the relative importance of barriers to
implementation for the other 11 theoretical domains on which this study was based.
Table 13 shows that across different measures of importance, a number of other theoretical domains
(in addition to Beliefs about consequences) included potentially important barriers to the implementation
of SDD. The most elaborated domain in round 1, and the domain rated as most important in round 3, was
Memory, attention and decision processes. However, as shown above, some less well-elaborated domains
at round 1, for example, Behavioural regulation, were rated within the most important at round 3.
Agreement ratings at round 3: consensus of opinions about selective
decontamination of the digestive tract
The Delphi literature operationalises consensus in various ways. In this study, we were interested not only
in the proportion of participants who agreed with each item, but also in the proportion of participants
who were uncertain about their agreement with the items. Hence, levels of consensus for the questions
‘To what extent do you agree or disagree…?, were assessed by noting the highest percentage of
participants whose scores fell within any three-point band on the nine-point scale.53 Table 14 displays a
summary of the item content, grouped by the mid-point of the most populous three-point band and by
consensus level. As shown in the table, there was high consensus (> 90% of sample within a three-point
band) around strong agreement (mid-point of 8) for a subset of items. There was also consensus around
uncertainty (mid-points around 4, 5 and 6) for different kinds of items.
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Self-reported knowledge score (round 2)
FIGURE 7 Self-reported knowledge of SDD evidence base and stability of responses from round 2 to round 3.
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TABLE 12 Mean ratings of importance of beliefs about the consequences of SDD at round 3
Item stem Mean rating
SDD increases antibiotic resistance 7.62
SDD would increase ICU C. difficile infections 7.17
The risks of SDD outweigh the beneﬁts 7.07
SDD reduces VAP 6.98
SDD reduces hospital-acquired infections 6.86
There is no mortality beneﬁt associated with SDD 6.70
Overall, SDD is cost-effective 6.69
Overall, SDD beneﬁts the patients to whom it is delivered 6.68
Units using SDD have better clinical outcomes 6.64
I have concerns about the speciﬁc antimicrobials you need to use 6.55
I am opposed to the i.v. component of SDD 6.52
SDD reduces length of stay 6.36
SDD causes unpleasant side-effects for patients 5.90
SDD increases nursing workload 5.86
SDD drugs are expensive 5.83
SDD increases pharmacy workload 5.24
SDD increase microbiology workload 5.05
Educating staff would be expensive 4.90
TABLE 13 Comparison of importance ratings of domains across rounds
Domain
Mean
importance
(round 3)
Extent of
elaboration
(round 1)
(number of
utterances coded)
Rated as
qualitatively
important (round 1)
(ratings based on
content of interviews)
Number of
items generated
for round 2
Memory, attention and
decision processes
7.88 154 Yes 4
Knowledge 7.48 154 Yes 3
Behavioural regulation 7.06 15 Yes 3
Skills 6.67 52 No 1
Motivation and goals 6.51 122 Yes 6
Environmental context
and resources
6.44 90 Yes 4
Nature of the behaviour 6.13 31 No 3
Social inﬂuences 6.07 6 Yes 2
Professional role and identity 5.65 13 Yes 3
Beliefs about capabilities 5.31 18 No 1
Emotion N/A 1 No 0
N/A, not applicable.
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TABLE 14 Summary of item content by each level of consensus
Consensus
Number
of items
Theoretical
domains Item
Mid-point of most populous three-point band: 8
> 90% 8 Memory, attention
and decision
processes
The decision to adopt SDD requires consensus between my
colleagues
Part of the decision to adopt SDD requires agreement about which
patients will receive it
Motivation We are addressing hospital-acquired infections using other strategies
We are addressing ventilator-associated pneumonia using other strategies
Behavioural
regulation
My hospital tries to reduce antibiotic use
Skills The skills required to administer SDD fall within the competencies of
our ICU nursing staff
Research
a
I would be more likely to participate in a RCT if patients in the
control arm received VAP bundles as usual care (including
chlorhexidine mouthwash/gel and head up positioning)
I would be more likely to participate in a RCT if cost–beneﬁt analysis
was included
75–90% 6 Research
a
Further SDD RCTs are ethical
I would be more likely to participate in a RCT if it included pretrial,
during-trial and post-trial monitoring of antibiotic resistance in all
patients whether in the RCT or not
I would be more likely to participate in a RCT if it included pretrial,
during-trial and post-trial monitoring of antibiotic resistance in
patients in the RCT
I would support my ICU participating in a nationwide RCT of SDD
Memory, attention
and decision
processes
The decision to adopt SDD requires a review and appraisal of the
current best evidence
Social inﬂuence SDD will not be adopted without a local champion
50–74% 6 Behavioural
regulation
There are no national guidelines about SDD
The local decision to adopt SDD would be inﬂuenced by regulatory
requirements
Motivation SDD is not on my Units list of clinical priorities
SDD is not a topic of discussion among my colleagues
Nature of the
behaviour
SDD would be a dramatic shift from our current practice
Research
a I would support my centre being involved in a study to promote the
adoption of SDD
Mid-point of most populous three-point band: 7
> 90% 0 N/A
75–90% 3 Beliefs about
capabilities
I could inﬂuence whether SDD is adopted in my hospital
Beliefs about
consequences
SDD increases nursing workload
Knowledge Research to date has not adequately addressed concerns about
antibiotic resistance and SDD
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TABLE 14 Summary of item content by each level of consensus (continued )
Consensus
Number
of items
Theoretical
domains Item
50–74% 5 Environmental
context and
resources
The SDD evidence base has been generated in countries with
different resistance proﬁles to my country
Knowledge I know to which patients I would administer SDD
Beliefs about
consequences
SDD would increase ICU C. difficile infections
Nature of the
behaviour
SDD is straightforward to deliver
Professional role
and identity
There are conﬂicting opinions on antibiotic use among medical
microbiologists/ID physicians and ICU physicians
Mid-point of most populous three-point band: 6
> 90% 0 N/A
75–90% 3 Beliefs about
consequences
Overall, SDD beneﬁts the patients to whom it is delivered
SDD reduces hospital-acquired infections
SDD increases pharmacy workload
50–74% 12 Beliefs about
consequences
SDD reduces VAP
SDD increases antibiotic resistance
SDD increases microbiology workload
I am opposed to the i.v. component of SDD
I have concerns about the speciﬁc antimicrobials you need to use
Environmental
context and
resources
SDD drugs are expensive
The SDD evidence base is not generalisable to my country
Nature of the
behaviour
The use of pastes may interfere with other treatments
Knowledge I know the SDD evidence base well enough to have an informed
opinion regarding its use
Motivation Our unit VAP rates are low
Social I am reassured that our position on SDD adoption is in line with
other hospitals
Research
a
I would be more likely to participate in a nationwide RCT of SDD if
mortality is the primary end point
Mid-point of most populous three-point band: 5
> 90% 0 N/A
75–90% 2 Beliefs about
consequences
Overall, SDD is cost-effective
SDD reduces length of stay
50–74% 1 Beliefs about
consequences
SDD causes unpleasant side effects for patients
continued
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Beliefs about consequences items (n = 18) made up 38% of the domains-based items, but a striking
feature of Table 14 is that all but one of these items had either a low level of consensus (e.g. 50–75%
consensus for SDD increases C. difficile) and/or consensus around the middle of the scale (e.g. SDD
reduces VAP, concerns about speciﬁc antimicrobials, cost-effectiveness, length of stay, mortality beneﬁt).
In general, the Beliefs about consequences items that were rated as more important (see Table 12) had
lower agreement scores (e.g. mortality beneﬁt was important, nursing workload was less important).
Another interesting ﬁnding is that no-one reported strong opposition to SDD although scores ranged from
1 to 7 (where 1 means not opposed to SDD and 9 means opposed to SDD).
TABLE 14 Summary of item content by each level of consensus (continued )
Consensus
Number
of items
Theoretical
domains Item
Mid-point of most populous three-point band: 4
> 90% 0 N/A
75–90% 2 Beliefs about
consequences
Units using SDD have better clinical outcomes
The risks of SDD outweigh the beneﬁts
50–74% 3 Beliefs about
consequences
There is no mortality beneﬁt associated with SDD
Environmental
context and
resources
The SDD evidence base is not generalisable to my patient population
Motivation SDD is outdated
Mid-point of most populous three-point band: 3
> 90% 0 N/A
75–90% 0 N/A
50–74% 1 Beliefs about
consequences
Educating staff would be expensive
Mid-point of most populous three-point band: 2
> 90% 0 N/A
75–90% 0 N/A
50–74% 3 Professional role
and identity
Prophylactic antibiotic use in SDD is at odds with my professional
responsibilities
Beliefs about
consequences
I am opposed to SDD
Research
a
I would be more likely to participate in a nationwide RCT of SDD if
patients in the control arm received selective oral decontamination
as usual care (oral antibiotic pastes only)
No consensus
(< 50%) 2 Professional role
and identity
Prophylactic antibiotic use in SDD is at odds with my professional
training
Researcha My concerns about antibiotic resistance limit my willingness to
participate in future RCTs of SDD
ID, infectious diseases; N/A, not applicable.
a Although not a theoretical domain, data relating to further SDD research are also included.
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To examine potential differences between professional groups, we closely inspected four key beliefs about
the consequences of SDD (‘There is no mortality benefit’, ‘The risks outweigh the benefits’, ‘SDD reduces
VAP’ and ‘SDD increases antibiotic resistance’). We selected these beliefs to illustrate patterns of group
responses because they were rated as important and had a range of levels of consensus, but the modal
values were towards the centre of the response scale (reﬂecting uncertainty). Responses of the mean
scores for the four professional groups showed that the most negative views were reported by pharmacists
and clinical leads for ‘There is no mortality benefit’, by microbiologists for ‘The risks outweigh the
benefits’, by pharmacists for ‘SDD reduces VAP’ and by intensivists for ‘SDD increases antibiotic resistance’.
In other words, there was no consistent pattern of unfavourable views based on professional group.
Furthermore, based on these items, the responses of participants who were current SDD users were only
slightly more positive (in the order of 0.5 of a scale point) than the responses of participants who were not
current SDD users. Owing to small group sizes, it was not appropriate to test the signiﬁcance of
these differences.
Non-normal distributions
Where consensus was ≤ 60% of responses occurring within a three-point band, the statistical description
no longer portrayed the nature of the distribution of responses. For over half of these items (n = 9), there
was evidence suggesting bimodality as shown in Figure 8.
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FIGURE 8 Non-normal distributions for items with consensus at ≤ 60% of responses occurring within a three-point
band. A notable pattern was that in seven of these nine items, at least 20% of the participants registered a score of 5,
reflecting uncertainty. (a) ‘SDD is straightforward to deliver’; (b) ‘I am reassured that our position on SDD
adoption is in line with other hospitals’; (c) ‘I would be more likely to participate in a RCT if mortality is the end
point’; (d) ‘I am opposed to the i.v. component of SDD’; (e) ‘SDD is outdated ’; (f) ‘The SDD evidence base is not
generalisable to my patient population’; (g) ‘I am opposed to SDD’; (h) ‘Prophylactic antibiotic use in SDD is at
odds with my professional training’; and (i) ‘My concerns about antibiotic resistance limit my willingness to
participate in future RCTs of SDD’. (continued)
DOI: 10.3310/hta18250 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 25
53
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
60
50
40
30
20
10
0
P
e
r 
ce
n
t
1 2 3 4 5 6 7 8 9
(b)
Responses
60
50
40
30
20
10
0
P
e
r 
ce
n
t
1 2 3 4 5 6 7 8 9
(c)
Responses
FIGURE 8 Non-normal distributions for items with consensus at ≤ 60% of responses occurring within a three-point
band. A notable pattern was that in seven of these nine items, at least 20% of the participants registered a score of 5,
reflecting uncertainty. (a) ‘SDD is straightforward to deliver’; (b) ‘I am reassured that our position on SDD
adoption is in line with other hospitals’; (c) ‘I would be more likely to participate in a RCT if mortality is the end
point’; (d) ‘I am opposed to the i.v. component of SDD’; (e) ‘SDD is outdated ’; (f) ‘The SDD evidence base is not
generalisable to my patient population’; (g) ‘I am opposed to SDD’; (h) ‘Prophylactic antibiotic use in SDD is at
odds with my professional training’; and (i) ‘My concerns about antibiotic resistance limit my willingness to
participate in future RCTs of SDD’. (continued)
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FIGURE 8 Non-normal distributions for items with consensus at ≤ 60% of responses occurring within a three-point
band. A notable pattern was that in seven of these nine items, at least 20% of the participants registered a score of 5,
reflecting uncertainty. (a) ‘SDD is straightforward to deliver’; (b) ‘I am reassured that our position on SDD
adoption is in line with other hospitals’; (c) ‘I would be more likely to participate in a RCT if mortality is the end
point’; (d) ‘I am opposed to the i.v. component of SDD’; (e) ‘SDD is outdated ’; (f) ‘The SDD evidence base is not
generalisable to my patient population’; (g) ‘I am opposed to SDD’; (h) ‘Prophylactic antibiotic use in SDD is at
odds with my professional training’; and (i) ‘My concerns about antibiotic resistance limit my willingness to
participate in future RCTs of SDD’. (continued)
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FIGURE 8 Non-normal distributions for items with consensus at ≤ 60% of responses occurring within a three-point
band. A notable pattern was that in seven of these nine items, at least 20% of the participants registered a score of 5,
reflecting uncertainty. (a) ‘SDD is straightforward to deliver’; (b) ‘I am reassured that our position on SDD
adoption is in line with other hospitals’; (c) ‘I would be more likely to participate in a RCT if mortality is the end
point’; (d) ‘I am opposed to the i.v. component of SDD’; (e) ‘SDD is outdated ’; (f) ‘The SDD evidence base is not
generalisable to my patient population’; (g) ‘I am opposed to SDD’; (h) ‘Prophylactic antibiotic use in SDD is at
odds with my professional training’; and (i) ‘My concerns about antibiotic resistance limit my willingness to
participate in future RCTs of SDD’. (continued)
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FIGURE 8 Non-normal distributions for items with consensus at ≤ 60% of responses occurring within a three-point
band. A notable pattern was that in seven of these nine items, at least 20% of the participants registered a score of 5,
reflecting uncertainty. (a) ‘SDD is straightforward to deliver’; (b) ‘I am reassured that our position on SDD
adoption is in line with other hospitals’; (c) ‘I would be more likely to participate in a RCT if mortality is the end
point’; (d) ‘I am opposed to the i.v. component of SDD’; (e) ‘SDD is outdated ’; (f) ‘The SDD evidence base is not
generalisable to my patient population’; (g) ‘I am opposed to SDD’; (h) ‘Prophylactic antibiotic use in SDD is at
odds with my professional training’; and (i) ‘My concerns about antibiotic resistance limit my willingness to
participate in future RCTs of SDD’.
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Discussion
This Delphi study was designed to address three research questions that could inform further SDD
research. The Delphi participants, consisting of experts from four key stakeholder groups, (1) provided their
views about the validity and adequacy of the SDD evidence base, (2) rated their agreement with, and
importance of, a range of potential positive and negative consequences of SDD and (3) rated the likely
barriers to implementing SDD in ICUs. This discussion draws on the results from round 2 and round 3 of
the study to answer each research question in turn. We then comment on the strengths and limitations of
this Delphi study, identify the methodological developments exempliﬁed and explain how this stage of the
SuDDICU study was used to inform the next stage.
Answers to research questions
i. The validity and adequacy of the existing SDD evidence base was perceived to be limited. There was
consensus around moderate agreement (7 on the nine-point scale) with the item ‘Research to date has
not addressed concerns of antibiotic resistance and SDD’ and consensus around slight agreement (6 on
a nine-point scale) with the items ‘The SDD evidence base is not generalisable to my patient
population’ and ‘The SDD evidence base is not generalisable to my country’. There was consensus
around the mid-point of the scale (reﬂecting uncertainty or equipoise) for the item ‘SDD evidence from
countries with different resistance profiles’. Taken together, these ﬁndings suggest that the Delphi
panel was not persuaded of either the adequacy or the external validity of the evidence base.
ii. A striking aspect of the results was the high level of consensus around uncertainty (or equipoise) for
many of the items from the domain Beliefs about consequences. For the nine items rated as most
important in driving participants’ overall opinion about SDD (i.e. the top 50% of items from Table 12),
the majority of agreement responses occurred within a three-point range with a mid-point of 4, 5 or 6.
The only exception to this was the item ‘SDD would increase ICU C. difﬁcile infections’, for which the
majority of responses occurred within a three-point range with a mid-point of 7. This pattern of
ﬁndings was similar across the four professional groups and across users and non-users of SDD, and
thus suggests a need for further evidence about the consequences of SDD.
iii. In contrast to the Beliefs about the consequences of SDD, the theoretical domains relating to the likely
barriers to implementing SDD in ICUs showed a different pattern of responses. Greater than 90%
consensus around the three-point range 7 to 9 (reﬂecting strong agreement) was evident for items
from the two domains that had the highest importance ratings (> 7). These items focused on perceived
barriers to the decision processes that would be required in order to adopt SDD (‘Requires agreement
among colleagues and agreement about which patients would receive SDD’) and aspects of motivation
(‘VAP and HAI are already being addressed using other strategies’). The other important barrier (i.e.
other domain with a mean importance rating > 7) was Knowledge. This is discussed in Strengths and
limitations. For items with levels of consensus below 60% (within a three-point range), true consensus
was not met as there was evidence of bimodality.
iv. Speciﬁc trial design and feasibility issues were also explored. The majority of participants would support
their ICU’s involvement in a nationwide RCT to evaluate the effectiveness of SDD and this ﬁnding was
assessed further in the national survey (see Chapter 5). There was a high level of consensus (> 90%) in
favour of participating in such a trial if the control arm received VAP bundles and if a cost–beneﬁt
analysis was included. There was also consensus (> 85%) that such a trial should include pretrial,
during-trial and post-trial monitoring of antibiotic resistance. Trial design features and their associated
challenges were also discussed in the interviews with international clinical triallists and are reported
in Chapter 6.
Strengths and limitations
This study beneﬁted from the inclusion of four key clinical groups that could have an inﬂuence on SDD
policy in ICUs or on the way in which SDD is delivered in practice. There was a high retention rate (85%)
of participants across the three Delphi rounds. There was evidence of high stability of responses between
rounds 2 and 3, although less knowledgeable participants shifted signiﬁcantly more than the rest of the
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sample after viewing the group-level feedback from round 2. This stability of opinion suggested that it was
appropriate to interpret the round 3 results and that proceeding to a fourth round was unlikely to produce
new ﬁndings. As for round 1 of the Delphi study, rounds 2 and 3 gathered opinion-based data that have
clear limitations. One belief that emerged in the Delphi study, and for which there was low consensus,
reﬂected the theoretical domain Professional role and identity and was worded in rounds 2 and 3 as
‘There are conflicting opinions on antibiotic use among Medical Microbiologists/ID Physicians and ICU
physicians’. The national survey provided the opportunity to test the accuracy of this belief systematically
as we sampled these two professions (intensive care consultants and clinical microbiologists) for the survey
stage of the study (reported in Chapter 5).
Self-rated knowledge of the ﬁeld was generally high, although a third of the participants rated their
knowledge of the evidence base as uncertain or low. This variation in knowledge of the evidence base is a
potential limitation of the study as it makes uncertainty difﬁcult to interpret. There has been longstanding
debate in the literature regarding the meaning of the ‘neutral’ response in Likert-type response scales (in
this case, the score of 5 in a 1–9 scale).60 When investigating views that may be based on knowledge of
evidence, interpretation is rendered even more uncertain. Box 6 presents three different meanings of a
neutral score in this context.
This point is important because it would be unethical to randomise patients to an effective treatment in a
new clinical trial of SDD if neutral scores on key items were interpreted as equipoise or uncertainty when
actually they could reﬂect ignorance. To check this possibility, we inspected cross-tabulations between
knowledge scores and scores on all the items relating to Beliefs about the consequences of SDD. If neutral
scores on the consequences items were over-represented by participants whose self-assessed knowledge
of the SDD evidence base was at or below the mid-point, this would suggest that a modal score of 5
largely reﬂected ignorance. These cross-tabulations showed that the mid-point on the Beliefs about
consequences items was endorsed by a large proportion of participants whose self-assessed knowledge of
the evidence base was high. The one exception was that participants with higher knowledge scores
tended to agree more strongly that ‘SDD reduces VAP’. Overall, this suggests that endorsement of the
mid-point signiﬁed options 1 or 2 from Box 6: uncertainty arising from evenly balanced evidence or gaps in
the evidence base.
Further methodological strengths
As noted in Chapter 3, Delphi methodology is often associated with achieving consensus whereas, in this
study, we aimed to assess consensus, identifying the most important views and barriers to implementing
SDD and, in particular, assessing the views of the four stakeholder groups about the current evidence base
for SDD. This objective (rather than any imperative to achieve consensus) informed the methodological
approach in this study.
Indices of group stability may mask individual instability if different subgroups change their views in
opposite directions. In this study there was evidence of stability at both the individual and group levels. To
our knowledge, this is the ﬁrst study to assess stability of views at both these levels. The observed stability
enhances our conﬁdence that the identiﬁed views will be relevant over time, unless the proﬁle of evidence
or the knowledge of the evidence changes.
BOX 6 On a scale of 1 to 9, responders may use the neutral score (5) to signify any of the following:
l Clinical equipoise (I am familiar with the evidence base and I believe the evidence is evenly balanced).
l Uncertainty (I am familiar with the evidence base and I believe there are gaps in valid evidence).
l Self-rated ignorance (I am unfamiliar with the evidence base and so I do not know).
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It is also rare in Delphi studies to identify consensus around uncertainty, where this exists, and to contrast
this with consensus around agreement. Given the overarching objective of the study (to identify the most
appropriate SDD research agenda), consensus around uncertainty was of great importance. With regard to
this, the ﬁndings were critically appraised to identify whether uncertainty was likely to have arisen from
inadequacies of the evidence base or inadequacies in individuals’ knowledge of the evidence. For the ﬁrst
time in a Delphi study in this ﬁeld, we explored, in detail, the distributions of responses beyond a simple
cut-off criterion for consensus by identifying different levels of consensus (> 90%, 75–90%, 50–74%).
Below 60% consensus levels, there was evidence of bimodality. In other words, instead of sample statistics
describing the views of one group (spread around a modal score), the distributions of scores suggested
that there were two or more subgroups each with their own (different) modal score. Importantly, the
distribution of responses for the item ‘I am opposed to SDD’ was spread around the two modes 1 (i.e. not
opposed) and 5 (i.e. uncertain). It is possible that this distribution reﬂected subgroups representing
professional groupings with different views of SDD, or groups of participants with either in-depth
knowledge or poorer knowledge of the SDD evidence base. The sample size for the Delphi study was not
sufﬁcient to address this question. Factors associated with opposition to, or support of, SDD were explored
further with the larger sample in the national survey, reported in Chapter 5.
A further strength of this study was its grounding in a theoretical framework that enabled us to distinguish
between factors related to the clinical evidence (i.e. Beliefs about consequences of SDD) and potential
barriers related to more practical issues to do with professional roles, resources and the management of
change. Box 7 presents the key ﬁndings from the Delphi study that inform the need for, and acceptability
of, a clinical effectiveness RCT or an implementation RCT.
BOX 7 How does this stage of the research inform the need for, and acceptability of, an effectiveness RCT or an
implementation RCT?
l There was consensus about uncertainty with regard to the clinical consequences of SDD. This ﬁnding
would appear to support the need for an effectiveness RCT.
l Furthermore, this uncertainty was not associated with poor knowledge of the evidence base in SDD.
These conclusions are tentative and were explored further in the national survey (reported in Chapter 5).
l Further effectiveness or implementation RCTs appeared to be acceptable, with most individuals in the
Delphi study being willing to participate in further randomised studies.
l There was strong support for speciﬁc design features of an effectiveness RCT, including VAP bundles
delivered to patients in the control arm, cost–beneﬁt analysis and pretrial, during-trial and post-trial
monitoring of antibiotic resistance.
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Chapter 5 A UK-wide survey of consultants
in intensive care medicine and consultant
clinical microbiologists
Background
The aim of this stage of the research was to identify current SDD practice and assess the acceptability and
feasibility of further RCTs, or other research designs on SDD, among a wide group of consultants in
intensive care medicine and consultant clinical microbiologists. This study was a large-scale online
questionnaire survey of all consultant members of the UK Intensive Care Society (ICS) and of clinical
microbiologists involved in intensive care in the UK [accessed through their membership of either the
Healthcare Infection Society (HIS) or the British Society for Antimicrobial Chemotherapy (BSAC)]. The study
was designed to complement and build on the results of the Delphi study (reported in Chapters 3 and 4)
by identifying the willingness (intentions) of intensive care consultants and clinical microbiologists to
participate in further SDD research and the predictors of these intentions. The survey was designed to
answer the following research questions:
Research question 6: What are the stated current practices and intentions about SDD of intensive care
consultants and clinical microbiologists with responsibility for critically ill patients about SDD?
Research question 7: If there are uncertainties in the evidence base, do these clinicians believe they could
be addressed in a clinical trial; what research questions, trial design(s) and interventions would be optimal
and what predicts these beliefs?
Methods
Sample
(a) Intensive care consultants
The membership list of the ICS (the primary society for intensive care professionals in the UK) was used to
approach intensive care consultants. The ICS database contains contact details for 2908 intensive care
consultants in the UK. The Intensive Care National Audit and Research Centre (ICNARC) database was also
used as a means of contacting intensive care consultants.
(b) Clinical microbiologists involved in intensive care
Membership lists of the HIS and the BSAC were used to identify potential consultant clinical microbiologist
participants involved in intensive care. The HIS database contains contact details for 629 clinical
microbiologists worldwide and the BSAC contains contact details for 866, with considerable overlap in
membership between the two societies. Both societies assisted with the recruitment procedure to
maximise the possibility that all clinical microbiologists working in intensive care in the UK (estimated at
20% of total membership) were given the opportunity to participate. Hence, we estimated that around
250 microbiologists would be eligible to participate.
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Materials
The development and validation of the questionnaire consisted of two steps:
1. Item generation. We included items relating to the issues identiﬁed in the Delphi study as important.
This included overall views about SDD, intention (willingness) to participate in a randomised trial and
the factors likely to inﬂuence these intentions (e.g. beliefs about the consequences of SDD, views about
the ethics of further SDD effectiveness research). The questionnaire commenced with preliminary
questions to check participant eligibility: (1) ‘Have you answered this questionnaire before?’ and
(2) ‘Do you have clinical involvement in the care of patients in intensive care?’. The questionnaire was
required to be relatively brief to maximise response rates and comprised 23 items. The ﬁrst question
asked about current SDD practice in the participants’ units. Further items assessed participants’
knowledge (item 2) and views about SDD (items 3 and 4). Beliefs about consequences was by far the
most elaborated domain in the Delphi study; therefore, the seven items with the highest importance
ratings from this domain at round 3 of the Delphi were included (items 5–11). Items 12–17 were
included to address research question 7. Response options followed guidance for questionnaire design
(seven options for a well-educated sample from 1, strongly disagree, to 7, strongly agree).61 Finally,
six items (items 18–23) were included to assess demographics characteristics in order to describe the
sample and assess the representativeness of the responder group. Participants were also provided with
the space to include free-format comments at the mid- and end point of the questionnaire. The
comments data were used to check the content validity (coverage) of the questionnaire as it was
assumed that participants would comment on any important issues that had been omitted from
the questionnaire. The ﬁnal version of the questionnaire is presented in Appendix 5.
2. Pretesting. The draft questionnaire (and cover letter) was pilot tested to assess wording, acceptability
and length, using personal interviews with four clinical collaborators (these individuals were not from
the sampling frame so that data from all intensive care consultants and microbiologists could be used in
the analysis). Each question was evaluated by the research team in the light of the pilot test ﬁndings
and reworded if necessary to enhance meaning and acceptability.62
Procedure
An e-mail invitation, containing a link to the online questionnaire, was sent to all members of the ICS on
1 December 2011 by the society, on behalf of the study team. Two reminder e-mails were sent to all ICS
members 3 weeks after the ﬁrst posting and 3 weeks after the Christmas and New Year holiday period.
Personalised e-mails were additionally sent to consultant members of the ICNARC case mix programme
on 14 February 2012 by the Director of ICNARC (KMR; one of the SuDDICU study investigators) requesting
their support for the survey and sending an electronic copy of the questionnaire and a link to the
online questionnaire.
E-mail invitations were sent to the clinical microbiologists by the HIS on 1 December 2011. The second
society (BSAC) sent the invitation to its members on 10 February 2012. We relied on the professional
societies to send reminders to their members if they deemed this appropriate based on other
communications being sent at the same time.
The questionnaire instrument was programmed so that clicking on the submit button resulted in upload of
data into an electronic database. Questionnaires were anonymous and so it was not possible to target
reminders to non-responders. The national survey was advertised at a national conference63 in order to
generate publicity and interest from key stakeholder groups and maximise response rates.
Data management and analysis
Analysis included simple descriptive statistical testing and statistical prediction techniques. First, responses
to each question were summarised using frequency distributions. Second, multiple regression techniques
(including linear regression and, when appropriate, logistic regression) were used to identify the predictors
(i.e. theoretical constructs and characteristics of responders) with intention to participate in the SDD
research. The differences between intensive care consultants and microbiologists were explored.
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The comments provided by participants were sorted into three categories: new information (reported in
the results section), elaboration of the reasons for giving certain responses and comments about the
procedure and quality of the questionnaire.
Ethics approval for the national survey was granted by the Research Ethics Board of the College of Life
Sciences and Medicine, University of Aberdeen (CERB/2011/8/633).
Results
Response rates
Invitations were sent to 2908 ICS members (including 1685 intensive care consultants), 528 members of
HIS (excluding 101 invitations that were not delivered), 866 BSAC members and 500 consultants registered
with ICNARC. As mentioned previously, there is likely to be considerable overlap across each of these
membership lists. A recruitment ﬂow chart is displayed in Figure 9.
Responses were received from 468 UK clinicians and the breakdown by professional group is shown in
Table 15. Clinicians were likely to be a member of more than one professional society; therefore, only an
estimate of the response rate could be generated. Furthermore, it was unclear how many e-mail addresses
would have been out of date or how many e-mail messages would have reached spam folders rather than
inboxes of eligible clinicians. We provide a worst-case response rate in Table 15.
Participant characteristics
Four hundred and nineteen participants were consultants in intensive care medicine and 49 were
consultant clinical microbiologists. The sample as a whole reported a high level of experience in clinical
practice (mean 19 years, SD 8 years). Participants also provided descriptive details about the hospital(s)
they worked in, shown in Table 16. For comparative purposes, data from the ICNARC database and UK
49 microbiologists
BSAC: 866 membersHIS: 629 members
Clinical microbiologists
Undelivered: 101
Unopened: 341
419 intensivists
ICNARC: 500
consultants
ICS: 2908 members
(1685 consultants)
Intensive care consultants
FIGURE 9 National survey recruitment flow chart.
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ICUs are presented alongside the participant characteristics of this sample. As shown in Table 16, the
SuDDICU sample had greater representation from larger units and from units afﬁliated with universities.
Participants were asked to report their hospital’s current policy with respect to SDD delivery. Six options
were offered:
1. not delivering SDD and have not considered this issue
2. not delivering SDD after careful consideration
3. not delivering SDD but issue currently being considered
4. delivered SDD in the past but reversed policy and now do not deliver
5. full SDD sometimes delivered but not protocolised, full SDD formally adopted
6. full SDD formally adopted, protocolised and routinely delivered to speciﬁc patient subgroups.
Responses are displayed in Figure 10.
Participants’ self-reported knowledge of the SDD evidence base was assessed with the item ‘I know
the SDD evidence base well enough to have an informed opinion regarding its use’. The mean response
(1, strongly disagree, to 7, strongly agree) to this item was 4.7 (SD 1.4). Intensive care consultants’
responses to this item had greater spread than the microbiologists’ responses, but the modal score was
5 (signifying slight agreement), as displayed in Figure 11.
TABLE 15 Recruitment ﬁgures by professional group
Professional group Participants Estimated denominator
Estimated minimum
response rates
Consultants in intensive care medicine 419 1685
a
25%
Consultant clinical microbiologists 49 250b 20%
Total 468 1935 24%
a Data from ICS secretariat, 2012, personal communication.
b An estimate based on the membership lists of the two major British professional associations for microbiologists: the
BSAC (secretariat, 2012, personal communication) and HIS (secretariat, 2012, personal communication), and the likely
overlap between these memberships (as proposed by the microbiologist on the research team).
TABLE 16 Details of participants’ hospitals
Hospital characteristics SuDDICU sample (%) ICNARC data, n (%)
University affiliation
Full university afﬁliation 52 75 (30)
Partial university afﬁliation 28 42 (17)
No university afﬁliation 19 134 (53)
Private 2 N/A
Number of beds in the ICU
< 10 26 130 (52)
10–20 46 107 (43)
> 20 27 14 (6)
N/A, not applicable.
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Free-text comments on content validity of the questionnaire
Four participants made comments on the content validity of the questionnaire. One of these suggested
that there should have been clearer differentiation between SDD and selective digestive decontamination.
The other three suggested that the questionnaire was insufﬁciently disease speciﬁc and that some
questions should have been asked with respect to speciﬁc disease categories or patient subpopulations
(e.g. trauma patients). A total of 80 participants left a comment and the vast majority of these elaborated
1. Not delivering SDD and
not considered
2. Not delivering SDD after
considering
3. Not delivering SDD and
currently considered
4. Delivered in past but
now not delivering
5. SDD sometimes
delivered but no protocol
6. SDD formally adopted,
delivered and protocolised
0 10 20 30 40
9.1
2.5
4.2
8.1
36.5
39.5
Per cent
FIGURE 10 SDD policy in participants’ hospitals.
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FIGURE 11 Self-reported knowledge of the SDD evidence base (1 = strongly disagree, 7 = strongly agree). Responses
to the item, ‘I know the SDD evidence base well enough to have an informed opinion of its use’. (a) Intensivists;
and (b) microbiologists.
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on their response to particular items. This information will be considered in the design of any future SDD
research, but is not reported further in this chapter.
Views about selective decontamination of the digestive tract
There was a bimodal distribution of responses in both professional groups for the item ‘I am opposed to
SDD’, as shown in Figure 12. The clinical microbiologist participants tended to be less favourable towards
SDD (i.e. towards the right of the scale; modal score of 6) than the intensive care consultant participants
(primary mode of 4), but there was a secondary mode of 2 signifying ‘not opposed’ in both groups.
The association between current SDD delivery and views about SDD is presented in Figure 13.
Strongly
disagree
6. SDD formally adopted,
delivered and protocolised
5. SDD sometimes
delivered but no protocol
4. Delivered in past but
now not delivering
2 3 4 5 6 Strongly
agree
3. Not delivering SDD and
currently considered
2. Not delivering SDD
after considering
1. Not delivering SDD and
not considered
I am opposed to SDD
FIGURE 13 Box and whisker plot of opposition to SDD by SDD delivery group (larger circles represent mean score).
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FIGURE 12 Opposition to SDD by professional group (1 = strongly disagree, 7 = strongly agree). Response to the item
‘I am opposed to SDD’. (a) Intensivists; and (b) microbiologists.
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A one-way analysis of variance on mean score of opposition indicated that there was a difference in mean
scores between the groups. Post hoc pairwise comparisons revealed that group 6, the participants
working in hospitals where SDD was formally adopted, protocolised and routinely delivered, scored
signiﬁcantly lower on opposition to SDD compared with groups 1, 2 and 4. These results were conﬁrmed
using non-parametric tests (Kruskal–Wallis test of medians).
Opposition to SDD was signiﬁcantly correlated with all seven items relating to the beliefs about the
consequences of SDD and with the item ‘I am opposed to the i.v. component of SDD’, as displayed in
Table 17. There was no signiﬁcant association between knowledge of the SDD evidence base and
opposition to SDD.
Regression analysis was performed to investigate multiple predictors of opposition to SDD. Nine item
variables and ﬁve dummy variables (to represent current practice) were entered into the analysis. As shown
in Table 18, there were eight signiﬁcant predictors: current practice (currently delivering full protocolised
SDD), opposition to the i.v. component of SDD, self-assessed knowledge of the evidence base and ﬁve
speciﬁc beliefs about the consequences of delivering SDD. The ﬁve speciﬁc beliefs were SDD increases
antibiotic resistance, SDD beneﬁts patients, SDD reduces HAIs, SDD reduces VAP and risks of SDD
outweigh beneﬁts.
Acceptability of further selective decontamination of the
digestive tract research
Most participants (85%) reported that the current uncertainties in the SDD evidence base should be
addressed in a new study. Participants’ views about whether or not it is ethically acceptable to conduct
further RCTs evaluating effectiveness are displayed in Figure 14. The mean score was 5.4 (SD 1.5) on the
scale range of 1–7, indicating that participants tended to agree that further effectiveness RCTs were
ethically acceptable.
TABLE 17 Correlation coefﬁcients between beliefs about SDD, knowledge of SDD and opposition to SDD
Item
Correlation coefﬁcient (for the
relationship with the question
‘I am opposed to SDD’) 95% CI p-value
I am opposed to the i.v. component of
SDD
+0.60 0.54 to 0.66 < 0.001
SDD increases antibiotic resistance +0.61 0.55 to 0.66 < 0.001
Overall, SDD beneﬁts the patients to whom
it is delivered
–0.59 –0.64 to –0.52 < 0.001
The risks of SDD outweigh the beneﬁts +0.23 0.14 to 0.31 < 0.001
SDD reduces HAIs –0.51 –0.57 to –0.44 < 0.001
SDD increases C. difficile infections +0.44 0.35 to 0.50 < 0.001
SDD reduces ventilator-associated
pneumonia
–0.43 –0.49 to –0.34 < 0.001
SDD reduces mortality –0.49 –0.55 to –0.41 < 0.001
I know the SDD evidence base well enough
to have an informed opinion of regarding
its use
–0.01 –0.09 to 0.09 0.82
DOI: 10.3310/hta18250 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 25
67
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
40
30
20
10
0
P
e
r 
ce
n
t
1 2 3 4 5 6 7
(a)
Responses
40
30
20
10
0
P
e
r 
ce
n
t
1 2 3 4 5 6 7
(b)
Responses
FIGURE 14 Views about ethical acceptability of further effectiveness RCTs (1 = strongly disagree, 7 = strongly agree).
Responses to the item ‘It is ethically acceptable to conduct further RCTs evaluating the effectiveness of SDD’.
(a) Intensivists; and (b) microbiologists.
TABLE 18 The predictors of opposition to SDD
Item Coefﬁcient 95% CI p-value
Not delivering SDD and not considered –0.05 –0.26 to 0.17 0.666
Not delivering SDD after considering [Reference category]
Not delivering SDD and currently considered –0.13 –0.49 to 0.23 0.479
Delivered in past but now not delivering 0.24 –0.21 to 0.70 0.297
SDD sometimes delivered but no protocol 0.25 –0.36 to 0.85 0.424
SDD formally adopted delivered and protocolised –0.67 –1.02 to –0.31 < 0.001
I know the SDD evidence base well enough to have an
informed opinion regarding its use
0.08 0.01 to 0.15 0.026
I am opposed to the i.v. component of SDD 0.33 0.27 to 0.40 < 0.001
SDD increases antibiotic resistance 0.22 0.13 to 0.31 < 0.001
Overall, SDD beneﬁts the patients to whom it is delivered –0.24 –0.35 to –0.13 < 0.001
The risks of SDD outweigh the beneﬁts 0.10 0.03 to 0.17 0.005
SDD reduces HAIs –0.15 –0.24 to –0.05 0.003
SDD increases C. difficile infections 0.08 –0.02 to 0.17 0.114
SDD reduces ventilator-associated pneumonia –0.12 –0.22 to –0.01 0.028
SDD reduces mortality –0.03 –0.14 to 0.08 0.616
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Ethical acceptability of further effectiveness research was signiﬁcantly correlated with four items relating to
the beliefs about the consequences of SDD, as displayed in Table 19.
Regression analysis was performed to investigate multiple predictors of views about the ethical
acceptability of further SDD effectiveness research. Seven variables were entered into the analysis. As
shown in Table 20, there were two signiﬁcant predictors: ‘Overall, SDD benefits the patients to whom it is
delivered’ and ‘SDD reduces VAP’.
It could be argued that instead of a linear relationship between ethical acceptability and beliefs about
consequences, there should be an inverted-U relationship between these factors. That is, if the evidence
base clearly shows beneﬁt or harm, then further effectiveness research will be uninformative, and
uncertainty (i.e. the neutral response on the Likert scale) should be associated with the highest levels of
ethical acceptability. To identify whether or not there was a signal in the data to support this possibility,
we inspected the scatterplots for two key beliefs about the consequences of SDD: increase in antibiotic
resistance and reduction in mortality. These scatterplots, displayed in Figure 15, indicate a weak signal for
a curvilinear relationship as proposed. However, the trend was not strong enough to test for an inverted
U–shaped relationship in a multivariate model.
TABLE 20 The predictors of views about the ethical acceptability of further SDD effectiveness research
Item Coefﬁcient 95% CI p-value
SDD increases antibiotic resistance 0.09 –0.03 to 0.21 0.15
Overall, SDD beneﬁts the patients to whom it is delivered 0.17 0.01 to 0.33 0.04
The risks of SDD outweigh the beneﬁts 0.07 –0.04 to 0.17 0.21
SDD reduces HAIs 0.10 –0.04 to 0.24 0.15
SDD increases C. difficile infections –0.07 –0.21 to 0.07 0.32
SDD reduces ventilator-associated pneumonia 0.18 0.02 to 0.33 0.02
SDD reduces mortality –0.08 –0.24 to 0.08 0.33
TABLE 19 Correlation coefﬁcients between beliefs about the consequences of SDD and ethical acceptability of
further SDD effectiveness research
Item
Correlation coefﬁcient (for the relationship
with the question ‘Further SDD effectiveness
research is ethical’) 95% CI p-value
SDD increases antibiotic resistance –0.05 –0.14 to 0.04 0.31
Overall, SDD beneﬁts the patients to
whom it is delivered
+0.21 0.12 to 0.30 < 0.001
The risks of SDD outweigh the
beneﬁts
+0.01 –0.08 to 0.10 0.79
SDD reduces HAIs +0.19 0.10 to 0.27 < 0.001
SDD increases C. difficile infections –0.08 –0.17 to 0.01 0.09
SDD reduces ventilator-associated
pneumonia
+0.22 0.13 to 0.30 < 0.001
SDD reduces mortality +0.13 0.04 to 0.22 0.004
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FIGURE 15 Scatterplots indicating a curvilinear relationship between ethical acceptability of further SDD
effectiveness research (on y-axis) and (a) ‘SDD increases antibiotic resistance’ and (b) ‘SDD reduces mortality’
(on x-axis). (1 = strongly disagree, 7 = strongly agree.)
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The multimethod nature of this study afforded the opportunity to examine the question of the relative
importance of different beliefs about the consequences of delivering SDD, using a multimeasure approach
to check whether or not three indices of importance converged. The three indices of importance were:
1. the frequency with which each belief was elicited in the Delphi round 1 interviews (as discussed
in Chapter 3)
2. importance ratings (possible range 1–9) made by the Delphi participants in round 3 (reported
in Chapter 4)
3. the size of the standardised regression coefﬁcients when the beliefs were used to predict scores
representing opposition to SDD (in the national survey, reported in Table 18).
The three indicators of importance for the Beliefs about consequences items in the national survey are
presented in Table 21 in order of apparent importance from round 1 data. The table shows that, on all
three measures, the potential effect of SDD on antibiotic resistance was the most important clinical
consequence of SDD. Furthermore, the rank orders of the importance indicators based on round 1 data
and regression coefﬁcients were consistent (except for one item with changed wording for the national
survey). The least convergent index of importance was the mean rating of importance at round 3.
Feasibility of further selective decontamination of the digestive tract research
Participants were asked to state whether they would be prepared for their patients or centre to be
randomised in an effectiveness RCT and the majority of participants indicated that they would (78.4%), as
displayed in Table 22. Furthermore, almost all participants (94.2%) reported that they would go along with
an effectiveness RCT if their colleagues supported it. Almost two-thirds of participants (63.5%) were
willing to support an implementation study. Only 14.3% of participants were unwilling to participate in
TABLE 21 The importance of seven possible clinical outcomes (beneﬁts and harms) using three indices: Delphi
round 1 number of utterances, Delphi round 3 importance ratings and national survey standardised regression
coefﬁcients predicting opposition to SDD
Item
Extent of elaboration
(number of utterances
round 1 interviews)
Mean ratings
of importance
(round 3)
Standardised regression
coefﬁcients to predict
opposition to SDD
SDD increases antibiotic resistance 92 7.6 0.20
Overall, SDD beneﬁts the patients to
whom it is delivered
60 6.7 –0.19
SDD reduces hospital-acquired infections 37 6.9 –0.12
SDD reduces VAP 29 7.0 –0.09
There is no mortality beneﬁt associated
with SDD
a
23 6.7 –0.02
The risks of SDD outweigh the beneﬁts 22 7.1 0.08
SDD would increase ICU C. difficile
infections
7 7.2 0.06
a This item was reworded for the national survey as ‘SDD reduces mortality’.
TABLE 22 Frequency of sample willing to participate in further research
Willing to participate
Total sample frequency
(n = 468) (%)
Intensivists frequency
(n = 419) (%)
Medical microbiologists
frequency (n = 49) (%)
Effectiveness RCT 367 (78.4) 346 (82.6) 21 (42.9)
Implementation study 297 (63.5) 280 (66.8) 17 (34.7)
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either an effectiveness RCT or an implementation study. The majority of participants (58.1%) indicated
they were willing to participate in either type of study design. A lower proportion of microbiologists than
intensive care consultants were prepared to participate in an effectiveness RCT (42.9%) or an
implementation study (34.7%).
Multiple regression analyses were conducted to examine the predictors of participants’ willingness to
participate in (1) an effectiveness RCT and (2) an implementation study. The results for the ﬁrst regression
analysis are displayed in Table 23.
Table 23 shows that willingness to participate in an effectiveness trial was predicted by participants’
responses to the items asking whether or not it is ethically acceptable to conduct further RCTs evaluating
the effectiveness of SDD and participants’ overall opposition to SDD. However, the most powerful
predictor of this item was whether or not a new study should address current uncertainties in the
evidence base.
The results of the regression analysis of willingness to participate in an implementation study are displayed
in Table 24. Willingness to participate in an implementation study was predicted by overall opposition to
SDD and responses to the item ‘Current uncertainties in the evidence base should be addressed in a
new study’.
Participants were further asked to specify the components of a control group for a possible future
effectiveness RCT of SDD. Responses are summarised in Table 25. The greatest proportion of participants
(90.4%) stated a desire for a control group that delivered VAP bundles. Slightly fewer participants
preferred the control group to include chlorhexidine mouthwash (85.7%) and a smaller proportion of
participants felt that the control group should include a ‘standard practice’ intervention that would reﬂect
variations in current practice. In terms of outcome measures, the majority of participants (91.9%)
agreed that an effectiveness RCT should include a measure of antibiotic resistance (details are presented
in Table 25).
TABLE 23 Regression analysis to predict willingness to participate in further effectiveness research
Item Odds ratio 95% CI p-value
I am opposed to SDD 0.74 0.61 to 0.91 0.004
I am opposed to the i.v. component of SDD 1.02 0.84 to 1.24 0.872
It is ethically acceptable to conduct further RCTs evaluating
the effectiveness of SDD
1.45 1.21 to 1.73 < 0.001
Current uncertainties in the evidence base should be addressed
in a new study
2.33 1.21 to 4.51 0.012
A UK-WIDE SURVEY OF CONSULTANTS
TABLE 24 Regression analysis of intention to participate in an implementation study
Item Odds ratio 95% CI p-value
I am opposed to SDD 0.51 0.42 to 0.62 < 0.001
I am opposed to the i.v. component of SDD 1.13 0.95 to 1.34 0.176
It is ethically acceptable to conduct further RCTs evaluating
the effectiveness of SDD
1.01 0.85 to 1.19 0.925
Current uncertainties in the evidence base should be addressed
in a new study
3.23 1.64 to 6.36 0.001
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Discussion
The national survey recruited 468 intensive care consultants and clinical microbiologists to identify current
SDD practice, current uncertainties in the evidence base and the feasibility of further SDD research.
Answers to research questions
In terms of current SDD practice, around 10% of the sample reported currently delivering SDD whereas
around 40% have not yet considered SDD.
The distribution of scores reﬂecting opposition to SDD was bimodal and this bimodality was evident
among both intensive care consultants and clinical microbiologists. In other words, both professional
groups included a substantial proportion (approximately 20%) who were not opposed to SDD. The other,
primary, mode was at the mid-point of the scale (reﬂecting uncertainty) for intensive care consultants and
at the ‘opposed’ end of the scale for microbiologists. Opposition to SDD was signiﬁcantly predicted by all
the beliefs about consequences items in the questionnaire but was not predicted by self-assessed
knowledge of the SDD evidence base.
A large majority of the participating clinicians reported that uncertainties should be addressed in a new
study, that further SDD research would be ethically acceptable and that they would be prepared to
participate in further SDD research. Hence, further research appears to be appropriate, acceptable and
(from the perspective of recruiting ICUs for a trial) feasible.
As would be expected, there was a strong association between current provision of SDD (with full
protocol) and support for SDD (see Table 18). In terms of participants’ beliefs, the strength of belief about
whether or not SDD increases antibiotic resistance was the strongest predictor of two key opinions:
opposition to SDD and the belief that further SDD research would be ethically acceptable. The strength of
belief that current uncertainties in the evidence base should be addressed in a new study was the
strongest predictor of two intentions: willingness to participate in future effectiveness research and
willingness to participate in future implementation research. There was strong support for the following
trial design features: antibiotic resistance to be measured as an outcome and control group to receive VAP
bundles or chlorhexidine mouthwash.
TABLE 25 Speciﬁcation of the components of an effectiveness RCT
Item
Intensivists,
n (%)
Clinical microbiologists,
n (%)
Total sample,
n (%)
An effectiveness RCT of SDD should include the following components
A control group that receives chlorhexidine mouth wash 366 (87.4) 35 (71.4) 401 (85.7)
A control group that receives ‘VAP bundles’ 382 (91.2) 41 (83.7) 423 (90.4)
A standard practice control group that reﬂects variations
in current practice
227 (54.2) 36 (73.5) 263 (56.2)
A measure of antibiotic resistance as an outcome 389 (92.8) 41 (83.7) 430 (91.9)
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Some differences were evident between intensive care consultants and clinical microbiologists, a ﬁnding
that is not surprising as many microbiologists see their professional role as centred around antimicrobial
stewardship. Hence, the profession repeatedly advances the rationalisation of antibiotic use as a
Department of Health priority.64 However, the current study suggests that not all clinical microbiologists
are certain of the evidence base to support this view in the context of SDD.
Strengths and limitations
The response rate was difﬁcult to estimate but was probably in excess of 25%. Thus, although the results
may not have been based on a representative sample, they do indicate a substantial mass of support
among the intensive care community for further SDD research. Indeed, the number of intensive care
consultants and clinical microbiologists who would be prepared to participate in an effectiveness trial or an
implementation trial involving SDD is far in excess of the number that would be required to mount such a
trial. Furthermore, this study reﬂects the largest number of clinical microbiologists’ views on SDD recorded
to date. However, the response rate remains a substantial limitation to the generalisability of these
ﬁndings. A further limitation is that only two of the four stakeholder groups from the Delphi study were
included in the survey study. However, these two groups (intensive care consultants and clinical
microbiologists) were the two groups that Delphi participants identiﬁed as potentially holding conﬂicting
views. Although there were some differences between these two groups, there was also considerable
overlap in terms of their support of, or opposition to, delivering SDD, as described in Figure 12.
A further limitation may be that the participant group possibly did not fully grasp what is meant by
‘implementation trial’. It is puzzling that so many participants (51%) reported being prepared to participate
in both an effectiveness trial and an implementation trial. On the face of it, an effectiveness trial should
be considered only when there are uncertainties in the evidence base, whereas an implementation trial
should be considered only when the evidence shows that an intervention has clear beneﬁt, but has
not yet been adopted. The implementation trial then evaluates the extent to which an intervention succeeds
in changing practice. Although a naive view is that implementation of evidence-based interventions into
routine practice is a simple matter of publishing a guideline, there is ample evidence that such passive
strategies are often insufﬁcient to improve patient care.65
This survey had a number of methodological strengths. First, the questionnaire items were generated from
theory-based interviews with four stakeholder groups (reported in Chapter 3) and were subsequently
selected for inclusion on the basis of an iterative process of prioritisation (reported in Chapter 4). The
importance of a range of clinical outcomes of SDD was assessed using multiple methods. An extremely
robust ﬁnding across indices of importance was that antibiotic resistance is the most important issue.
Hence, careful attention should be given to measuring this in any further SDD research. Importance ratings
did not converge with the other indices of importance. This has implications for Delphi methodology, as
ratings of importance are key to the assessment of clinical consensus using this approach.53
A further strength is that we identiﬁed that further trials are feasible (i.e. a sufﬁciently large number of
clinicians would be prepared to participate) and also ethically acceptable. Ethical acceptability could
arguably be a function of uncertainty about the evidence base (rather than being a function of certainty
that the intervention is effective). There was a small signal in the data to suggest this may be the way in
which clinicians think about ethical acceptability and such thinking could be investigated in more detail in
future research. Box 8 presents the key ﬁndings from the national survey that inform the need for, and
acceptability of, a clinical effectiveness RCT or an implementation RCT.
A UK-WIDE SURVEY OF CONSULTANTS
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BOX 8 How does this stage of the research inform the need for, and acceptability of, an effectiveness or an
implementation RCT?
l The national survey replicated the major ﬁndings of the Delphi study in that clinicians are uncertain about
the evidence relating to clinical outcomes of SDD, including potential harms, and that more research
is needed.
l Further SDD research was feasible, with 85% of intensive care consultants and clinical microbiologists in
the sample being prepared to participate in future SDD research.
l Further effectiveness or implementation RCTs were regarded as ethically acceptable.
l Monitoring of antibiotic resistance in the context of a trial would be essential. Importance was assessed in
three ways and this was the most important consequence of SDD, according to all three measures.
l Despite reporting uncertainty about the effectiveness the SDD evidence base, the majority of participants
were willing to participate in implementation research to increase uptake of SDD. This suggests that
clinicians may not be aware of what implementation research involves and when it is appropriate.
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Chapter 6 Feasibility of possible future
randomised trials of selective decontamination
of the digestive tract: interview study with
international triallists
Background
Chapters 4 and 5 (Delphi study) reported stakeholders’ beliefs about SDD and about the importance of
further research in SDD. However, while further research might be desirable, it remains unclear what
challenges or barriers may be encountered should further SDD research be proposed. Therefore, the aim
of the study reported in this chapter was to investigate potential feasibility issues associated with possible
future RCTs involving SDD from the perspective of experienced international triallists (expert triallists
with experience of the design and conduct of trials in intensive care and/or the design and conduct of
implementation trials). Implementation trials are randomised studies designed to evaluate interventions
that aim to increase the uptake of evidence-based health care. Such trials are designed to address quality
gaps, rather than evidence gaps, and they address the well-known lag between evidence of effectiveness
and care quality. There is substantial evidence that dissemination alone (of evidence or even of guidelines)
is often insufﬁcient to achieve changes in clinical practice.65
Hence, this study focused on the challenges involved in both the design and delivery of (1) an effectiveness
trial and (2) an implementation trial of SDD in intensive care. We sought to identify possible problems with
feasibility and acceptability (including ethical issues), views about trial design and beliefs about practical
barriers to recruitment and intervention delivery. We also sought comment on potential ways to overcome
these problems and recommendations about trial design (including eligibility criteria and the nature of the
control condition). The overarching research question guiding this study was:
Research question 8: What are the likely challenges in undertaking a large multinational randomised
controlled study of SDD in ICUs?
Methods
Sample
A list of expert international triallists with known expertise in intensive care trials and/or implementation
trials was developed by members of the international research team (MKC, BHC, GB, GSM and one
Australian collaborator). As this study sought the views of experts with in-depth experience in their ﬁeld,
the target sample size was relatively small, being set at 10. This number was likely to provide a suitable
balance between the expected homogeneity of the sample and the study’s objective of eliciting views from
those who might favour a clinical trial and those who might argue for an implementation trial. To ensure
that 10 interviews were available for analysis, we identiﬁed an initial list of 20 expert triallists to approach.
Potential participants from the UK, North America, Europe and Australia were identiﬁed from their public
proﬁle and the research team’s knowledge of the ﬁeld, and were invited to take part if they had expertise
in (1) randomised clinical trials of intensive care interventions or (2) implementation trials.66
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Data collection
Semistructured one-to-one telephone interviews were conducted using a topic guide developed from
expert experience and informed by the identiﬁcation (from earlier phases of the study) of clinicians’ interest
in further SDD research. Telephone interviews were considered a more efﬁcient use of resources (i.e. time,
cost, effort) than face-to-face interviews for generating data on this international sample.67 Topic guide
prompts included questions about participants’ preference for an effectiveness or implementation trial and
aspects of trial design (e.g. individual vs. cluster randomisation), speciﬁcation of the components of the
SDD intervention and of control group care, outcome measurement, recruitment and ethical
considerations. The topic guide for these interviews is included in Appendix 6.
Procedure
The UK clinical lead (GB) sent a personal e-mail to each potential participant informing them that they
would be invited to take part in the study and would receive an information sheet and consent form, by
e-mail, from the project manager (EMD). Those expressing an interest in taking part were contacted to set
up mutually convenient times for a 30-minute recorded telephone interview. A senior triallist (GB)
conducted all interviews by telephone and began by giving a summary of the SuDDICU study. Participants
were asked to provide their general views of conducting further research about SDD in ICUs and any
issues they foresaw arising in undertaking such research. Participants were then asked to consider two
possible trial types: a RCT to evaluate the effectiveness of SDD or a RCT to evaluate a behaviour
change intervention (aimed at health-care professionals and ICUs) to increase uptake of SDD (i.e. an
implementation trial). They were asked to indicate whether or not they had an initial preference for
discussing one particular type of trial (effectiveness vs. implementation). The interviewer returned to the
other option if time allowed. Prompts were used to elicit trial design features and associated challenges
and barriers. Triallists were encouraged to talk freely and prompts were used only if the participants did
not cover speciﬁc areas relating to the research question. While triallists’ preferences for effectiveness or
implementation trials and for speciﬁc trial design features (e.g. cluster randomisation) were explored
during interview, these were not the primary focus of this stage of the research. Preferences were elicited
to provide the context to ask about challenges and barriers to undertaking a large multinational RCT of
SDD in ICUs. Interviews were audio recorded and transcribed verbatim.
Sample characteristics were not requested during interview, as participants’ eligibility for this study was
based on information available from participants’ public proﬁles (e.g. the country in which they work and
their clinical and research expertise) rather than on demographic information (e.g. age).
Data management and analysis
Interview transcripts were analysed thematically using a framework approach.36 The technique involves a
systematic process of inductive qualitative data analysis. Familiarisation with the content of each transcript
was followed by the creation of ‘charts’ (i.e. Word document tables) to summarise issues identiﬁed as
relating to potential challenges and barriers to undertaking further research in the ﬁeld of SDD. The issues
identiﬁed were grouped into themes, discussed within the research team, reﬁned and checked against the
charts to ensure that all relevant issues were accommodated.
One researcher conducted the initial coding of the ﬁrst six transcripts, working systematically through the
transcripts as they became available and highlighting all text referring to (1) trial design/conduct or (2) trial
challenges/barriers. In order to retain the context of each quotation, highlighted sections were extensive
and inclusive of all text relevant to a particular design feature or challenge. Highlighted text from each
transcript was then copied into Word document tables (‘Charting’).36 A second researcher (MEP) reviewed
the coding/highlighting on two transcripts to check that no relevant text had been excluded. MEP
conducted the initial coding of the remaining transcripts and undertook the second phase of analysis:
identifying initial themes and using the themes to group together quotations from different participants.
The headings and content of the tables produced during the charting phase were reﬁned in numerous
versions until all relevant data were tabulated without overlap or duplication. Data were then systematically
examined and emerging typologies discussed with other members of the research team (GB, JJF, EMD) to
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ensure clinical sensibility and methodological rigour. In this study (and in the rest of the SUDDICU study) the
terms ‘acceptability’ and ‘feasibility’ were deﬁned, respectively, as a willingness to participate in further
SDD randomised trials and an ability to participate or to conduct such trials.1
Ethics approval for this study was obtained from the University of Aberdeen College of Life Sciences and
Medicine Ethics Review Board (Ref: CERB/2011/3/610).
Results
Participant characteristics
Twenty-two international triallists were identiﬁed as meeting the eligibility criteria and were invited to
participate. Sixteen triallists were recruited and 13 were interviewed. However, the audio-recording
equipment failed during three interviews, with a resultant loss of data from these participants (T2, T4 and
T8). The 10 interviews that generated completed transcripts were included in the analysis and form the
data presented below. The interviewer’s notes from the other three interviews are presented at the end of
the results section (see Findings based on notes from the three interviews that were not transcribed).
Of the 10 triallist interviews available for analysis, four triallists were from Canada, three from Australia,
two from the USA and one was from Europe. All 10 triallists had expertise in randomised clinical trials of
intensive care interventions and three of them also had expertise in leading implementation trials.
Context for discussing challenges: effectiveness or implementation trial?
First, we focus on participants’ views about the current evidence base in SDD and, in the light of these,
their views about appropriate implementation strategies.
Of the 10 triallists whose interviews were analysed, nine reported being persuaded by the evidence in
favour of SDD. These triallists offered their opinions about the interventions that would be effective in
changing the behaviour of the relevant clinicians, or suggested research designs to evaluate the
effectiveness of behaviour change interventions. These views are presented in Table 26. This table presents
multiple rows for some participants, as this helps to retain the context of the linked quotations.
TABLE 26 Views of nine triallists about the existing evidence base and about how to change practice
Participant
ID
Quotes suggesting that
participants are
convinced by the
current evidence
base for SDD
Quotes suggesting that
participants are uncertain
about the balance between
potential beneﬁts harms
of SDD
Quotes proposing how to
change SDD practice
1 I think that if you look at
the Cochrane analysis . . .
I think you have to accept
the data, however you
may be unhappy about it,
that it works.
. . . [uncertain about] the effect
that widespread use of this
would have on the microbial
ecology of ICU populations
around the globe.
I think that in order to . . . to
change behaviour of entire
intensive care units . . . you’re
still going to have to convince
people. So in an ideal world I
would personally vote that a
large multi centre trial be
instituted.
1 [I’m] actually reasonably
convinced by the
literature . . .
I’m convinced it does work but
. . . I’m not convinced what
happens to the microbiology.
I think that’s still an open
question so do a big study and
find out.
but [to] really change people’s
behaviour I think that it [a
large trial] is going to be
necessary so it’s unfortunate
but that’s how I feel about it.
continued
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TABLE 26 Views of nine triallists about the existing evidence base and about how to change practice (continued )
Participant
ID
Quotes suggesting that
participants are
convinced by the
current evidence
base for SDD
Quotes suggesting that
participants are uncertain
about the balance between
potential beneﬁts harms
of SDD
Quotes proposing how to
change SDD practice
1 I’ve been a big fan of
the idea since it was
proposed 30 years ago,
. . . I really like the idea of
colonisation resistance
and we definitely can
show this in animals,
there’s no doubt we do
this all the time on our rat
experiments and it’s very,
very clear that certain
antibiotics really do disrupt
colonisation resistance;
colonisation resistance is a
real thing . . .
– I wish that we could convince
our colleagues of this and
think we won’t be able to do
it unless somebody gets the
courage to do it in a big way.
3 I’ve always been a little bit
of a fan of it [SDD] and
always wondered whether
our reasons are scientific
for not adopting it.
– . . . before going straight to a
behavioural interventional
trial I would focus on the
psyche of key opinions, which
is exactly what you are doing.
5 It is pretty clear there are
signals for pneumonia
prevention and if you put
all the trials together
there is also a mortality
advantage. So I think
the data are quite
compelling . . .
. . . but obviously you’ve heard
the many reasons why people
are not convinced and most of
the concern is about emerging
resistance which has not
necessarily been documented at
all, or not done well.
So I don’t think another big
trial, unless it is very large and
very generalisable, is too likely
to change practice.
5 The VAP signal is already
strong . . .
. . . the VAP rates are going
down because we have . . .
more ancillary VAP prevention
strateg[ies], [so] we need to
have a plausible control event
rate.
. . . should [include] economic
evaluation, given,
effectiveness is not sometimes
enough to change practice
unless the associated
economic evaluation suggests
the benefit.
6 [Name] brought up SDD
at the [clinical] meeting
. . . and said ‘Why are we
not recommending this, it
has got better evidence
than everything else’, and
there [were] a lot of
people around the table
who started shuffling and
looking at their feet and
then the chair decided
to have a vote . . . There
was just strong
opposition to it, which
was irrational . . .
People just are not convinced by
the evidence.
I am not convinced that a
kind of behaviour
change-type research or
programme that is not tied to
very convincing evidence
would change people’s
practice or behaviour.
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TABLE 26 Views of nine triallists about the existing evidence base and about how to change practice (continued )
Participant
ID
Quotes suggesting that
participants are
convinced by the
current evidence
base for SDD
Quotes suggesting that
participants are uncertain
about the balance between
potential beneﬁts harms
of SDD
Quotes proposing how to
change SDD practice
6 – [In cluster trials] there is a large
number of people within the
clusters that are allocated to
SDD who actually do not get it
because they are not going to
be in the ICU long enough or
they are intubated or whatever,
and if they come down from a
ward, you don’t know what
they are bringing with them . . .
. . . so I’ve erred towards
thinking, if you want to
convince people, what would
convince people and make
them change their mind
would actually be a
conventional individual
patient randomised trial
7 – – We [should] ask people
whether this [a trial] would
make them change practice.
The trial design that is voted
by the majority as the trial
design that would make them
change practice would have
to be the one that you would
want to do . . . But then the
trial design and statistical
analysis are of such . . .
complexity and such a
proneness to error that
no-one will react to it. They
will say, that is interesting;
god knows what it means,
goodbye.
7 Why [are] people not
doing this therapy when
they are doing other
therapies that have a
lesser evidence base
behind them?
– What I think will change
practice is only a double-blind
placebo controlled traditional
individual randomisation
based trial of the order of
8 to 10,000 people.
9 [referring to] the [country
name] propaganda [that]
it only works in Holland.
I’m not sure about that.
The data . . . is valid. It’s
not only Holland data, I
think there’s some other
data as well . . . some
German data.
I think the [country name] don’t
want it and that’s always a
blocker because they will always
talk against it.
I think you’ve got to do the
trial and . . . that you want to
test whether SDD works. The
two big questions in my mind
[are] a) are you going to do
clustering randomisation and
b) how you’re going to
involve SOD?
10 I can remember the
systematic reviews of
nationalities published in
the BMJ in the mid-90s
saying it appeared to be
an effective intervention
so I was quite surprised
when . . . 10 to 15 years
later . . . it was still not
being implemented in
ICU settings.
. . . my sense of the field is that
the concern is more about
harms. . . . I feel it’s quite
legitimate for doctors in ICU
settings to be cautious about
new technology if they believe
there are harms associated with
it, particularly if also they’re
getting a lot of push back from
their infection control people.
And on that basis I would be
reasonably comfortable to
suggest that . . . the right way
forward would be to do a
definitive . . . randomised
control trial, . . . well it would
have to be a cluster
randomised control trial.
continued
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TABLE 26 Views of nine triallists about the existing evidence base and about how to change practice (continued )
Participant
ID
Quotes suggesting that
participants are
convinced by the
current evidence
base for SDD
Quotes suggesting that
participants are uncertain
about the balance between
potential beneﬁts harms
of SDD
Quotes proposing how to
change SDD practice
10 I think [it’s] quite unusual
to have so much evidence
and still to feel that there
are unresolved issues.
It’s not clear how informed
everyone [is about] the evidence
around SDD, . . . the benefits
and harms . . . But my sense is
there a group of highly
informed clinicians who just
worry about the likely harms
and that for me would probably
[be] justification for some form
of further clinical trial rather
than implementation trial.
–
11 This intervention is not
highly toxic, it’s not
difficult to implement and
the . . . potential adverse
effects are minimal. It’s
the perceptions that
clinicians have to the
contrary that make the
implementation of this
very challenging, and the
theoretical aspects of
what everybody’s worried
about.
– [In an implementation trial]
I would assume that you’re
going to . . . run the study
long enough to be able to
measure behaviour change,
but also to determine
whether your resistance
profiles change at each
hospital.
11 [Interviewer
summarising
and reflecting
participant’s
earlier responses]
We’ve avoided looking at
an effectiveness trial
because you think the
data is probably there, it’s
more people’s attitude of
mind or . . . institution;
attitude of other people
around.
the tendency sometimes is . . .
as you’re looking at trying to
tease out what the barriers are
[you include collaborators], and
then [once you get to the
intervention study] you . . . go,
great, I’ve got that, I don’t need
these people any more.
As you develop your
intervention, it will be
important to continue to have
collaboration from the ICU
clinic physician, nurse, nurse
educators potentially,
Pharmacists, Medical
Microbiologists and your
behaviour change experts in a
collaborative manner.
2 [Interviewer
responding to
previous utterance]
That’s right. It’s the right
of the individual versus
the rights of society.
I think that is probably a
problem with the uptake . . .
resistance is seen at a societal or
population level.
I would probably go for a
cluster trial where you are
evaluating both the
effectiveness as well as the
uptake and translational
aspects of your intervention,
in both arms, . . . not the
uptake in the control arms
but . . . attitudes and beliefs.
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From Table 26, six triallists were persuaded by the evidence of effectiveness but also noted widespread
uncertainty with respect to potential harms of SDD, at least at the population level. Four of these
participants recommended an effectiveness trial that focused on microbial ecology and one also noted the
importance of an economic evaluation. Two participants recommended an implementation trial with
clinical measures as secondary outcomes and one recommended a behavioural intervention trial based on
the ﬁndings from the current series of studies.
Analysis of challenges and barriers
This section focuses on the reported challenges and barriers to further SDD research and to the design and
conduct issues associated with a possible future effectiveness RCT comparing SDD against a control group
(as this design was prioritised in nine out of 10 interviews analysed). Potential challenges and barriers
relevant to different stages in the design of future SDD research, and/or any subsequent RCT, were
identiﬁed from the data. These were conceptualised into four levels depicting the hierarchy of potential
challenges (i.e. from the broad challenge of conducting any further SDD research to practical barriers
associated with speciﬁc aspects of trial conduct) (Figure 16).
While triallists tended to describe a range of potential challenges, there were few suggestions of ways in
which such challenges could be overcome. The ﬁndings presented below provide a descriptive account of
triallists’ views.
Challenges to the acceptability and feasibility of further selective
decontamination of the digestive tract research in intensive care units
The ﬁrst level of challenges related to the acceptability of SDD as an intervention and to the acceptability
of any further SDD research. These challenges were seen to represent potential barriers that would need
to be overcome before proceeding with any effectiveness RCT (of any design).
It was suggested that gaining sufﬁcient international support for further SDD research could be
a challenge (T, triallist participant code):
I am not sure how many people in the world there are that are willing to do that [support further
SDD research], which have such a strong belief in this intervention.
T7
Achieving widespread multidisciplinary endorsement and support for further SDD research in ICU was
identiﬁed as a potential challenge.
. . . not only have you got to overcome the ICU, the surgeons and everyone else, but you’ve also got
all these different views in terms of infectious diseases and microbiology about what we should and
shouldn’t be doing.
T6
1. Challenges to the acceptability and feasibility of any further SDD research 
2. Challenges to the acceptability and feasibility of conducting a definitive
effectiveness RCT (i.e. large, international, multicentre trial)
3. Challenges relating to specific design features of an effectiveness RCT
4. Practical barriers to trial conduct
FIGURE 16 Hierarchy of challenges to further SDD randomised trials.
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However, such endorsement and support was noted to be a prerequisite for conducting further research
to evaluate either the effectiveness of SDD in ICU, or a behavioural intervention to increase SDD uptake.
I think it is getting ICUs that want to play ball and where it goes beyond more than just verbal
commitment, that there is commitment from the entire team and the hospital, I think is paramount.
T12
Another suggested barrier to further SDD research focused on perceptions of tension between the
individual and societal consequences of delivering SDD in ICU (i.e. the potential beneﬁt to individual
patients receiving SDD vs. the concerns about the societal/population impact of antibiotic resistance
resulting from the routine delivery of SDD).
. . . the key aspects to me are the resistances seen at the population level whereas the preventing the
infection with SDD is more at the individual than population level . . .
T12
These ﬁndings suggest that the acceptability of SDD as an intervention may not be related to the
perceived effectiveness of SDD in individual patients, but to beliefs that these beneﬁts are outweighed by
the potential harms of SDD at a population/societal level.
Challenges to the acceptability and feasibility of conducting a definitive
effectiveness randomised controlled trial comparing selective
decontamination of the digestive tract with a control group
It was suggested that even if clinicians were convinced of the beneﬁt of SDD as an intervention, and that
support for further SDD research in ICUs could be achieved, there were acceptability and feasibility issues
that present further barriers/challenges.
Triallists reported that, were a deﬁnitive effectiveness RCT to be planned, it would have to be large.
. . . it would be a trial of that order, 6000 or 7000 people, ideally executed across the world.
T7
The size and international nature of such a trial was suggested by participant T7 to present acceptability
and feasibility issues, for example the level of personal commitment required from a chief investigator to
run such a trial and the challenge of gaining international funding:
I hope you have sold your children to medical science because you are not going to have time to do
anything else and just huge personal burdens. It is a big deal; I would not take it on; it would have to
be someone younger with more energy.
T7
Barriers relating to specific design features of an effectiveness randomised
controlled trial comparing selective decontamination of the digestive tract
with a control group
In addition to the general challenges of conducting a deﬁnitive multinational effectiveness RCT,
triallists identiﬁed potential barriers relating to the speciﬁc design features of such a trial (e.g. unit
of randomisation).
Triallists’ views on the speciﬁc design features of a deﬁnitive effectiveness RCT varied, as did their views on
the barriers related to speciﬁc features. The majority of discussion focused on triallists’ perceptions of the
challenges associated with the choice of clinical intervention and comparison/control, when the
intervention would be started, outcome measures, unit of randomisation and level of consent.
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Specification of the clinical intervention and control
The lack of a formal and universally accepted SDD regimen was suggested by triallists to pose potential
acceptability issues for a trial.
The discussion of what you use as antibiotics in such a protocol . . . would you use some sort of
so-called ‘old fashioned’ antibiotic like cefotaxime or do we now need to go to something else . . .
T6
One triallist stressed the importance of transparency in the intervention development phase and
consultation with stakeholders to address this issue and optimise acceptability of both the trial and
the intervention.
I think in developing what the intervention is, the different aspects of the intervention for SDD, it
obviously has to be built from consensus . . . amongst intensivists in terms of their buy-in, so going
beyond the current group of co-investigators and . . . testing it on people who are outside that group
would be really important . . . documenting . . . the process of determining what the . . . intervention
is and even publishing that would be important too.
T12
Establishing current international standard care for ICU infection prevention and choosing an appropriate
comparison/control for a SDD effectiveness trial were also identiﬁed as problematic. It was suggested that
the widespread use of oral antiseptics (e.g. chlorhexidine) and/or the use of other procedures associated
with SOD or ventilator bundles (e.g. semi-recumbent positioning, subglottic suctioning) present a challenge
to determining the components of the intervention and control arms in a deﬁnitive SDD effectiveness trial.
If people are using chlorhexidine universally and I cannot really see why not except for the usual, that
it takes forever to get people to change behaviour, given the low cost, given the benefit of
chlorhexidine and its availability, then both groups should have chlorhexidine . . . So I think we need
to be very, very careful about how we handle oral antiseptics when we’re considering an SDD trial.
T5
If you/I are going to develop a trial, I think that there is now SOD and this is complicating everything
. . . how you’re going to involve SOD? In other words, are we going to have three arms or are you
going to leave out SOD . . . you have to address the problem of SOD.
T9
. . . the subglottic suctioning and . . . the positioning of the paste and all that kind of stuff [is] now
considered basically standard care in most places . . . I think it might be difficult to randomise people
to doing that or not doing that.
T1
One suggestion to overcome the variation in usual care was to ignore it and accept a lack of
standardisation in the care received by patients in the trial control group (i.e. assume a completely
pragmatic design).
I would do absolutely nothing, I would just say this is a large multicentre individual randomisation
base pragmatic trial . . . Let’s not create a world where we know everything about a place that
doesn’t exist. Let’s keep the world dirty, messy, chaotic, random, insane, etc., as it is, and within that
world, let’s just change one thing.
T7
The potential beneﬁt of conducting a double-blinded trial using placebo oral pastes, mouthwashes and i.v.
components was mentioned during the interviews. However, the associated ethical implications and
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practical challenges were not discussed, although one triallist reported experience of using placebo oral
pastes during a trial to treat, rather than prevent, infections in an ICU context.
We just did an intervention of SDD. We tried breaking an outbreak. We got a neutral paste. That’s
how we blinded it. In the placebo arm we used a neutral paste.
T9
Outcome measures
Triallists suggested a number of outcome measures that could be used to evaluate the effectiveness of
SDD. The most commonly discussed measures were mortality, VAP and antibiotic resistance patterns.
However, triallists reported potential challenges with the use of each of these measures. Mortality
(timescale unspeciﬁed by participants) was proposed by some triallists to be the optimal primary outcome
measure as it is straightforward to measure and a large, multinational SDD effectiveness trial that
demonstrated a signiﬁcant effect on mortality would be persuasive and conclusive.
. . . giving clarity around mortality outcome would be crucial. So international, multinational, large,
focused on mortality.
T5
Nevertheless, it was suggested by others that the low incidence of mortality limits its suitability as a
primary outcome measure to evaluate the effectiveness of SDD.
So it [SDD] might actually be an impossibly high hurdle to change mortality . . . if you enrolled a
thousand patients . . . cut 100 VAPs to 80 VAPs and so you’ve changed 20 VAPs, of those 20 VAPs,
there might only have been one extra death in the 20 VAPs, so you’ve enrolled a thousand patients
and [avoided] one extra death.
T3
The main challenge identiﬁed with the use of VAP as an outcome measure related to difﬁculties with its
deﬁnition and diagnosis.
I think the major problems are diagnosing a pneumonia you know, which is always been a vexatious
issue and so I think because it’s a relatively loose diagnosis, that’s one issue.
T13
It was also suggested that, as with mortality, the low incidence of VAP in ICUs was a potential barrier to its
acceptability as an outcome measure and to the feasibility of its use in a trial to evaluate the effectiveness
of SDD (particularly in the context of the widespread use of SOD).
. . . we don’t have much in the way of Gram-negative VAP that . . . we’re aware of. So whether or
not we need a different approach for more of a Gram-positive VAP, but again, we don’t seem to be
having much of that at the moment. So my worry is that it’s a relatively low-grade problem and
you’re having to treat everyone or everyone who’s at high risk for a low-grade problem.
T13
Bacteraemia was suggested by some triallists as a viable alternative outcome measure to VAP.
If you really wanted to know something, I would do some hard stuff like bacteraemia. It would have
to be logistically simple, objective, easily ascertained, easily monitored, identified without question by
somebody else, like bacteraemia would be and that is the end of that.
T7
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It was acknowledged by a number of triallists that the inclusion of some measure of antibiotic resistance
would be worthwhile to address the current lack of evidence of the effect of SDD on rates and
patterns of antibiotic resistant pathogens. However, it was suggested that such an outcome measure
would be costly and would impact on power calculations and other aspects of the trial design such as the
unit of randomisation.
. . . we cycled antibiotics and we looked at a resistance and it is hard. It’s very hard. You need a hell of
a lot of events to . . . get decent numbers out of it. I think that’s just unachievable . . . you know,
you’re looking at thousands and thousands of patients and that’s why I said microbiology . . . to me is
hideous. No way are you going to overcome that.
T9
. . . it [incidence of multidrug resistant pathogens] would be very difficult . . . what kind of power
calculations can you do if you wanted to use incidence of development of multi germ resistance
pathogens . . . because you really don’t know what’s going to happen and there’s such a big
variation. I think it . . . would be difficult . . . as your primary influence even though it’s really
critical issue.
T1
Unit of randomisation
Triallists reported advantages and disadvantages associated with using cluster randomisation or individual
patient randomisation in a SDD effectiveness RCT. Two triallists suggested the unit of randomisation and
choice of outcome measure are inextricably linked.
. . . you can’t really do an ICU population level outcome if you are randomising at the patient level.
T3
The problem is if you randomising individual patients, you’re ignoring the possibility of a horizontal
spread . . . and therefore you’ve got to cluster randomise.
T9
Reasons given in favour of randomisation at the individual patient level, or against cluster randomisation, were:
1. Individual randomisation is more feasible for a worldwide study.
I would think that the cluster randomisation as a worldwide phenomenon for SDD is going to be very
difficult so you are going to have to look at individual randomisation.
T9
2. Differing baselines in ICUs.
A cluster RCT is a scary high-risk position because if there’s a difference in baseline severity of illness
within the ICU then you’re in trouble.
T3
3. Recruitment challenges to cluster randomisation resulting from lack of willingness of a sufﬁciently large
number of units.
A cluster randomised trial requires dozens and dozens of units agreeing to be allocated to one or the
other . . . there may not be sufficient of units who may say yes to agreeing to participate for months
or years in a randomised trial whereby either one get it or not. It is hard. So the logistics of doing a
cluster randomisation are enormous . . . because this is so loaded and everybody has opinions.
T5
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Level of consent
The unit of randomisation and level of consent were sometimes linked by triallists when expressing their
views on the potential challenges associated with gaining consent at the individual patient level.
. . . the cluster trial would be a much more efficient design because you could make much more use
of all patients. I think at, an individual level, you know that is not always the case because, of those
eligible, very few end up being consented or being enrolled and then having full consent . . . the
consent not withdrawn I guess I should say in this case. So I think again, . . . from the public health
perspective, using a cluster trial is not only efficient, it is just the right thing to do and I am fairly
adamant about that.
T12
There were also suggestions that the use of individual patient consent in a cluster-randomised trial was
impractical and could potentially affect recruitment.
. . . if you do it by individual form of consent obviously some people will say ‘no’ and then you’ll have
a hard time doing your analysis because some people would have been put into it.
T1
Barriers resulting from international differences in models of consent and research governance procedures
were also mentioned during interview.
I would imagine there would be some countries if not regions . . . whereby an approach to units being
randomised might be more palatable when alternate models of consent have already been endorsed,
such as waived or deferred consent, [as in studies in] some parts of Europe and parts of Australia.
T5
It was suggested that it may be difﬁcult to get approval in the USA for a trial that used unit level consent.
On the downside would be the individual consent . . . very hard in the US to configure an alternate
consent model other than the standard which would be first person consent which we can’t do much
on the ICU or a priori substitute who can legally consent. I think it’s hard for Americans to plot
anything other than that model.
T5
In contrast, research governance procedures in Australia were reported to allow delayed consent
(i.e. gaining consent from a patient or relative after enrolment into the trial) in order to aid trial
recruitment. However, it was suggested that such a model may not be acceptable elsewhere in the world.
Well this is a study that you probably would allow delayed consent for here in Australia because it so
much facilitates patient recruitment . . . In our experience delayed consent confirmation takes about
20 minutes and prospective consent takes about 60 and 70 minutes and again, if you are running a
trial of 20 people, that’s okay. If you are running a trial for 10,000 people, that is 10,000 hours of
work that you have to add and that’s really hard, and your consent rate will decrease and your
recruitment rate will also decrease and then people will develop trial fatigue.
T7
Practical barriers to trial conduct
In addition to the potential challenges associated with conducting further SDD research and the design of
a trial to evaluate the effectiveness of SDD, the triallists suggested that there may be a fourth level of
challenge associated with practical barriers to the conduct of such a trial. These potential barriers were also
examined in earlier stages of this study. The following results should be seen in the light of other study
ﬁndings, which are integrated in Chapter 7.
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Three triallists stated that, in their experience, nurses ﬁnd administering some SDD components (e.g. oral
pastes) unpleasant and/or burdensome.
. . . some of those oral based solutions are gooey, sticky mess that frankly nurses find a pain . . . the
chlorhexidine products I think are nicer to use. So there’s a practical barrier around making sure that
is not [difficult] to use.
T3
We pretty much used an oral paste as well as GI and the nurses hated it. We put it in several times a
day and everyone hated it, paste around the mouth and in the gut. The nurses hated doing it. So to
get it implemented, to get compliance is going to be hard . . .
T9
There were also perceptions of increased nursing and/or pharmacy workload associated with the
preparation or delivery of SDD components.
. . . it’s a lot of nurse time with all the pastes and all of that . . . [named hospital] make up their own
drug but I don’t think it’s generally like off the shelf available; you’ve got to make up the paste which
is a lot of work.
T13
The challenges of maintaining intervention ﬁdelity and preventing trial fatigue were also brieﬂy discussed
and ideas to overcome such issues were proposed.
In terms of the implementation and compliance from nursing staff, that is an education process . . .
you’ve got to have your investigators and research nurses running an education programme for the
bedside nurses and providing them with feedback and lunches and breakfast meetings where you tell
them all about the trial and how it is going.
T6
Findings based on notes from the three interviews that were not transcribed
The interviewer’s notes from three triallist interviews for which recording failed and hence were not
transcribed are summarised below.
Interview triallist 2
This triallist supported a further compelling interventional trial in SDD that would need mortality as an
outcome, would need to track any microbiological changes arising as a consequence and would
demonstrate any economic impact. It would need to be a cluster randomised trial to accommodate any
beneﬁt from unit-wide microbiological ﬂora changes and would need to be an intercontinental study.
Barriers included the sheer scale required for this venture.
Interview triallist 4
This triallist felt SDD was problematic to investigate given uncertainties with current evidence, problems
with when to start SDD (day 0 or day 3 and, thus, variability in who gets the intervention), problems with
VAP as an end point and difﬁculties in ethics in that different countries may or may not allow cluster
randomised studies. Overall they were supportive of an intervention study but believed better data were
needed to design the ideal trial.
Interview triallist 8
Triallist 8 posed several important challenges to address before progressing to a further intervention trial
(which is what they felt was needed). These included how to blind such a trial, something that this
participant felt was vital, how to identify good leaders for the trial and which countries this should be
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conducted in for credibility. The issue of different microbiological resistance patterns in different countries
was also relevant to this credibility. They believed more evidence was required to understand exactly the
groups to receive the treatment and how to deal with chlorhexidine in the treatment (and control) groups.
They also wanted clariﬁcation of the place of SOD in such a study.
It can be seen that these three interviews broadly included themes elicited in the 10 previously reported
interviews and that the hierarchy described was also applied within these interviews.
Summary of results
In summary, triallists were interviewed from across a wide spectrum both geographically and from their
area of specialist expertise. The majority spent most time discussing an effectiveness trial. This was the case
for the intensive care clinical triallists, while those with implementation trial expertise discussed both types
of trial. The hierarchy outlined in Figure 17 holds as a framework for summarising the responses of all
the triallists.
Discussion
Major challenges in future studies
There were differing views from triallists on the need for further research on SDD. Not all the triallists were
convinced that further research was justiﬁed or feasible although the majority felt that it was warranted
and important. The challenges identiﬁed by triallists are summarised in Figure 17. There was no consensus
amongst the triallists on approaches to dealing with the challenges presented in this hierarchy.
1. Challenges to the acceptability and feasibility of any further SDD research
Gaining sufficient international multidisciplinary support
Concerns about the harms of SDD at population level
•
•
•
•
•
2. Challenges to the acceptability and feasibility of conducting a definite
effectiveness RCT (i.e. large, international, multicentre RCT)
The scale of the trial
Funding such a trial
Personal commitment from a chief investigator required to run such a trial
•
•
•
•
•
•
3. Challenges relating to specific design features of an effectiveness RCT
Conduct: international differences in models of consent and research
goverance
Randomisation: cluster of individual patient allocation
Participants: which patient populations to target
Intervention: lack of formal and universally accepted SDD regimen
Control: variation in ‘usual care’; how to include SOD and/or ventilator
bundles
Outcomes: defining VAP. Low incidence of VAP and mortality. Cost,
logistics and design implications of measuring antibiotic resistance
•
•
•
4. Practical barriers to RCT conduct
SDD unpleasant to deliver
SDD burdensome for nurses
Increased nursing and/or pharmacy workload
FIGURE 17 Summary of hierarchy challenges of conducting further SDD randomised trials, as reported by triallists.
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Triallists from both an effectiveness and an implementation background highlighted the complexities of
further research. The triallists focused on approaches to an effectiveness study and few views emerged on
the appropriateness of, or approaches to, an implementation study. This may be partly due to the lack of
clarity about the core components of an implementation trial.
All triallists proposed that an effectiveness trial would be large and demanding and that this could well
lead to burnout for the chief investigator and team. They also identiﬁed the need for multidisciplinary
support to conduct and complete an effectiveness study. All agreed with the requirement for any study to
be multinational, although there was not clarity as to which countries could, or should, be included.
Triallists also identiﬁed key stakeholders such as clinical microbiologist and infectious disease clinicians as
potential facilitators or barriers to the successful conduct and completion of any study. Nurses and
pharmacists delivering SDD were suggested as potentially raising sustainability challenges owing to
workload acceptability, although this was discussed more as anecdote than fact.
Study design issues
There was a range of views on the primary end points because of perceived problems with the size and
cost of the study and the ability to identify funding. There was concern about using VAP as an end point
owing to difﬁculties in establishing an agreed and standardised diagnosis. Many triallists identiﬁed
antibiotic resistance as an important end point; however, most preferred this as a secondary end point.
The nature of the control group was frequently discussed. Triallists acknowledged the widespread use of
chlorhexidine and VAP bundles and there were varied views on whether or not there should be clear
speciﬁcation of the control group through to a more pragmatic control group without speciﬁcation.
There was no consensus on the ideal unit of randomisation. The potential beneﬁts of unit level
randomisation were discussed with regard to both individual beneﬁt and harm. The issue of unit of
randomisation also brought into focus the question of patient consent. It was clear that different countries
would approach this in different ways from an ethical perspective.
The impact of SDD on the local microbiological ﬂora was widely discussed. Most saw this as a parallel issue
to the primary end point, yet an important one, and most felt this should be measured to convince the
community that resistance patterns were not adversely affected.
A editorial on SDD in 2012 also plays out the conﬂicts.68 This editorial discussed study design, outcome
measures, the impact of antibiotic resistance, the role of SOD and chlorhexidine and the place for a
cost–beneﬁt analysis amongst other issues. This article concluded that a cluster-randomised design should
be the basis of future effectiveness studies with unambiguous end points such as mortality. It also
identiﬁed that this would be a very large study with a requirement for detailed monitoring of resistance
patterns and recognised the need to undertake the study in a range of settings with different
microbiological ecology.68 The current ﬁndings are thus consistent with recently published opinion.
Strengths and limitations
In drawing these ﬁndings together, one should of course distinguish between the participants’ views that
are based on their experience and expertise as triallists and their personal views derived from other forms
of evidence. Speciﬁcally, data from other stages of this study (e.g. whether or not nurses ﬁnd it
burdensome to deliver SDD) or from the published literature (e.g. techniques that are effective in changing
professional behaviour) can inform some of the opinion-based evidence presented in this chapter. There
was an interesting pattern of ﬁndings with respect to triallists’ beliefs about what will change behaviour
(see Table 26). Although people may believe that more evidence will change clinical behaviour, the weight
of evidence in the ﬁeld of implementation research is that this not an effective approach. There is also a
potential ethical question of randomising patients to a control group merely to persuade clinicians of what
existing evidence already shows. Hence, a limitation of this study is that the participants may have gone
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beyond their level of expertise in presenting their own hypotheses about barriers to SDD delivery or about
how best to change clinicians’ behaviour.
A further limitation of the study was that we did not succeed in engaging sufﬁcient numbers of European
triallists who have led SDD effectiveness trials. Their speciﬁc expertise would have been invaluable. Apart
from this, the geographical spread of the sample across three continents and four health systems was a
strength of this study.
Box 9 presents the key ﬁndings from the triallist interview study that inform the need for, and acceptability
of, a clinical effectiveness RCT or an implementation RCT. The majority of triallists either accepted that
further SDD effectiveness research should be carried out or were actively interested in participating.
At least two were not convinced and a third felt that the scale of the venture was probably too great.
However, this is set against the persisting issue of concern about resistance and the potential for
antimicrobial resistance to lead to harm for an individual patient, even if the ICU population overall
beneﬁts. However, this study was designed to address the research question concerning challenges to
conducting a trial, so we did not discuss non-trial designs in these interviews (e.g. studies of microbial
resistance patterns). Hence, these ﬁndings should not be taken as an indication that a randomised trial is
the only appropriate kind of study design for further SDD research.
BOX 9 How does this stage of the research inform the need for, and acceptability of, an effectiveness RCT or an
implementation study?
l Most triallists reported there was a place for a further effectiveness trial.
l Numerous important challenges to the ideal design of an effectiveness trial were identiﬁed at
multiple levels.
l One triallist clearly felt further study not warranted from a futility point of view.
l An implementation study was not dismissed, but to deﬁne the potential nature of this would need more
speciﬁc interrogation.
l We did not discuss non-trial designs in these interviews.
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Chapter 7 General discussion and synthesis
The results of the four stages of research presented in this monograph were designed to lead to anevidence-based decision about whether to proceed to (1) a trial to evaluate the effectiveness of SDD,
(2) an implementation trial (development and evaluation of an intervention to increase uptake of SDD) or
(3) further exploratory research. There was also the possibility of a lack of belief in the relevance, topicality,
appropriateness or clinical interest in this intervention, or a lack of equipoise owing to a belief of proven or
potential harm being associated with the intervention, which would make further studies inappropriate
and unethical.
Methods of synthesis
In collaboration with the leads of parallel studies in Australia/New Zealand, Canada and the UK, it was
identiﬁed a priori that an international project steering group would make an assessment of whether or
not a future trial is necessary, justiﬁable, acceptable and feasible based on a set of decision rules. The
decision rules, as proposed in the study protocol, were to be based on the study ﬁndings and were
as follows:
Decision rule 1: If support for SDD is low or variable and predicted by scores for speciﬁc beliefs about
the consequences (beneﬁts and harms) of implementing SDD, it may be judged appropriate to proceed to
a clinical effectiveness trial. Such a pattern of results would suggest that dissatisfaction with the current
evidence base explains the lack of uptake.
Decision rule 2: If support for SDD is low or variable and predicted by scores relating to social inﬂuence
(e.g. pressure from colleagues in other disciplines), this would suggest that an implementation intervention
could be effective if delivered by an identiﬁed opinion leader, clinical lead or local ‘champion’ through
team meetings. We would probably proceed to an implementation trial to evaluate such an intervention.
Decision rule 3: If support for SDD is low or variable and predicted by beliefs relating to lack of capacity
to implement SDD (e.g. resource issues), this would suggest that an implementation intervention could
be effective if it focuses on barrier identiﬁcation and generation of strategies to overcome barriers,
known as ‘coping planning’,55 we would probably proceed to an implementation trial to evaluate such
an intervention.
Decision rule 4: By contrast, if support for SDD is high (i.e. if there are ceiling effects and restricted
variance), then the current low level of implementation will be attributable to an intention–behaviour gap,
suggesting that external barriers prevent clinical staff from translating their intentions into action. This
pattern of results would suggest that an implementation trial to test strategies for facilitating uptake may
be appropriate.
Findings about acceptability and feasibility of a clinical trial would also inform the decision of how to
proceed. Speciﬁcally:
Decision rule 5: If willingness (intention) to participate in an effectiveness trial is low, we are unlikely to
proceed to such a trial.
Decision rule 6: If willingness (intention) to participate in an effectiveness trial is high, this would indicate
that an effectiveness trial is sufﬁciently acceptable to proceed.
We also took into account scores for the factors that were perceived to make participation more likely.
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Decision rule 7: If either of the stakeholder groups (intensive care consultants or microbiologists) seems to
be uniformly of the opinion that there are no design features that would make a trial acceptable, and/or if
a third (or more) of the members of the two groups deem any such trial unacceptable, an effectiveness
trial would be unlikely to be pursued.
Decision rule 8: Depending on the views expressed about the existing evidence base (i.e. if the
intervention is viewed as potentially beneﬁcial) we would consider the role of an implementation trial to
change clinical practice. If appropriate, the change techniques that would form the components of such
an intervention would be selected using methods previously shown to effectively change behaviour in
other settings.69
In addition, we used the results of the investigation of two ICUs for which SDD had been implemented,
consensus data from the Delphi study, results of the national survey and ﬁndings from the interviews with
triallists to inform the:
l behavioural (practical, organisational and management) issues that would need to be addressed in
order to mount a trial
l ethical issues relating to informed acceptance of trial entry among eligible patients
l trial design issues including measurement of outcome and process variables.
Evidence for relevance, topicality, appropriateness and clinical
interest in selective decontamination of the digestive tract
In the context of a TDF of clinical behaviour change, we asked speciﬁc questions in the Delphi study
relating to the domain Motivation and goals. This domain focuses on the relevance, topicality,
appropriateness and clinical interest in SDD. There was low-level consensus (50–75%) for the relevant
items, tending towards agreement with the statements, ‘SDD is not on my Unit’s list of priorities’ and ‘SDD
is not a topic of discussion among my colleagues’, but tending towards disagreement (with bimodality) for
the item, ‘SDD is outdated’. Overall, there was a range of levels of engagement with the issue of SDD.
To assess the feasibility and acceptability of further effectiveness research, we also asked three key
questions, in both the Delphi study and the national survey, about:
l support for, or opposition to, SDD
l whether or not further SDD RCTs are ethical
l willingness to participate in a national RCT of SDD.
Responses to the question I am opposed to selective
decontamination of the digestive tract
Findings from the Delphi study (see Chapter 2) and the national survey (see Chapter 5) showed remarkable
similarity, with bimodal distributions in which the modes were (1) the neutral score (indicating uncertainty)
and (2) disagreement (indicating that a substantial portion of each sample was not opposed to SDD).
In the survey, there was evidence of bimodality in both groups (intensive care consultants and clinical
microbiologists). Clinical microbiologists were split between being opposed and not opposed (modes of 6
and 2 on the seven-point scale), whereas intensive care consultants were split between being neutral and
not opposed (modes of 4 and 2 on the seven-point scale) (see Figure 12).
The evidence from the Delphi and national survey (see Chapters 3, 4 and 5) conﬁrm the perception that
clinicians reported dealing with HAIs such as VAP using strategies other than SDD. This may reduce the
relevance of SDD since prevention of HAIs such as VAP may be seen as the key mode of action and,
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therefore, efﬁcacy of SDD could be seen as a low priority. There is further evidence that SDD was not a
high clinical priority or topic of discussion amongst clinicians. However, when asked if participants were
‘opposed to SDD’, they had notably mixed responses (indicated by a bimodal distribution of scores) and
participants did not think prophylactic antibiotic usage in SDD was against their training or responsibilities.
Further evidence on relevance is presented in Whether or not further selective decontamination of the
digestive tract randomised controlled trials are ethical: clinical equipoise and uncertainty.
Whether or not further selective decontamination of the
digestive tract randomised controlled trials are ethical:
clinical equipoise and uncertainty
In the Delphi study, responses to questions about the consequences of SDD indicated that there was
consensus around equipoise and/or uncertainty. Speciﬁcally, there were a high number of responses
around the mid-point of the response scales. Similar distributions were evident in the national survey
data. In addition, we asked questions that related directly to clinical equipoise and uncertainty regarding
the evidence base for SDD in both study stages. Further information on equipoise and uncertainty can also
be gleaned from the data in Willingness to participate in further research in selective decontamination of
the digestive tract.
In the Delphi study and national survey, there was a clear ﬁnding that further RCTs are ethical and that
current uncertainties in the evidence base should be addressed in a new study. There was also a message
that the existing evidence base may not be generalisable to the participants’ practice. These observations
strongly suggest the existence of a state of clinical equipoise for individuals within the clinical community.
This statement is supported by uncertainty in responses to beliefs about the potential beneﬁts of SDD such
as effects on mortality, HAIs, VAP or cost-effectiveness. There was also uncertainty in responses about
beliefs on the potential harms related to SDD such as effects on antibiotics resistance and, more generally,
whether or not the harm outweighs the beneﬁts.
Willingness to participate in further research in selective
decontamination of the digestive tract
Evidence of willingness to participate in further research came from the Delphi study and the
national survey.
The evidence is interesting – there seemed to be clear support for participation in further research in the
ﬁeld of SDD evidenced by participants’ agreement with the statement, ‘current uncertainties in the
evidence base should be addressed in a new study’. There are three main research designs that could be
utilised to undertake this further research: efﬁcacy/effectiveness RCTs, implementation studies or
prospective non-randomised study designs. The signiﬁcant majority of clinicians stated they would be
prepared for their patients to be randomised to either SDD or control in an effectiveness study. Despite the
importance attached to the issue of antibiotic resistance, the response to the question suggesting concerns
with antibiotic resistance would limit participation was answered in a neutral fashion. This is balanced by
the clear signal for any future effectiveness study to include a pretrial, during-trial and post-trial monitoring
of antibiotic resistance and this statement was strongly supported by participants.
For the question most directly related to support for an implementation study in the Delphi, ‘I would
support my centre being involved in a study to promote the adoption of SDD’, there seemed to be
moderately strong support. This is a little hard to explain since it would be expected that clinicians would
favour this option only if they believed that the SDD literature contained compelling evidence for efﬁcacy
or effectiveness for SDD and that respondents did not have equipoise owing to this strong supportive
evidence. This does not seem to be the case (see Whether or not further selective decontamination of the
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digestive tract randomised controlled trials are ethical: clinical equipoise and uncertainty). However, two of
the triallists interviewed suggested that an implementation study could be combined with the collection
of data regarding effectiveness, thereby addressing the objectives of both an effectiveness and an
implementation trial. Furthermore, when asked about knowledge of the evidence base, a substantial
number of respondents admitted they did not know the evidence base well enough to make an informed
opinion regarding the use of SDD.
Qualitative evidence from the interviews with clinical triallists showed that 9 out of 10 of these triallists
(including triallists with signiﬁcant experience in implementation research) focused primarily on an
effectiveness study throughout interview, despite eight of the nine reporting being individually persuaded
by the evidence of SDD’s effectiveness. However, the triallists did express doubts about the potential
harms, a ﬁnding that converged with both the Delphi study and the survey. Only one triallist focused solely
on an implementation study.
Finally, the question of performing further non-randomised studies was not raised by participants in any
phase of the research. There could be an argument for performing matched or comparative cohort studies
to try to answer some of the remaining questions regarding SDD. However, it could be argued that with
the high degree of remaining uncertainty and equipoise about both the beneﬁts and potential harms
associated with SDD, a randomised trial design is the most efﬁcient and ethical research method with the
lowest risk to patients if harms are realised.
Design features of an effectiveness randomised controlled trial
Interviews with clinical triallists were the main method used to identify trial design and conduct issues.
However, some information was also obtained from the Delphi study and the national survey.
Delphi participants generally agreed with the statement ‘I would be more likely to participate in an RCT if
mortality is the end point’, but national survey respondents less so. This end point was also supported in
the triallist interviews. A full cost–beneﬁt analysis was also identiﬁed as an integral part of any future study
in the Delphi study but was not a strongly stated issue from the clinical triallists. Delphi participants
would strongly favour a chlorhexidine and/or a VAP bundle (including chlorhexidine mouthwash and
semi-recumbent positioning) for the control arm of a future study. Delphi participants identiﬁed a strong
desire for future efﬁcacy/effectiveness studies to include a pretrial, during-trial and post-trial monitoring of
antibiotic resistance. This was also raised in the triallist interviews.
Challenges of an effectiveness randomised controlled trial
Data on the challenges for an effectiveness RCT come from the case studies (see Chapter 2), the Delphi
study (see Chapters 3 and 4) and the interviews with triallists (see Chapter 6).
In the case studies, there was marked variation in the clinical as well as behavioural speciﬁcation of the
intervention, and this is also noted from the available literature on SDD. Clearly, the accurate clinical and
behavioural speciﬁcation of the intervention will be crucial to the acceptability and success of any future
study and this needs careful consideration. The lack of a clear speciﬁcation of the intervention was also
identiﬁed as a barrier by the triallists in the interview study.
The Delphi study raised some signiﬁcant concerns with the conduct of an effectiveness RCT including
major issues such as culture change, requirement for local champions and possible conﬂicting opinions
between clinical microbiologists and intensive care consultants, although our results suggest this is possibly
less marked than perhaps suspected (see Chapters 4 and 5). These issues may present major challenges to
any future study.
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There are also concerns about workload for nurses, pharmacists and clinical microbiologists. In the case
studies reported in Chapter 2, it was actually doctors who identiﬁed the increase in nursing workload
more than nurses themselves. Clearly, appropriate support for staff time and intervention development
and delivery costs will have to be built into any future RCT. Encouragingly, participants also identify some
facilitators such as SDD being straightforward to deliver and that educating staff would not be expensive.
The interviews with triallists also gave valuable information on challenges of conducting such a study, and
these are discussed in length in Chapter 6. The major challenges identiﬁed included the acceptability and
support for SDD as an intervention, the difﬁculty in balancing the tensions between the individual and
societal consequences related to SDD, the international and multicentre nature as well as the very large
size of any proposed future study. These are major barriers and threats to the feasibility of such a study.
There was also much discussion about cluster versus individual randomisation and their relative merits
within an effectiveness trial. Furthermore, triallists identiﬁed the interaction between trial design and trial
feasibility, choice of outcomes, level of consent and trial costs. The control group for such a study was also
seen as crucial to the success and acceptability of the trial result. All of these issues would need careful
consideration in the development of any future proposed trial.
Application of decision rules
We synthesised the ﬁndings from the multifaceted study described in this report by applying the decision
rules to address the question of what, if any, further SDD research is appropriate and feasible?
l Decision rule 1. Results of the Delphi study and national survey indicate that this criterion was met,
although the issues related to difﬁculty in participating are identiﬁed in decision rule 6.
l Decision rule 2. Results of the Delphi study and national survey indicate that this criterion was not met.
l Decision rule 3. Results of the Delphi study and national survey indicate that this criterion was not met.
l Decision rule 4. As support for SDD was mixed (see Figure 12), the data did not meet this criterion.
l Decision rule 5. This criterion was not met, as willingness to participate in a trial was high.
l Decision rule 6. This criterion was met and has to be considered with decision rule 1.
l Decision rule 7. These criteria were not met. A further trial was seen as acceptable by the majority,
although some participants were ﬁrmly of the view that the evidence base was clear enough to
proceed with implementation.
l Decision rule 8. This criterion was not met, in general. However, as noted above, in the Delphi study,
the national survey and the triallist interviews, some participants felt that it would now be appropriate
to implement SDD or to conduct an implementation trial.
We identiﬁed the behavioural (practical, organisational and management) issues that would need to be
addressed and fully considered in any future study design. We also identiﬁed that there were ethical issues
relating to informed consent among eligible patients and further detailed ethical study would have to be
undertaken if a future proposed trial is planned.
Strengths and limitations
The conclusions from application of the decision rules should be viewed with caution owing to the low
response rate in the UK-wide survey. It is possible that willingness data were biased as physicians who are
more interested in participating in SDD research may have self-selected into this sample. Nonetheless, it is
clear that sufﬁcient numbers of physicians expressed interest for an effectiveness trial to appear feasible in
the UK. The possibility of non-trial designs did not emerge in the interview stages of the study and such
designs may require further consideration.
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In general, the multilens, multimethod approach adopted by the SuDDICU feasibility study facilitated an
investigation that was both in depth and broad based. Clinical, practical and methodological issues were
examined using a robust theoretical structure; yet the exploration also allowed new issues to be elicited
and taken forward for detailed investigation. In the Delphi study, ﬁndings from the qualitative (see
Chapter 3) and quantitative (see Chapter 4) phases were congruent and these were also conﬁrmed in the
nationwide survey (see Chapter 5). Across the facets of the study, a clear picture emerged of the strengths
and weaknesses in the SDD evidence base. The study thus identiﬁed consistent patterns of uncertainty
about the evidence that should be addressed in future SDD research.
However, these ﬁndings are set in a rapidly changing context. First, it is evident that other strategies to
address infection are currently being used in ICUs. Second, and perhaps related to the ﬁrst, rates of VAP
may be reducing in some ICUs. Hence, the ﬁndings reported in this study may be time sensitive and it may
be that the methods of investigation illustrated here are of more lasting signiﬁcance than the speciﬁc
clinical ﬁndings. Nonetheless, it is clear, based on the level of consensus around uncertainty about the
evidence for and against SDD, that further research is warranted at this time.
Conclusions
Having considered all the data from the four substudies, presented in this report in Chapters 2–6, and the
application of the a priori decision rules, we draw a number of conclusions that have implications for
health care and for further research.
Implications for health care
l There was a striking level of uncertainty about the effects of SDD on clinical outcomes that are
regarded as important. This uncertainty suggests that there is considerable potential for improvement
in prevention of HAIs in critically ill patients but further evidence is required to clarify the balance
between potential individual-level beneﬁts (e.g. infections, mortality) and potential society-level harms
(e.g. antibiotic resistance) related to SDD.
l There was signiﬁcant confusion apparent in clinicians’ understanding and perceptions of the
components that constitute SDD and related interventions, e.g. SOD. The importance of detailed
guidance on what constitutes different interventions was clear.
l For those units considering the adoption of SDD, it was apparent from our research that the delivery
of SDD is feasible and can be adopted into unit practices. However, a detailed speciﬁcation of the
proposed clinical and behavioural components of the intervention should be developed.
l This study highlighted that the introduction of SDD, whether into routine practice or within a research
context, requires consensus across a range of different stakeholders (including ICU colleagues, clinical
microbiologists and medical directors/those with decisional authority within units). Our study also
highlighted that medical microbiologists appear to be more opposed to SDD than intensivists.
Representatives of these stakeholder groups should be engaged early in any discussions around
the use/introduction of SDD.
l A substantial minority of participants reported that SDD would be adopted (apparently quite
straightforwardly) if adoption was mandated by regulatory bodies.
l There was acknowledgement that the infections that SDD was developed to target (such as VAP)
are currently less of a problem owing to other current prophylaxis and treatment regimens.
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Recommendations for research
Further SDD research was viewed as important, acceptable and feasible to the key stakeholder groups who
participated in this study. However, further effectiveness research would need to be on a scale that raises
challenges for trial design and trial conduct. Research priorities, in rank order, are as follows:
1. A study within UK ICU is required to model resistance patterns as a function of SDD use.
2. Further large-scale effectiveness trials of SDD in intensive care practice are required to answer
the remaining uncertainties, especially those issues relating to antimicrobial resistance.
3. There is a general willingness to participate in a future effectiveness RCT of SDD; however, support for
further research is time-sensitive (owing to the changing context) and is not unanimous. Future research
needs to address the substantial barriers to acceptance and participation in any future trial. These
barriers should be addressed with reference to the study ﬁndings, for example (1) clinicians with lower
self-assessed knowledge of the SDD evidence base shifted their opinions following feedback about
others’ views, suggesting a role for discussion among clinical colleagues; (2) concerns about antibiotic
resistance and other potential harms were of paramount importance, suggesting the importance of
emphasising that a UK trial would assess antibiotic resistance patterns; (3) consensus between ICU
colleagues was seen as important, suggesting that consensus building and development are key to
acceptance and participation; and (4) a substantial proportion of clinicians would be prepared to
participate in a trial of SDD if their colleagues were in favour, suggesting that the presence of a SDD
champion in an ICU could inﬂuence participation.
4. Future trials should include (1) a primary mortality outcome, (2) pretrial, during-trial and post-trial
monitoring of antimicrobial resistance, (3) a control group that includes chlorhexidine and/or VAP
bundles, (4) a cost–beneﬁt analysis, and (5) a qualitative study to investigate the ﬁdelity of the
SDD intervention as delivered.
5. Groups proposing to undertake such a trial need to overcome the following challenges: (1) gaining
sufﬁcient acceptance of the trial, (2) gaining adequate participation in a trial, (3) the clear speciﬁcation
of the trial intervention, (4) major methodological issues relating to trial design and conduct,
(5) clariﬁcation of the acceptability (to ethics committees) of cluster-level consent in the case of
a cluster RCT and (6) major funding issues.
6. At this time, there is a much lower level of interest in adoption of SDD, or studies designed to
encourage implementation of SDD, into practice.
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Appendix 3 Regulatory governance report
Report of the delays caused by local governance
approval process
The study was submitted for R&D approval on 2 December 2010 to the Scottish central co-ordinating
centre [NHS Research Scotland Permissions Coordinating Centre (NRSPCC)]. Local approvals for Scottish
sites followed in December and January (Forth Valley 22 December 2010, Greater Glasgow and Clyde 23
December 2010, Fife 6 January 2011, Lothian 13 January 2011 and Grampian 27 January 2011). However,
the local approvals process in England and Wales involved extreme delays. The extreme delay in receiving
approvals had a negative impact upon recruitment by both delaying targets and potentially reducing the
diversity of the sample (as, to limit damage to the study timeline, we were forced to send recruitment
invitations based on where we had received approvals rather than to purposively sample based on diversity
factors). An outline of the problems experienced in obtaining approvals.
We received notiﬁcation that the project had been validated by the co-ordinating centre for England and
Wales (NIHR Co-ordinated System for gaining NHS Permission) on 20 December 2010 and that study wide
checks were completed on 31 January 2011. The lead Comprehensive Local Research Network for the
study (Essex and Hertfordshire) informed us that the target time for processing approvals is 30 days.
However, of the 47 NHS trusts we were targeting in England and Wales, approvals were still outstanding
for 15 trusts when recruitment closed 6 months after the application was submitted. For at least one R&D
ofﬁce (Pennine Acute Hospitals NHS Trust), the delay in approving the study can be attributed to
miscommunication between R&D ofﬁces regarding the use of a generic site-speciﬁc information (SSI) form
for this study. The Pennine ofﬁce informed us that they had been waiting to receive notiﬁcation of a SSI
before beginning the approvals process (despite this having been made available to all R&D departments
via the NIHR Co-ordinated System for gaining NHS Permission and lead Comprehensive Local Research
Network when approval was ﬁrst sought).
The Welsh approvals process was hampered by miscommunication between the Scottish central
coordinating centre and the ofﬁces in Wales. NRSPCC submitted the application to the Welsh Research
Management ofﬁce without being aware that the study was a secondary care study and could not be
managed by the Welsh central system (which is exclusively for primary care studies). The Welsh ofﬁce sent
no reply to inform the NRSPCC of this mistake and nor did they contact the study team. When NRSPCC
became aware of the mistake, they negotiated a rapid review of the study application and permission was
received from one Welsh NHS trust (Cardiff and Vale NHS Trust) and two participants were recruited from
Wales before recruitment had to close.
The Northern Ireland approvals process for the study was also problematic. The Southern Health and Social
Care Trust at ﬁrst agreed to review the study and produce a global governance report, which would cover
all NHS trusts in Northern Ireland. However, 4 weeks after making our application, we received notiﬁcation
from the Research Manager for the Southern Health and Social Care Trust that they were no longer willing
to process the study through the research governance approval system because the view received from the
relevant staff was that they did not wish to participate because the nosocomial infection rate was already
extremely small and the treatment was perceived to be very expensive. In other words, key staff were not
in favour of SDD and decided to pre-empt the study ﬁndings, thereby potentially biasing the results of this
study by excluding these important views. It appears that the judgement of this R&D ofﬁce was given
without consideration to the peer review performed by HTA and the ethics committee. Despite this
setback, the study was approved by Western Health and Social Care Trust on 19 May 2011 and one
participant was recruited from Northern Ireland.
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Appendix 4 Detailed data for Delphi study
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FIGURE 18 Consensus of 90% or higher around mid-value of 8. (continued)
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FIGURE 18 Consensus of 90% or higher around mid-value of 8. (continued)
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FIGURE 18 Consensus of 90% or higher around mid-value of 8.
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FIGURE 19 75–90% consensus around mid-value of 8. (continued)
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FIGURE 19 75–90% consensus around mid-value of 8. (continued)
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FIGURE 19 75–90% consensus around mid-value of 8.
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FIGURE 20 75–90% consensus around mid-value of 7.
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FIGURE 21 75–90% consensus around mid-value of 6.
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FIGURE 22 75–90% consensus around mid-value of 5.
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FIGURE 23 75–90% consensus around mid-value of 4.
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FIGURE 24 50–75% consensus around mid-value of 8. (continued)
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FIGURE 24 50–75% consensus around mid-value of 8.
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FIGURE 25 50–75% consensus around mid-value of 7. ID, infectious diseases. (continued)
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FIGURE 25 50–75% consensus around mid-value of 7. ID, infectious diseases.
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FIGURE 26 50–75% consensus around mid-value of 6. (continued)
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FIGURE 26 50–75% consensus around mid-value of 6.
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FIGURE 27 50–75% consensus around mid-value of 2, 3, 4 and 5. (continued)
DOI: 10.3310/hta18250 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 25
145
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9
0
10
20
30
40
50
60
(d)
P
e
r 
ce
n
t
I
M
P
C
G
ro
u
p
The SDD evidence base is not generalisable
to my patient population
1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9
0
10
20
30
40
50
60
(e)
P
e
r 
ce
n
t
I
M
P
C
G
ro
u
p
Educating staff would be expensive
1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9
0
10
20
30
40
50
60
(f)
P
e
r 
ce
n
t
I
M
P
C
G
ro
u
p
Prophylactic antibiotic use in SDD is at
odds with my professional responsibilities
FIGURE 27 50–75% consensus around mid-value of 2, 3, 4 and 5.
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FIGURE 28 Lack of consensus.
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Appendix 5 Materials for national survey
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